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Abstract
THE ROLE OF THE HYPOXIA-INDUCIBLE FACTOR 2 IN PANCREATIC
CANCER: MECHANISMS OF TUMOR IMMUNOSUPPRESSION AND
INTESTINAL RADIOPROTECTION
Carolina J. García García, B.S.

Advisory Professor: Cullen M. Taniguchi, M.D., Ph.D.

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with dismal prognosis.
The only curative option for patients is surgery, but over 80% of patients are not surgical
candidates. Unfortunately, PDAC is resistant to the three remaining options. PDAC is
characterized by a profoundly hypoxic and immunosuppressive stroma, which contributes to its
therapeutic recalcitrance. Alpha-smooth muscle actin+ (αSMA+) cancer-associated fibroblasts
(CAFs) are the most abundant stromal component, as well as mediators of stromal deposition.
The hypoxia-inducible factors (HIF1 and HIF2) coordinate responses to hypoxia, yet, despite their
known association to poor patient outcomes, their functions within the PDAC tumor
microenvironment (TME) remain unknown. This dissertation examines the roles of the HIFs in
PDAC with the objective of exploiting this tumor’s profoundly hypoxic status to improve
immunotherapy and radiotherapy.

viii

We used a dual recombinase mouse model that developed autochthonous PDAC and
restricted the deletion of HIFs to αSMA+ CAFs. Interestingly, CAF-specific deletion of Hif2a,
but not Hif1a, suppressed tumor growth and significantly improved survival. Moreover, deletion
of Hif2α in CAFs decreased the recruitment of immunosuppressive macrophages and regulatory
T cells and increased the presence of effector immune cells in tumors. CAF treatment with
PT2399, a clinically relevant HIF2 inhibitor, significantly reduced macrophage chemotaxis and
M2 polarization, and improved responses to checkpoint immunotherapy in two syngeneic mouse
models. Together, these data suggest that stromal HIF2 is an essential component of PDAC and
is a druggable therapeutic target that could relieve TME immunosuppression and enhance
immunotherapy responses in this disease.
Moreover, radiotherapy for PDAC is challenging because of its proximity to the
exquisitely radiosensitive small intestine (SI). Our group previously showed that HIF2
stabilization protects against SI radiotoxicity in mice, but the mechanisms behind this remain
elusive. Since PDAC displays maximal stabilization of the HIFs, we hypothesized that HIF2’s
regenerative function in the SI can be exploited to reduce toxicities while optimizing radiotherapy.
We overexpressed HIF2 in SI organoids and found that Wnt5a was among the top upregulated
transcripts. Luciferase reporter assays showed that HIF2 directly activates the WNT5A promoter
via a hypoxia response element. Furthermore, through knockout and rescue experiments, we
found that Wnt5a is necessary and sufficient for SI radioprotection. Together, our results suggest
that HIF2 radioprotects the SI, at least in part, by inducing Wnt5a expression.
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Chapter I: Introduction

1

1.1 Why Oxygen (and Hypoxia) is Important
Oxygen is sometimes referred to as the “molecule of life.” Without oxygen, humans and
other aerobic organisms would perish. And, it is precisely the accumulation of oxygen in our
atmosphere, produced by cyanobacteria photosynthesis, that propelled the evolution of simple life
into complex life over two billion years ago.1 At the cellular and molecular level, oxygen serves
as a critical substrate for many biological processes and functions. Oxygen is necessary for carbon
double bonds to be introduced into fatty acids, for mitochondria to produce adenosine triphosphate
(ATP) to supply energy to our cells, tissues, and organs, and for collagen to mature and provide
structural organization in connective tissues and beyond.2 However, oxygen availability can
fluctuate secondary to environmental, geographical, or physio-anatomical changes, such as a fire
causing rapid consumption of oxygen in the air of a room, or increased altitude which means less
atmospheric pressure and less oxygen levels, or molecules of fat causing local inflammation and
clogged blood vessels, preventing oxygen from reaching tissues. Thus, organisms have
mechanisms to sense and adapt to these fluctuations in oxygen availability.

1.2 How Living Organisms Sense Oxygen & Respond to Hypoxia
Oxygen sensing molecular systems that enable organismal adaptation to oxygen
deficiency (hypoxia) can be traced back to early metazoan organisms.3-5 Cells sense oxygen
concentration (tension) through several proteins that require molecular oxygen (O2) to carry out
their activities, and thus, are broadly classified as dioxygenases. Dioxygenases sense hypoxia and
trigger a signal transduction cascade to alert and prepare the organism to respond by either
enhancing oxygen transport and delivery or by promoting survival in hypoxia. In this subsection,
a brief overview of the biochemical properties that characterize oxygen sensors is provided,
2

followed by a summary of the molecular mechanisms by which oxygen sensors trigger a hypoxic
response, coupled to examples of what conforms the hypoxic response in certain tissue types.
Dioxygenases have varying O2 affinities (KM), and thus, experts have proposed that their
functions vary based on the tissue’s level of oxygen (i.e. anoxia vs. hypoxia vs. physioxia).6
Broadly speaking, certain oxygenases are quite primitive and do not require any cofactors to
function (e.g. bacterial 2,4-dioxygenases, Renilla luciferase monooxygenase), but the majority of
dioxygenases that are relevant to human health and disease are more elaborate and require some
type of transitional metal center or organic cofactor within their structure to bind oxygen.7, 8
Ferrous iron is the metal cofactor most commonly used by dioxygenases due to its lower oxidation
state.7 Other transitional metals less commonly used by dioxygenases are copper, divalent
manganese, cobalt, and nickel.9 Iron-containing dioxygenases can be divided into heme- and
nonheme-dependent, with the latter having more established roles in oxygen sensing. Heme
prosthetic groups are made up of a protoporphyrin ring with a central iron atom that binds O2.
Nonheme iron dioxygenases bind O2 through coordinated protein motifs, such as the conserved
2-His-1-carboxylate ‘facial triad’ motif (His-His-Glu/Asp) which contains a flexible iron
center,10, 11 and these dioxygenases can be further classified based on whether they require 2oxoglutarate (2-OG) as a cofactor or not.12
It is important to note that not every oxygenase is involved in the organismal hypoxic
response. In the past few decades, the hypoxia biology field has made significant advances in
understanding oxygen sensing and the organismal hypoxia response,13 yet there are many sensors
whose functions are more recently being elucidated,14 and many more which remain to be
studied.15 Some known oxygen sensors are: the EGLN family of prolyl hydroxylase enzymes, the
family of Jumonji C (JmjC) domain-containing histone lysine demethylases (both belong to the
3

superfamily of nonheme iron- and 2-OG-dependent dioxygenases),6, 14, 16 as well as the electron
transport chain, and the family of NADPH oxidase enzymes (which structurally, are hemedependent dioxygenases).6,

16, 17

Table 1 summarizes oxygen sensors, their O2 binding

mechanism, their molecular effectors, and the physiological responses induced by them.

Table 1. Overview of Oxygen Sensors & Hypoxic Response Mechanisms.
Dioxygenases
Sensor
Superfamily
&
Family

Molecular
Effector

Oxidoreductases

(Iron/2-OG-dependent)
EGLNs

JmjC-KDMs

(prolyl-4

(histone lysine

hydroxylases)

demethylases)

KDM5A
HIF1 & HIF2

~
KDM6A

ETC Complex IV
(carotid body)

ETC Complexes
I & III

H3K4me3 &

NADH &

Transcription of

H3K36me3à

H2O2à inhibits ion

Signal

dozens of genes

gene activation

channels

Induced

(e.g. GLUT1, EPO,

~

à catecholamine

OCT4, VEGF)

H3K27me3à

released to sinus

gene repression

nerve

Metabolic shift,
Tissue

erythropoiesis,

Response

angiogenesis, stem
cell survival

~
Stem cell
survival, cell fate

(pulmonary blood
vessels)

Superoxide
Inhibits K+
channelsà opens
Ca2+ channels
~
Induces HIF1,
NF-κB & NRF2
signaling
Pulmonary

Metabolic shift,
EMT

NADPH oxidase

vasoconstriction
hyperventilation

~

induced by brainstem

Antioxidant
defense, replicative
senescence

The superfamily of nonheme iron- and 2-OG-dependent dioxygenases includes the
well-known EGLN family of prolyl hydroxylases, the JmjC domain-containing histone lysine
4

demethylases (JmjC-KDMs), the ten-eleven translocation (TET) DNA hydroxylases,18 and ~50
other understudied enzymes.19 Because oxygen sensors from this superfamily require 2-OG (also
known as α-ketoglutarate, α-KG), which is an intermediate metabolite from the citric acid (TCA)
cycle, these enzymes serve as a point of convergence between hypoxic signaling and adaptation
with cell metabolism. Unsurprisingly, much of the hypoxic response involves regulation of
metabolic pathways (this is discussed in more details below).20 To sense fluctuations in O2,
dioxygenases need to exhibit low O2 affinity (high KM). Collagen prolyl hydroxylases and TET
DNA hydroxylases, for example, are 2-OG-dependent dioxygenases with high O2 affinities (low
KM), and thus might not play roles in the hypoxic response.18 Conversely, the EGLN family of
prolyl hydroxylases (different from collagen prolyl hydroxylases) and the family of JmjC-KDMs
exhibit low O2 affinity (high KM), and are currently considered to be the master regulators of the
hypoxic response.6,

14, 16

The following five paragraphs summarize the current knowledge

regarding the role of EGLN prolyl hydroxylases, the JmjC-KDMs, and TET DNA hydroxylases
as oxygen sensors.
Perhaps the most widely studied and recognized oxygen sensing mechanism is the
EGLN/HIF/VHL axis for which William Kaelin, Peter Ratcliffe, and Gregg Semenza received
the 2019 Nobel Prize in Physiology or Medicine.13 The EGLN family of prolyl hydroxylases
are named after their C. elegans ortholog, the Egg laying nine gene (Egl-9). There are three
mammalian isoforms (EGLN1-3), and they are also known as Hypoxia-Inducible Factor (HIF)
Prolyl Hydroxylases (HIF-PHs or HPHs, for short) and as Prolyl Hydroxylase domain-containing
proteins (PHDs) in the literature. Unfortunately, the numbering system isn’t consistent throughout
the various aliases: EGLN1 = PHD2 and HPH2, EGLN2 = PHD1 and HPH1, and EGLN3 = PHD3
and HPH3.21 EGLN proteins serve as cellular oxygen sensors that regulate acute and chronic
5

adaptation to hypoxia through the degradation of the HIFs in the presence of oxygen.22 The EGLN
family hydroxylates conserved proline residues on the alpha subunit of the HIFs in the presence
of iron, O2, and 2-OG, allowing the von Hippel-Lindau (VHL) E3 ubiquitin ligase complex to
bind and tag HIFα for proteosomal degradation (Figure 1).21-28 HIFs are heterodimeric
transcription factors of the bHLH-PAS family of proteins that are consistently being produced
and degraded, but can quickly become stabilized through hypoxia, EGLN inhibition, or loss of
VHL activity, allowing them to modulate cell metabolism and survival through induction of an
orchestrated gene expression program.22 There are three mammalian HIF isoforms (HIF1-3) and
each consists of a labile alpha subunit (HIF1α, HIF2α, or HIF3α), which contains a highly
conserved oxygen-dependent degradation domain (ODD), and of a constitutively stable beta
subunit (HIF1β, also known as ARNT, aryl hydrocarbon nuclear translocator) that become
dimerized in the nucleus.22, 23 HIFs induce transcription of hundreds of genes with the help of coactivators (e.g. p300/CPB), through their bHLH domains which bind E-box-like canonical
hypoxia response elements (HREs) that contain a 5’-[A/G]CGTG-3’ sequence in promoter and
enhancer regions of target genes (Figure 1).22 HIFs respond to acute hypoxia by reducing the
organismal and cellular O2 demand through a metabolic shift to glycolysis and increased
mitophagy.20, 22, 29 When HIF activation is prolonged, they improve O2 supply by enhancing
hematopoiesis and inducing angiogenesis, and they promote tissue healing and regeneration by
promoting stem cell growth and tissue remodeling, such that tissues become preconditioned and
protected against further damage.20, 22, 29
HIF1 and HIF2 are the transcriptional drivers of the hypoxic response, and despite having
high sequence similarity and inducing overlapping genes, they also induce distinct genes.30, 31
This gene selectivity stems from their ability to recruit distinct coactivators through their N-termi6

Figure 1. Oxygen sensing and induction of the hypoxic response via the EGLN/HIF/VHL axis.

nal transactivation domain (TAD), whereas they regulate overlapping target genes by recruiting
the same coactivators to their C-terminal TAD (C-TAD).31 Studies have shown that functional
HREs in enhancer regions are more likely to be cell-type specific, while HREs in promoters are
more likely employed across many cell types.30, 31 Moreover, HIF2 exhibits more constrained
tissue-specific expression and vaster promoter-distant binding (i.e. enhancer binding) than HIF1,
suggesting that it plays a greater role in defining tissue-specific hypoxic responses.6, 30 Lastly,
HIFs are regulated by another 2-OG-dependent dioxygenase called Factor Inhibiting HIF (FIH),
which regulates HIFα stability, albeit to a lesser degree, via hydroxylation of a conserved
asparagine residue in the C-TADs, thereby disrupting HIF transactivation activity.6, 31 However,
FIH has a lower KM for O2 than the EGLNs, thus it maintains activity and HIF regulation under
hypoxia,31 and behaves less like well-established oxygen sensors.
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Research in the past decade has made it evident that there is an epigenetic remodeling
component to the hypoxic response.14, 18, 32, 33 Epigenetic regulation of gene expression ensues
through modifications at the histone and DNA levels, and recent studies suggest that through
modifications at the RNA level too.34,

35

Methylations are the most common epigenetic

modifications, and they can induce or repress overall gene expression, but in addition to these,
hypoxia has also been shown to regulate epigenetic acetylation.36 Several of the enzymes that
carry out these modifications are members of the superfamily of nonheme iron- and 2-OGdependent dioxygenases, including the JmjC-KDMs and the TET DNA hydroxylases.19
The JmjC-KDMs are now well established as oxygen sensors.14, 16 As dioxygenases, they
become inhibited in early hypoxia, leading to upregulation of histone methylations that help
coordinate the subsequent transcriptional changes of the hypoxic response in normal physiology
and in disease.14, 32, 33 These KDMs, which exhibit substrate specificities,16 are evolutionarily
conserved from yeast to humans, suggesting that in phylogenetic terms, oxygen sensing by
chromatin is older than oxygen sensing by HIFs.32,

37-39

KDM5A and KDM6A are HIF-

independent oxygen sensors,32, 33 while KDM4C and KDM5B are induced by HIF1, KDM5C is
induced by HIF2, and KDM3A and KDM4B are induced by both HIF1 and HIF2.16,

40-46

Moreover, histone deacetylases (HDACs) have been shown to enhance HIF1 activity by
regulating the acetylation status of its coactivators.47
At the DNA level, methylation is regulated by DNA methyltransferases and by DNA
demethylases, such as the TET DNA hydroxylases, and hypoxia has been shown to alter both
types of enzymes.48 TET DNA hydroxylases are dioxygenases that oxidize 5-methylcytosine to
5-hydroxymethylcytosine, 5-formylcytosine, and 5-carboxylcytosine, and have been postulated
as O2 sensors.18 They exhibit quite low oxygen KM compared to EGLNs and JmjC-KDMs, yet in
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vitro studies have shown that their activity is significantly reduced by hypoxia.18, 49 However, in
these studies, hypoxia was shown to decrease the 2-OG precursor glutamate and to increase the
2-OG antagonist succinate, which can reduce TET DNA hydroxylase activity.49 Thus, whether
TET DNA hydroxylases are bona fide O2 sensors or a downstream effector of the hypoxic
response remains unclear. Lastly, hypoxia has also been shown to regulate RNA posttranscriptional modifications by RNA methyltransferases (e.g. METTL3/14) and RNA
demethylases (e.g. ALKBH5 RNA demethylase) in a HIF-dependent manner, but their roles as
direct oxygen sensors have not been established.18, 34, 35, 50 Thus, hypoxia has been reported to
modulate epigenetic regulation of gene expression at all three levels, in both HIF-dependent and
-independent manners.18, 36
Moving away from the superfamily of nonheme iron- and 2-OG-dependent dioxygenases,
mitochondria also play a role in O2 sensing and initiating the hypoxic response. During aerobic
cellular respiration, the electron transport chain (ETC) generates reactive oxygen species
(ROS) as it transports electrons through redox centers to generate ATP. ROS are produced
primarily in mitochondrial complexes I and III, also known as NADH-ubiquinone oxidoreductase
and Coenzyme Q–cytochrome c reductase, respectively.6, 51, 52 Complex I produces superoxide
(O2-) during the transfer of electrons from NADH to Coenzyme Q, whereas complex III produces
ubisemiquinone during ubiquinol generation from ubiquinone.51, 52 Paradoxically, hypoxia causes
the ETC to increase ROS production.6, 51, 52 This burst in ROS occurs because hypoxia decreases
the activity of complex IV (cytochrome c oxidase), causing a backlog of electrons throughout the
ETC and an accumulation of ubiquinol, leading to a switch of electron transport to the reverse
direction.53 These oxidants serve as second messengers to trigger electrophysiological,
transcriptional, and post-translational adaptations to both acute and chronic hypoxia (Table 1).6,
9

51, 53

Of note, oxygen sensing through the ETC requires some level of O2, as it becomes less

relevant of a hypoxic response regulatory mechanism under severe anoxic conditions.6, 54
Neurosecretory and arterial smooth muscle cells sense hypoxia through a mitochondriato-plasma membrane signaling mechanism that involves the ETC and hypoxia-responsive ion
channels, allowing them to induce acute responses in the cardiorespiratory systems using ROS as
second messengers.6, 53, 55, 56 In the carotid body, for example, glomus cells sense hypoxia through
their specialized mitochondrial complex IV, which contain atypical subunit isoforms that have
low O2 affinity (on heme moieties), and interestingly, their expression is maintained by high levels
of HIF2.53 The inactivation of complex IV during acute hypoxia reverses the ETC, causing a burst
in superoxide and NADH production from complex I.53 This superoxide is channeled into the
mitochondrial intermembrane space where it is converted to H2O2, that then diffuses to the cytosol
and, together with NADH, inactivate potassium channels in the plasma membrane.53 Thus, the
ETC functions as a sensor and an effector of hypoxia, inducing membrane depolarization, which
activates voltage-gated calcium channels, causing subsequent release of catecholamine to afferent
fibers of the sinus nerve.53, 55, 56 These signals travel to the brainstem respiratory center which
induces hyperventilation.6, 55, 56 Similar mechanisms have been shown in neuroepithelial bodies
of the lungs, where cells sense O2 fluctuations in inspired air, and in neonatal adrenal chromaffin
cells, where they sense O2 in neonatal blood.55, 56 Vascular smooth muscle cells in the systemic
blood vessels also respond to low O2 via hypoxia responsive potassium channels that induce
vasomotor contraction in a similar way than glomus cells in the carotid body.53, 55, 56 Furthermore,
studies have also shown that HIF-induced upregulation of ion channels is essential for chronic
hypoxic adaptation.56
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The family of NADPH oxidases are membrane multi-subunit complexes that bind O2
through heme moieties and use it to oxidize NADPH and NADH, generating superoxide.17, 51
Depending on the location of the complex, the superoxide is generated intracellularly and
packaged into phagosomes, or it can be released intracellularly. Multiple studies have suggested
a role for NADPH oxidases and ROS as pulmonary O2 sensors.57, 58 In the context of acute hypoxia
(seconds to minutes), the lung undergoes vasoconstriction to maintain an appropriate ventilation
to perfusion ratio and optimize gas exchange. Research has shown that this is dependent on
NADPH oxidase expression in pulmonary vascular smooth muscle cells, as knockout of the
p47phox subunit of the complex abrogated the physio-anatomical response to acute hypoxia.59
NADPH oxidases have also been implicated in the context of chronic alveolar hypoxia (days to
months/years), in which each of the lung vascular cell types undergoes biochemical and functional
changes, leading to vessel hypertrophy, pulmonary hypertension, and eventually right heart
failure.60 Chronic hypoxia induces activation of pulmonary artery adventitial fibroblasts into a
myofibroblast phenotype, which produce ROS that promote smooth muscle cell contraction and
increase vascular tension, and also induce vessel structural remodeling via extracellular matrix
production.60 Knockout of gp91phox, another subunit of the NADPH oxidase complex, in mice
abrogated chronic hypoxia-induced ROS production and abolished the vascular remodeling
phenotype that leads to pulmonary hypertension.61
Thus, ROS produced by the ETC and by NADPH oxidase function as second messengers
of hypoxia. Importantly, ROS can also inhibit the EGLNs, leading to stabilization of the HIFs,
and the JmjC-KDMs, inducing a hypoxia-like response.14, 62 Moreover, iron chelators and 2-OG
antagonists (e.g. succinate, fumarate) can also trigger a hypoxia-like response.14 In conclusion,
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organisms use a combination of all these oxygen sensing mechanisms to coordinate an adaptation
to acute and chronic hypoxia.

1.3 The Burden of Pancreatic Cancer, its Tumor Microenvironment & Current
Treatments
Pancreatic cancer is a devastating disease that affects over 80,000 people yearly
in the USA. 63 In 2021, 60,430 people were diagnosed with this disease, and it is
estimated that in 2022, 62,210 people will be diagnosed. 63, 64 Despite it not being the
most prevalent cancer, pancreatic cancer is one of the deadliest ones. Numerically,
pancreatic cancer is currently the third cause of cancer-related deaths in the USA, and
it is expected to become the second deadliest cancer by 2030. 65 Among all cancers, it
has the lowest 5-year survival rate, currently at 11%. 63 In 2021, 48,220 people died
from pancreatic cancer, and it is estimated that in 2022, 49,830 patients will die from
this disease. 63, 64 In the past decade, the survival rate of pancreatic cancer has improved
from 6% to 11%, reflecting the outpour of biomedical and clinical research, together
with improved patient education and advocacy. 66 However, as pancreatic cancer
researchers and clinicians, we still have a long way to go.
Pancreatic tumors can be exocrine or neuroendocrine, with more than 90% of
tumors being exocrine. The most common type of pancreatic cancer is pancreatic ductal
adenocarcinoma (PDAC). 67 The two main reasons why PDAC is so devastating are
because it is driven by a very aggressive tumor biology and because it is diagnosed
late. Patients are diagnosed late because the symptoms of pancreatic cancer are quite
vague and tend to develop over time. The symptoms include weight loss, fatigue,
12

depression, abdominal pain, loss of appetite, nausea, jaundice, and changes in stool.
Most cases of pancreatic cancer arise due to bad luck, but some known risk factors
include long-standing diabetes, chronic and/or hereditary pancreatitis, smoking, heavy
alcohol intake, age > 60, obesity, diets high in processed and red meats, family history,
and hereditary mutations. 67 However, increased preventive surveillance in high risk
patients could improve diagnosis at earlier, more manageable, stages of disease.
At the molecular level, PDAC tumors display a low mutational burden, 68 with
some studies reporting only 1-2 mutations per tumor. 69 Around 90-95% of PDAC cases
arise due to activating mutations in the KRAS2 oncogene. 67 As tumors progress, they
inactivate tumor suppressors, such as p16/CDKN2A, SMAD4, and TP53. 67 From a
histopathological

standpoint,

PDAC

carcinogenesis

generates

a

prominent

desmoplastic response that leads to extensive deposition of a fibroinflammatory
stroma. 70 This stroma is estimated to compose 80-95% of the bulk of human tumors, 71
and it increases intratumoral pressure causing blood vessels to collapse, 72 leading to
profound tumor hypoxia. 73 After years of research, the field of PDAC understands that
the tumor stroma plays an important role in the biology and response to therapy.
The stroma encompasses the tumor microenvironment (TME), and is composed
of acellular and cellular components (Figure 2). The acellular components are
extracellular matrix molecules deposited largely by cancer-associated fibroblasts
(CAFs), and this make a large portion of the TME. The cellular component includes
CAFs, endothelial cells and pericytes, pro-tumor and anti-tumor immune cells, and
nerve fibers. CAFs are a heterogeneous population that predominantly arise from tissue
resident pancreatic stellate cells (PSCs), but can also arise from bone marrow-derived
13

Figure 2. Pancreatic cancers have an immunosuppressed TME. The largest component of the TME
is the heterogenous CAF population and the fibrous extracellular matrix (produced by myofibroblastic
CAFs). Adapted from “Tumor Microenvironment”, by BioRender (2022). Retrieved from
https://app.biorender.com/biorender-templates.

mesenchymal stem cells, or can interconvert from adipocytes, pericytes, or endothelial
cells. 74 CAFs promote tumor progression by modulating tumor metabolism, by
secreting soluble factors that support growth, angiogenesis, and invasion, by
remodeling the extracellular matrix, and by stimulating an immunosuppressive, protumor, TME. 74 Thus, in PDAC, most immune cells serve to suppress anti-tumor immune
14

functions. The most common cells in the PDAC microenvironment are myeloid-derived
suppressive cells (MDSCs), tumor-associated macrophages (TAMs), and regulatory T
cells (Tregs; Figure 2). These cells, suppress the endogenous anti-tumor responses in
various ways, which enables pre-invasive pancreatic lesions to persist and then
progress to invasive disease. 75 Anti-tumor immune cells, such as effector T cells,
dendritic cells (DCs), and natural killer (NK) cells, are very scarce in pre-invasive
lesions and the few that can be found in advanced PDAC are not active. 75
Curative treatment for pancreatic cancer requires trimodality therapy, which consists of
the triad of surgery, chemotherapy, and radiotherapy. The exact treatment regimen given to
patients depends on their disease stage and their overall health status, but the best chance of
survival comes with surgery. Unfortunately, 76% of PDAC patients are not surgical
candidates because they are diagnosed when their disease has spread regionally or
distantly. 63 Thus, chemotherapy is the first line of therapy in PDAC. The two common
regimens are gemcitabine combined with albumin-bound paclitaxel, and the
combination of 5-florouracil/leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX).
However, PDAC is innately recalcitrant to chemotherapy, and most tumors progress. 76
Radiotherapy on the other hand, can be used to locally treat both resectable and
unresectable PDAC. 77 The cytotoxicity induced by radiation largely depends on the
formation of ROS from O 2 . Intraoperative measurement of O 2 levels in human PDAC
patients revealed that PDAC tumors are extremely hypoxic, which limits the efficacy
of radiotherapy (see section 1.4 How Cancers Hijack the Hypoxic Response to
Thrive). 73 Thus, higher doses of radiation are required to ablate PDAC. However,
because of the pancreas’ proximity to the extremely radiosensitive duodenum, radiation
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dose escalation is not feasible without causing undesirable toxicities to patients (see
section 1.6 Mimicking Hypoxia to Counteract Radiation-Induced Gastrointestinal
Toxicities). 78
Newer treatment modalities include targeted therapies and immunotherapy. The few
targeted therapies approved for PDAC are only useful for a minority of patients, whose tumors fit
certain molecular criteria.76 On the other hand, immunotherapy has revolutionized cancer
treatment, but unfortunately, it has not achieved as much clinical benefit in PDAC.68 In part, this
is due to PDAC’s low mutational burden,68 which results in a low production of tumor neoantigens
that could incite an anti-tumor immune response. PDAC immunotherapy resistance is also related
to the high density of immunosuppressive cells that populate the TME, and the physical barrier
imposed by the fibrous stroma, which prevents effector immune cells from reaching the tumor’s
core (Figure 2). Moreover, PDAC’s recalcitrance to chemotherapy is also associated to the dense
stroma (see section 1.5 The Role of the Tumor Stroma in Pancreatic Cancer Therapy
Failure & Strategies to Modulate It). 72, 76, 79, 80

1.4 How Cancers Hijack the Hypoxic Response to Thrive: The Role of the EGLN/HIF
Axis in Pancreatic Cancer & its Microenvironmental Mileu
Rapidly growing solid tumors, like PDAC, are characteristically hypoxic.73 Acute tumor
hypoxia is driven by a perfusion limitation due to aberrant, leaky, and collapsed vessels, whereas
chronic tumor hypoxia is driven by a diffusion limitation (i.e. insufficient angiogenesis).20, 29, 81
In general terms, the field of cancer biology has followed the dogma that hypoxia is an effect of
rapid cancer growth,82 however, dysfunctional activation of the hypoxic responses can also be the
cause of cancer initiation.83, 84 Regardless of the order, the past two decades of research have made
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it clear that cancers hijack and amplify the various hypoxic responses, discussed in the previous
section, to adapt and thrive in harsh environments.20, 29 In particular, constitutive expression of
HIF1 and HIF2 has been correlated with poor prognosis and multi-treatment resistance in many
cancers, across all types of tissues.20 Studies have shown that hypoxia induces replication stress
and genomic instability, which activates DNA damage response pathways, and this contributes to
resistance to chemotherapy and radiotherapy.18, 29 In renal cell carcinoma, for example, loss of the
tumor suppressor VHL leads to constitutive stabilization of HIF2 and an aggressive vascular
tumor phenotype.84 Oncogenes have also been shown to induce expression of HIFs independently
of oxygen availability.85 Tumors also generate ROS, succinate, fumarate, and 2-hydroxyglutarate,
which can stabilize HIFs by inhibiting the EGLN proteins.14, 62
As discussed previously, PDAC tumors are extremely hypoxic, 73 and high HIF1,8688

HIF2,89 and HIF390 expression correlates with worse clinical outcomes. Hypoxic pockets with

high HIF1 and HIF2 expression can be found in metaplastic pancreatic ducts and early preinvasive lesions.83, 91 Table 2 summarizes the known roles of HIF1, HIF2, and HIF3 in the various
cell compartments of the TME. Unexpectedly, knockout (KO) of HIF1 in the epithelial
compartment of murine pancreata enhances spontaneous PDAC oncogenesis and results in more
poorly differentiated tumors, more metastases, and shorter survival, indicating that HIF1 plays a
tumor suppressor role in PDAC.91, 92 HIF1 signaling in PDAC cells opposes recruitment of a
subtype of pro-tumor B cells to early91 and advanced92 lesions, which promote TME
immunosuppression and support PDAC initiation and progression, in a non-cell-autonomous
fashion.93 The aggressiveness of this phenotype appears to be related to p53 stabilization by
HIF1,92 as there were no differences in metastases or survival rates in a PDAC model with intact
p53.91 However, studies using an orthotopic xenograft model of gemcitabine-resistant PDAC
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(with oncogenic Kras and null p53 mutations) showed that HIF1 inhibition sensitizes tumors to
gemcitabine and improves survival.94 In that study, the authors found that HIF1 increases
glycolysis and de novo pyrimidine biosynthesis, which then molecularly antagonize gemcitabine,
making PDAC cells resistant.94 There was no survival advantage granted by inhibition of HIF1 in
gemcitabine sensitive tumors. Moreover, these oncogenic traits overshadow HIF1’s more proven
tumor suppressor role in PDAC, and may be explained by the fact that B cells of athymic nude
mice, used for xenograft models, do not mature properly,95 thus, HIF1’s role in cancer-immune
crosstalk cannot be properly established in these models.
On the other hand, HIF2 KO in the epithelial compartment of murine pancreata halted the
progression of genetically-induced pre-invasive neoplasia into full-blown PDAC, but it also did
not impact overall survival.83 Contrary to HIF1, HIF2 likely plays an oncogenic role in PDAC
initiation. HIF2 indirectly induces β-catenin expression83 and they form a complex that
strengthens the stability and activity of both proteins, driving epithelial-to-mesenchymal
transition.89 Interestingly, HIF3 signaling in the PDAC epithelial compartment also plays an
oncogenic role, as shown in xenograft models.90 It would be interesting to study the role of HIF3
in PDAC initiation and its potential modulation of cancer-immune cell crosstalk using
spontaneous mouse models. Thus, HIFs appear to have contradictory roles in the pathobiology of
PDAC, that are essential for cancer initiation, but not all necessary for its subsequent progression.
However, given that PDAC cells make up only a small portion of the cellularity in pancreatic
tumors, the role of the HIFs in the TME is quite relevant.
In general, tumors resistant to checkpoint immunotherapy are hypoxic.96 The hypoxic
pancreatic stroma and TME maintain this immune privilege and immunotherapy resistance
through various mechanisms96 (see section 1.5 The Role of the Tumor Stroma in
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Pancreatic Cancer Therapy Failure & Strategies to Modulate It). Unsurprisingly,
hypoxia plays a role in the stromagenesis of PDAC.97 HIF1 expression in PDAC cells induces
them to secrete sonic hedgehog ligand, which activates pancreatic resident fibroblasts to deposit
fibrous tissue and to convert into CAFs. 97 This study, however, did not evaluate whether HIF2
was expressed and played a role, but given its oncogenic role in the PDAC epithelial
compartment,83, 89 it would be important to determine HIF2’s relative role in stromagenesis.
Moreover, though it is clear that hypoxia and desmoplasia potentiate each other,98-100 the function
of HIF signaling within pancreatic CAFs themselves remains unknown. Studies in breast
cancer models revealed that HIF1 KO, but not HIF2 KO, in CAFs accelerated tumor
progression. 101 Yet, their relative roles in PDAC may be tissue dependent and should
be directly assessed, particularly because CAFs can have different lineage origins in
these two cancers.
There are also no studies evaluating the relative roles of the HIFs in endothelial
cells in PDAC. Studies in breast cancer models revealed that HIF1 KO in endothelial
cells decreased metastasis, whereas HIF2 KO in endothelial cells increased
metastasis. 102 These two studies in breast cancer underscore the fact that the HIFs can have
differential cell-specific functions within the TME: CAF HIF1 appears to be tumor suppressive,
whereas endothelial HIF1 appears to be oncogenic.
Lastly, both HIF1 and HIF2 have well established roles in immunity, as they mediate the
adaptation of immune cells to infected and inflamed tissues under both normoxia and hypoxia.103
As mentioned previously, most immune cells in the PDAC microenvironment are pro-tumor,
including MDSCs, TAMs, and Tregs (Figure 2). Anti-tumor immune cells, such as effector T
cells, DCs, and NK cells, are scarce and/or suppressed. Macrophages are functionally classified
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as either M1, which are classically activated, phagocytic, and pro-inflammatory, or M2, which
are alternatively activated during the resolution phase of inflammation, and thus display an
immunosuppressive and pro-fibrotic phenotype.104 In many cancers, including PDAC, TAMs are
M2-type macrophages, which together with the more immature MDSCs, are associated with
worse outcomes due to their immunosuppressive nature.104, 105 HIF1 is known to promote M1
polarization, whereas HIF2 is known to promote M2 polarization.103 Moreover, studies in
spontaneous murine tumor models have revealed that HIF2 KO in myeloid-derived cells decreases
TAM infiltration in carcinogen-induced colon and hepatocellular cancers by downregulating
chemotactic receptors, and this significantly decreased tumor progression.106 In the contrary,
studies using syngeneic flank tumor models of Lewis lung carcinoma showed that stabilization of
HIFs via EGLN inhibition using FG-4592, a drug that is currently under consideration by the US
Food and Drug Administration (FDA) for anemia of chronic kidney disease, decreased tumor
growth.107 In these flank models, stabilization of HIFs normalized tumor angiogenesis, and
improved perfusion, decreased hypoxia, and increased infiltration by activated TAMs that
displayed higher glycolytic, phagocytic, and pro-angiogenic activity (i.e. more of an M1
phenotype).107 This anti-tumor TAM phenotype was driven by HIF1, as knocking out HIF1 in
myeloid-derived cells led to no responsiveness to FG-4592 in terms of tumor growth.107 These
two studies highlight that HIF1 and HIF2 can have contradictory functions on a single cell type
(i.e. macrophages). Importantly, the HIF1-driven anti-tumor TAM phenotype was observed in a
flank model,107 thus, improved immunosurveillance and M1 macrophage activity could be
secondary to the injection. In autochthonous cancer models, TAMs become re-educated towards
an M2 phenotype as tumors progress, via signaling crosstalk with CAFs and cancer cells.108
Moreover, PDAC specific models are required to investigate the roles of HIF1 and HIF2 in
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pancreatic TAMs because approximately 30% of them originate from embryonic pancreas tissue
resident macrophages, which proliferate in situ and in parallel to the tumor.109 Through a series
of brilliant experiments, the DeNardo Lab showed that TAMs derived from tissue resident
macrophages give rise predominantly to stromagenic M2 macrophages, and are necessary for the
progression of pre-invasive lesions to invasive disease.109 Hence, an autochthonous model might
be better suited to investigate the relative contribution of HIF1 and HIF2 to established TAM
functions in pancreatic cancer.
HIFs have quite opposing roles in T cell biology too.103 HIF1 becomes stabilized in
activated CD4+ and CD8+ T cells, regardless of O2 availability, where it drives the metabolic
reprogramming that induces glycolysis for cells to sustain their activation .103, 110 Moreover, HIF1
shifts the differentiation and function of T cells towards inflammatory Th1 and Th17 cells through
this glycolytic shift, as well as by inducing IL-17 expression in Th17 differentiating cells.103
Furthermore, HIF1 directly opposes Treg differentiation by promoting degradation of the FoxP3
transcription factor,103,

111

and again, by inducing a glycolytic shift.103 On the other hand,

researchers using a FoxP3-specific KO of the HIFs found that HIF2 is necessary for Treg
immunosuppressive function because it negatively regulates HIF1 at the transcriptional and posttranscriptional levels.111 Although important in certain cancer types, Neutrophils, B cells, DCs,
and NK cells are beyond the scope of this dissertation.
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Table 2. Role of the HIFs in PDAC.
Cell Type
Tumor

HIF1

HIF2

HIF3

Suppressive in GEMM

Oncogenic in GEMM

Oncogenic in

(opposes pro-tumor B cell

(potentiates β-catenin)83, 89

xenograft

subset)91; Oncogenic in xenograft

model90

model (gemcitabine resistance)94
CAFs

Unknown (Suppressive in breast

Unknown (Neutral in breast ca.

ca. model)101

model)101

Endothelial Unknown (Oncogenic in breast
ca. model)102
Myeloid

Unknown (Suppressive in Lewis

Unknown (Oncogenic in
Colon/liver ca. models)

Sustains CD4+ and CD8+ T cell

Necessary for Treg function

activity (Not on cancer

(Colorectal ca. & melanoma

models)

Unknown

106

lung ca. model)

103

Unknown

ca. model)102
107

T cells

Unknown (Suppressive in breast

Unknown

Unknown

models)111

GEMM, genetically engineered mouse model.

1.5 The Role of the Tumor Stroma in Pancreatic Cancer Therapy Failure &
Strategies to Modulate It
In the previous sections, we have discussed one of PDAC’s most characteristic feature:
the tumor stroma. The robust stromagenesis that ensues in PDAC occurs in parallel to
oncogenesis, and even surpasses it, with stromal fibrosis forming up to 95% of the bulk of PDAC
tumors.70, 71 This stroma is central to both the profound hypoxia and the therapeutic recalcitrance
that characterize PDAC (Figure 3).72, 73, 76 Consequently, modulating CAFs and the stroma is an
approach that could improve PDAC therapy outcomes, and thus, the development of such
therapies has become of great interest to the field.112-115 In this section, a brief review of the CAF
subtypes and the mechanisms by which the stroma is known to hinder chemotherapy and
immunotherapy efficacy will be provided, followed by a short discussion of the various
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Figure 3. The role of the PDAC stroma in therapy failure. Adapted from “Tumor Extracellular
Matrix Reduces Therapeutic Efficiency in Solid Tumors”, by BioRender (2022). Retrieved from
https://app.biorender.com/biorender-templates.

approaches to targeting the tumor stroma.74
Conceptually, the ways in which the stroma hinders therapy success can be
divided into physical and biological mechanisms (Figure 3). First, the extensive deposition
of hyaluronic acid physically increases intratumoral pressure, which compresses the blood vessels
and thus impairs drug delivery.72, 116, 117 The CAF-produced extracellular matrix also traps or
‘sequesters’ CD8+ T cells, which results in immune desserts throughout the tumor, and contributes
to the failure of immunotherapy.80 However, this ‘trapping’ mechanism is selective, as other –
pro-tumor– immune cells, such as TAMs and MDSCs, are well distributed throughout PDAC
tumors.80, 109, 118, 119 Over a decade ago, several groups showed that this selective immune access
was associated to cytokine and chemokine expression by stromal cells.119 Thus, the tumor stroma
directly contributes to immunotherapy resistance through biological mechanisms too (Figure 3).
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Many of these mechanisms are executed through fibroblasts/CAFs, which are hijacked during
oncogenesis-stromagenesis, and reprogrammed to become a cancer cell’s dream sidekick.
Through their metabolome, surfaceome, matrisome, and secretome, CAFs support cancer growth
and invasion, as well as modulate crosstalk with macrophages and endothelial cells, and interfere
with T cell functions.74, 80 However, not all CAFs are created equal.
As mentioned previously, CAFs are a heterogeneous population in terms of their
originating cell, their phenotype, and their functions in the TME.74, 80, 120 The field of CAF biology
came to the consensus that these cancer sidekicks should be classified according to their function,
and not according to dogmatic marker schemes, while keeping in mind that they display functional
diversity.74 The three main CAF subtypes in PDAC (and in other cancer types) are
myofibroblastic CAFs (myCAFs), inflammatory CAFs (iCAFs), and antigen-presenting
CAFs (apCAFs). 74, 80, 121, 122 As their names imply, myCAFs are contractile CAFs with
matrix producing/remodeling capabilities, iCAFs are immunomodulatory, 121 and
apCAFs present decoy antigens to suppress anti-tumor T cell responses. 122 Importantly,
these CAF subtypes are dynamic and dependent on their microenvironmental signaling
context, thus, they have the ability to interconvert between subtypes based on cellular
and spatial cues. 122,

123

Nevertheless, some markers widely used to distinguish CAF

functional subtypes are αSMA, fibroblast activation protein (FAP), and CD74, which
mark myCAFs, iCAFs, and apCAFs, respectively. 121,

122, 124

However, it’s worth

repeating that these are not absolute markers of functional status, and that actual
functional assessments or evaluation of a larger panel of known markers is much more
informative.
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Dozens of clinical trials that involve CAF and/or tumor stroma modulation are
underway.74, 80 There are three approaches to targeting CAFs/the tumor stroma: (1) by physically
altering CAF/stromal quantity (with the idea of removing the barrier that prevents drug and
immune cell access), (2) by altering CAF subtype interconversion, or (3) by altering specific CAF
functions. Efforts to physically disrupt the hypoxic stromal component (approach #1) through
sonic hedgehog protein inhibition,79, 125-130 selective fibroblast depletion,131 or recombinant human
hyaluronidase116, 132, 133 have effectively lowered stromal content but have paradoxically led to
worse outcomes in both preclinical studies and clinical trials. These paradoxical results are due to
the fact that the PDAC stroma acts as a physical barrier that prevents cancer cells from
metastasizing (Figure 3).125,

128, 131

Thus, physically altering the PDAC stroma is clinically

counterproductive.134
Other groups have proposed exploiting CAF plasticity to promote the conversion of protumor CAFs into anti-tumor ones (approach #2).123 This can be achieved by targeting the
pathways that drive CAF subtype states. For example, some trials are using vitamin D to revert
CAFs to quiescent states.74 In reprogrammed CAFs, the myCAF phenotype is known to be driven
by TGF-β signaling, which induces αSMA expression and contractility, whereas iCAF phenotype
is driven by IL-1-induction of JAK/STAT signaling and is directly inhibited by TGF-β
signaling.123 It is not yet clear what drives the apCAF state, but this subtype may originate through
mesothelial-to-mesenchymal transition.135 Several clinical trials are testing the safety of targeting
TGF-β signaling in PDAC and other solid tumors through small molecules (e.g. NCT02734160,
NCT02937272, NCT03666832, and NCT0182729), monoclonal antibody (NCT02947165), or a
‘trap’ protein (NCT03451773).80 Given that TGF-β signaling is necessary to maintain myCAFs
and prevent their interconversion into iCAFs,123 it will be interesting to see the results of these
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clinical trials.136 Other groups have showed promising results in preclinical trials targeting FAP+
iCAFs through targeted cytokine delivery80 and chimeric antigen receptor-T cell therapy.137
The 3rd approach is to target intrinsic CAF functions that support tumor progression in the
TME. For example, by targeting the signaling pathways by which CAFs secrete
immunosuppressive molecules. In this dissertation, we evaluate the role of hypoxia (i.e. HIF1 and
HIF2) in the PDAC stroma and whether it is a potential avenue to exploit CAFs.

1.6 Mimicking Hypoxia to Counteract Radiation-Induced Gastrointestinal Toxicities
Throughout this introductory chapter we have discussed that in addition to being
recalcitrant to immunotherapy, PDAC is also quite resistant to radiotherapy, due to its profoundly
hypoxic state (see section 1.3 The Burden of Pancreatic Cancer, its Tumor
Microenvironment & Current Treatments and section 1.4 How Cancers Hijack the
Hypoxic Response to Thrive). This is unfortunate because radiotherapy is given locally and
non-invasively, and it can be used to shrink tumors enough to make them surgically resectable,
thus enabling the only curative option.77 In fact, high dose radiation has been shown to improve
survival in patients with unresectable PDAC.138 However, curative radiation doses to tumors
in the head of the pancreas are almost unachievable, due to their proximity to the highly
radiosensitive small intestine. 78, 139 Indeed, many clinical trials have underscored how
common gastrointestinal (GI) radiotoxicity is among cancer patients. 140-142 Consequently, PDAC radiotherapy (as well as radiation to other abdominal cancers) is administered at
sub-curative doses to avoid GI radiotoxicity. Thus, radiation-induced GI toxicities are the
strongest impediment to improving radiation treatments for unresectable PDAC, which
represent ~76% of PDAC cases.
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Figure 4. The intestinal crypt.

Radiation leads to intestinal injury by inducing cell death in the crypt intestinal stem cell
(ISC, Figure 4) and endothelial compartments.143, 144 The small intestine is constantly turning
over, which allows it to sustain perpetual mechanical and genotoxic stress.144, 145 Under normal
physiological conditions, the intestinal crypts maintain a functional GI absorptive lumen through
ISC self-renewal and production of a constant supply of epithelial cells.146 ISC death, such as that
induced by radiation, impairs intestinal crypt regeneration and leads to a shortage of the reserve
cells that replace cells undergoing turnover, causing subsequent blunting of the villi.143, 145, 147
This in turn compromises epithelial integrity, resulting in mucosal barrier dysfunction,
malabsorption, diarrhea, electrolyte imbalances, dehydration, bacterial translocation into the
bloodstream, sepsis, and potentially death.144
Recent clinical trials using highly precise 3D conformal radiation modalities, such as
stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy, have shown better
patient outcomes,138, 148, 149 yet these modalities still do not entirely elude the small intestines.
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More importantly, these sophisticated modalities are not widely accessible, as they require costly
equipment and advanced expertise that is limited to some academic centers in developed nations.
Thus, biological approaches to decreasing GI radiotoxicity might be more accessible and
sustainable.
An alternative to reduce GI radiotoxicity to cancer patients worldwide is to use a GI
radioprotector to prevent radiation-induced damage and/or to improve GI regeneration and repair
following radiotherapy.148 Ideally, this radioprotector would be used prophylactically for patients
undergoing radiotherapy, and could possibly be used as a medical countermeasure too. However,
there are currently no FDA-approved radioprotectors of the GI tract. A radioprotector or mitigator
reduces cell death and tissue damage and/or promotes tissue regeneration. The following three
paragraphs summarize the GI radioprotectors that are in clinical investigational phases
(amifostine, avasopasem/rucosopasem, Entolomid™, Ex-RAD®, and and OrbeShield™), as well
as another promising GI radioprotector that is still in pre-clinical stage (gamma-tocotrienol).
Amifostine, also known as WR-2721 in the literature, is the only FDA-approved
radioprotective drug, and it is indicated for cancer patients receiving head and neck radiation, to
prevent salivary gland injury150 and mucositis.151 Amifostine is a pro-drug free radical scavenger
that also protects against chemotherapy-induced kidney and neural injury.150 Interestingly,
amifostine transiently stabilizes HIF1 via changes in mitochondrial membrane potential and ROS
levels, though HIF2 levels were not assessed in this study.152 However, due to its mechanism of
scavenging free radicals, amifostine is short-lived and thus needs to be administered just before
the radiation exposure (< 30 min).150 Moreover, it causes severe side effects, including severe
hypotension, nausea, and vomiting, which limit its clinical utility.153 Amifostine is given
intravenously, and not orally, because there is significant enteral metabolism into its active form,
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preventing the drug from reaching therapeutic levels in circulation.154 Our lab took advantage of
this pharmacologic limitation, which allows enough accumulation of amifostine’s active form
only in the small intestine, and proved that its oral administration prevents radiation-induced death
from GI toxicity in mice, and prolong survival in spontaneous PDAC models treated with
SBRT.155 However, additional studies are warranted to test the safety profile on PDAC patients,
as well as to test whether combining high dose SBRT and oral amifostine radioprotection with
chemotherapy and/or immunotherapies provides better outcomes.
Avasopasem and rucosopasem, also known as GC4419 and GC4711, respectively, are
selective superoxide dismutase mimetic analogs that both radioprotect the GI tract and
radiosensitize cancer cells.148, 156, 157 Rucosopasem is currently being investigated in combination
with SBRT following chemotherapy in PDAC patients in a Phase 2b clinical trial
(NCT04698915).157
Three additional drugs are currently being evaluated in Phase 1 clinical trials as GI (+/bone marrow) radioprotection countermeasures, following the Animal Rule of the FDA:
Entolimid™ (CBLB502), Ex-RAD® (ON01210), and OrbeShield™ (beclomethasone 17,21diproprionate).158 Entolimid™ is a Toll-like receptor 5 agonist, derived from bacterial flagellin,
that activates NF-κB signaling and protects the GI and bone marrow systems from radiation
injury.159 This drug has several Phase 1 studies ongoing, and a completed one revealed a good
safety profile.159 Ex-RAD® is a small molecule kinase inhibitor that activates PI3K/Akt signaling
and protects the GI and bone marrow systems from radiation injury, and successfully completed
Phase 1 trials.158 OrbeShield™ is a highly potent corticosteroid that reduces radiation-induced GI
mucosal inflammation, and it successfully completed a Phase 1/2 study.158 All three drugs
received investigational new drug status from the FDA, and Entolimid™ and OrbeShield™ were
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also granted fast-track and organ drug statuses.158, 159 Lastly, gamma-tocotrienol is a vitamin E
isomer and HMG-CoA reductase inhibitor that has been shown to radioprotect the oral mucosa
and GI tract, and is currently in pre-clinical studies using non-human primates.158 Thus, there are
several promising GI radioprotectors on the pipeline, but their clinical utility and safety in cancer
patients remains to be studied.
As mentioned previously, the HIFs promote tissue healing by inducing tissue remodeling
and regeneration,160 stem cell survival and growth,20 as well as maintenance of epithelial
integrity.161 The intestine has a physiologic hypoxia gradient that forms along the crypt-villus axis
due to its vascular anatomy,162 and HIFs regulate various genes required for intestinal barrier
function.163 Hence, as could be intuited, mimicking hypoxia genetically and pharmacologically
counteracts radiation-induced GI toxicities.164, 165 Our group has shown that stabilization of HIF2,
but not HIF1, through inhibition or epithelial-specific KO of the EGLN family prevents radiationinduced death from GI toxicity in mice, without sparing tumors.164, 165 Inhibition of the EGLNs,
using a 2-OG analog called DMOG, improved ISC survival and crypt regeneration, as well as
increased tissue integrity and vessel density, in a Vascular endothelial growth factor (VEGF)dependent manner, suggesting an involvement of the endothelial compartment in the postradiation GI recovery.164 However, endothelial-specific stabilization of the HIFs did not prevent
radiation-induced death from GI toxicity, indicating that HIF2’s radioprotective effects are
through the ISC compartment.164
Given the oncogenic role that HIF2 seems to play in the PDAC epithelial compartment
(Table 2), it is important to note that EGLN inhibition using FG-4592 did not increase expression
of HIFs in tumors, because it appears that HIFs are already maximally expressed.165 Similarly,
other groups have shown that EGLN inhibition radioprotects ISCs.166, 167 Thus, targeting HIF2
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signaling is an attractive approach to counteract GI radiotoxicities in PDAC. Yet, the molecular
mechanisms by which HIF2 confers small intestinal radioprotection remain unclear. Dissecting
out these molecular mechanisms is important to better understand how hypoxia regulates normal
tissue dynamics and to develop well-characterized GI radioprotectors with minimal side effects.

1.7 Conclusions
Pancreatic cancer is a devastating disease that is characterized –from its inception to its
progression– by hypoxic pockets, stromagenesis, and immunosuppressive immune infiltration. In
this introductory chapter, we discussed the pathophysiology and burden of pancreatic cancer,
emphasizing the role of the tumor stroma and TME in disease progression and resistance to
treatments. Additionally, we outlined how living organisms sense oxygen and respond to hypoxia,
with special attention to the EGLN/HIF signaling axis. We reviewed how cancers, particularly
pancreatic cancer, hijack the hypoxic response to thrive. Conversely, we reviewed how the
hypoxic response can be exploited by normal tissues (i.e. the small intestines) to recover from
radiation injury. The known roles of HIF1 and HIF2 in pancreatic cancer were mentioned, and we
highlighted that their function within the pancreatic TME remained unknown. We discussed some
nuances of using and interpreting data from various mouse models, including important
differences in cancer types, technique used to establish the tumors, and whether mice are
immunocompetent. Finally, we outlined strategies to modulate the pancreatic tumor stroma,
emphasizing those that target CAFs.

31

1.8

Hypotheses and Research Goals
This dissertation investigates the role of the hypoxia-inducible factors, the major

mediators of the hypoxic response, in pancreatic cancer with the objective of exploiting this
tumor’s profoundly hypoxic status to improve immunotherapy and radiotherapy. Despite the
obvious relationship of pancreatic cancer to hypoxia, the tumor stroma, and therapy resistance,
the role of the HIFs within the tumor stroma remains unknown. I hypothesize that the HIFs drive
TME immunosuppression through the tumor stroma and CAFs. I further hypothesize that by
targeting the HIFs, we can improve responses to immunotherapy in pancreatic cancer. In the
second chapter, we investigated the function of HIF1 and HIF2 in pancreatic CAFs using an
autochthonous PDAC model that employs two recombinases in order to genetically engineer two
cellular compartments independently. Moreover, because PDAC is profoundly hypoxic and likely
displays maximal stabilization of the HIFs, I also hypothesize that HIF2’s regenerative function
in the small intestine can be exploited to optimize PDAC radiotherapy while reducing GI
radiotoxicities. Thus, in the third chapter, I explore the molecular mechanisms by which HIF2
confers small intestinal radioprotection. Dissecting out these molecular mechanisms is important
in order to develop GI radioprotective strategies that enable intestinal regeneration without
protecting tumors.
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Chapter II: Stromal HIF2 Regulates the Pancreatic Tumor Immune
Microenvironment and is a Potential Therapeutic Target to Enhance Responses
to Immunotherapy

A portion of this chapter is based upon “Garcia Garcia CJ*, Huang Y*, Fuentes NR*, Turner
MC, Monberg ME, Lin D, Nguyen ND, Fujimoto TN, Zhao J, Lee JJ, Bernard V, Yu M,
Delahoussaye AM, Jimenez Sacarello I, Caggiano EG, Phan J, Deorukhkar A, Molkentine JM,
Saur D, Maitra A, Taniguchi CM. Stromal HIF2 Regulates Immune Suppression in Pancreatic
Cancer. Gastroenterology. 2022;S0016-5085(22)00154-8. [Online ahead of print.] doi:
10.1053/j.gastro/2022.02.024. *Authors contributed equally to this work.” This is an openaccess article, available under the Creative Commons CC-BY-NC-ND license and
permits non-commercial use of the work as published, without adaptation or alteration
provided the work is fully attributed.
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2.1 Abstract
Background & Aims. PDAC has a hypoxic, immunosuppressive stroma, which contributes
to its resistance to immune checkpoint blockade therapies. The HIFs mediate the cellular response
to hypoxia, but their role within the PDAC tumor microenvironment remains unknown.
Methods. We used a dual recombinase mouse model to delete Hif1a or Hif2a in α-smooth
muscle actin (αSMA)-expressing CAFs arising within spontaneous pancreatic tumors. The effects
of CAF HIF2 expression on tumor progression and composition of the tumor microenvironment
were evaluated by Kaplan-Meier analysis, quantitative real-time polymerase chain reaction,
histology, immunostaining, and by both bulk and single-cell RNA sequencing. CAF-macrophage
crosstalk was modeled ex vivo using conditioned media from CAFs after treatment with hypoxia
and PT2399, a HIF2 inhibitor currently in clinical trials. Syngeneic flank and orthotopic PDAC
models were used to assess whether HIF2 inhibition improves response to immune checkpoint
blockade.
Results. CAF-specific deletion of Hif2a, but not Hif1a, suppressed PDAC tumor
progression and growth, and improved survival of mice by 50% (n = 21-23 mice/group, Log-rank
P = .0009). Deletion of CAF-HIF2 modestly reduced tumor fibrosis and significantly decreased
the intratumoral recruitment of immunosuppressive M2 macrophages and regulatory T cells.
Treatment with the clinical HIF2 inhibitor PT2399 significantly reduced in vitro macrophage
chemotaxis and M2 polarization, and improved tumor responses to immunotherapy in both
syngeneic PDAC mouse models.
Conclusions. Together, these data suggest that stromal HIF2 is an essential component of
PDAC pathobiology and is a druggable therapeutic target that could relieve tumor
microenvironment immunosuppression and enhance immune responses in this disease.
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Figure 5. Graphical abstract of Chapter 2. Created with BioRender.com.

2.2 Introduction and Rationale
PDAC responds poorly to most cancer treatments, including immunotherapy.68 This
therapeutic recalcitrance may stem from PDAC’s extensive desmoplastic stroma, which
suppresses anti-tumor immunity119 and increases intratumoral pressure,117 resulting in severe
hypoxia73 and impaired drug delivery.116 CAFs are the main components and producers of stroma
in PDAC.115 Efforts to physically disrupt the hypoxic stromal component through Sonic hedgehog
protein inhibition,126 selective fibroblast depletion, or recombinant human hyaluronidase168 have
effectively lowered stromal content but paradoxically led to worse outcomes in both preclinical
studies and clinical trials. These data argue that the initially promising strategy of physically
ablating the PDAC stroma may be clinically counterproductive, warranting a different approach.
HIF1 and HIF2 are stabilized in low oxygen and have been hypothesized to mediate the
therapeutic resistance94, 169 and aggressive growth of PDAC.86, 89 Deletion of HIF191 or HIF283 in
the pancreatic epithelial compartment failed to change overall survival in mice with spontaneous
PDAC. However, the function of HIFs in other prominent compartments of the pancreatic TME
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remains unclear. Given the importance of the tumor stroma in PDAC oncobiology, we
investigated the role of HIF signaling in CAFs and its impact on the PDAC TME.
Here, we elucidated the function of the HIFs within the PDAC stroma using a dual
recombinase model to spatiotemporally alter HIF1 or HIF2 signaling only in activated fibroblasts
reprogrammed within spontaneous murine pancreatic tumors (i.e. CAFs). We found that CAFspecific deletion of HIF2, but not HIF1, improved survival from pancreatic cancer by reducing
the recruitment of immunosuppressive macrophages. We further showed that therapeutic HIF2
inhibition improved responses to immune checkpoint blockade, indicating this is a potential
combinatorial therapeutic strategy for PDAC.

2.3 Materials and Methods
Mice
All experimental mouse work adhered to the standards articulated in the Animal Research:
Reporting of In Vivo Experiments guidelines. Additionally, all mouse work was approved by the
Institutional Animal Care and Use Committee of The University of Texas MD Anderson Cancer
Center. Both female and male mice were used in this study. Mice were maintained on a 12-hour
light/dark cycle and were provided with sterilized water and either standard rodent chow (Prolab
Isopro RMH 3000 irradiated feed) or a tamoxifen diet (Teklad, TD.130855, 250 mg
tamoxifen/kg). Experiments were carried out during the light cycle.
FSF-KrasG12D/+;P53frt/frt mice were gifts from Dr. David Kirsch (Duke University)170, 171.
Pdx1Flp/+ mice were gifts from Dr. Dieter Saur (Technical University, Munich)172. αSMACreERT2/+
mice were gifts from Dr. Richard Premont (Case Western Reserve University)173. Hif1α
(RRID:IMSR_JAX:007561),

Hif2α

fl/fl

(RRID:IMSR_JAX:008407),
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fl/fl

LSL-tdTomato

(RRID:IMSR_JAX:007914), and C57BL/6 (RRID:IMSR_JAX:000664) mice were obtained
from Jackson Laboratories. FSF-KrasG12D/+;P53frt/frt mice were bred with Pdx1Flp mice to produce
FSF-KrasG12D/+;P53frt/frt;Pdx1Flp/+ (KPF) mice. KPF mice were bred with αSMACreERT2/+ mice and
their progeny were bred with Hif1α fl/fl and Hif2α fl/fl mice to produce KPF CAF-HIF1 and KPF
CAF-HIF2 mice, respectively. LSL-KrasG12D/+;Trp53fl/fl;Ptf1aCre/+ (KPC) mice and EGLN1/2/3fl/fl
mice were previously bred and backcrossed to C57BL/6 mice in our lab.164, 165 Genotyping was
performed as described previously.23, 174 Littermate controls were used in all experiments. Mice
were screened for tumors by weekly ultrasounds as previously described.165

Isolation of Fibroblasts and CAFs
Mice harboring a tdTomato reporter were bred with αSMACreERT2/+;Hif2α
produce αSMACreERT2/+;Hif2α

fl/fl

fl/fl

mice to

;tdTomatoLSL/LSL mice. Normal pancreata from the tdTomato

progeny and from EGLN1/2/3fl/fl mice, and whole tumors from KPC and KPF CAF-HIF2 mice
were minced and digested with 1 mg/mL Collagenase V (Sigma, C9263-500MG) for 30 minutes
at 37°C and 130 rpm/min followed by digestion with TrypLE (Thermo Fisher Scientific,
12605036) for 10 minutes at 37°C. Cells were seeded in T175 flasks with DMEM (ATCC, 302002) plus 10% (v/v) FBS (MilliporeSigma, F4135) and 1% Pen/Strep. Upon reaching 70%
confluence, cells were passaged and incubated at 37°C for 30 minutes before the media was
refreshed. The attached cells became enriched for fibroblasts or CAFs after 5-10 passages. Normal
fibroblasts were immortalized with a pBABE-hygro-hTERT lentivirus175 (Addgene plasmid
#1773; RRID:Addgene_1773), which was a gift from Bob Weinberg.
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Ex Vivo Analysis of Recombination in αSMA+ Fibroblasts
Hif2α

fl/fl

; αSMACreERT2/+; tdTomatoLSL/LSL fibroblasts were treated with DMSO, 4-

hydroxytamoxifen (4-OHT), or Adeno-Cre as a positive control. Fibroblasts were then genotyped
as described previously23 and imaged with an Olympus FV500 laser scanning confocal
microscope (Olympus USA).

Histopathology, Immunohistochemistry, and Immunofluorescence
Spontaneous PDAC tumors were harvested from KPF CAF-HIF2 wild-type (WT) and
knockout (KO) mice and fixed with 10% neutral buffered formalin, subjected to ethanol
dehydration, washed in Histoclear (National Diagnostics, HS2001GLL), and embedded in
paraffin. Then 5-µm-thick tissue slices were cut, mounted onto slides, and stained with H&E.
Masson’s trichrome staining was performed in the Research Histology Core Lab at MD Anderson.
Histopathologic assessment of H&E staining and fibrosis scoring of trichrome-stained tumor
slides were performed by a pathologist, who was blinded to genotype.
Immunohistochemistry (IHC) was performed as previously described165 using anti-HIF2a
(1:200,

Abcam

ab199,

RRID:AB_1140040),

RRID:AB_302739),

anti-Meca32

(1:200,

anti-F4/80
Novus

(1:200,
Biologicals

Abcam

ab6640,

NB100-77668,

RRID:AB_1084448), and anti-FoxP3 (1:200, Abcam ab20034, RRID:AB_445284) antibodies.
Slides were counterstained with Hematoxylin QS (Vector Laboratories, H3404-100,
RRID:AB_2336843) and imaged with a BioTek Cytation 5 Cell Imaging Multi-Mode Reader
(RRID:SCR_019732) or Leica Aperio CS2 digital pathology slide scanner. F4/80 and FoxP3
images were analyzed by quantifying the number of positively stained cells per field (20x). For
vessel density analysis, the National Institutes of Health (NIH)’s ImageJ software (ImageJ,
38

RRID:SCR_003070; Fiji, RRID:SCR_002285) was used with a custom macro to identify, mask,
and determine %vessel coverage.
Immunofluorescence (IF) was performed using anti-HIF2α (1:200, Abcam ab199) and
anti-αSMA (1:200, Abcam ab7817, RRID:AB_2223021) and secondary antibodies goat antiRabbit Alexa Fluor 555 (1:200, ThermoFisher A-21429, RRID:AB_2535850) and goat antiMouse Alexa Fluor 488 (1:200, ThermoFisher A-11029, RRID:AB_2534088). Analysis was
performed using National Institutes of Health ImageJ software with a custom macro to quantify
relative fluorescent intensity of HIF2α in αSMA+ cells. Briefly, αSMA was used to define a
binary cell mask that was applied to HIF2α images. Average fluorescent intensity of the mask
images was subsequently recorded.

Generation of HIF2 KO CAF Cell Line
Please see “Isolation of Fibroblasts and CAFs” above for details about how the KPFderived Hif2fl/fl CAF lines were harvested and established. Recombination was induced ex vivo
via infection with Adeno-Cre-eGFP (VVC-U of Iowa-1174) or control Adeno-eGFP (VVC-U of
Iowa-4) at MOI 100. Viral vectors were provided by the University of Iowa Viral Vector Core.
(http://www.medicine.uiowa.edu/vectorcore). For single subclone expansion, 500 cells were
seeded in 10 cm2 plates and colonies were allowed to form. Single colonies were picked and
expanded, then PCR genotyping23 and immunoblotting165 were performed as previously described
to validate HIF2 KO in pure subclones. For immunoblotting, anti-HIF2α (1:500, Abcam ab199)
and anti-Vinculin (1:1000, Cell Signaling Technology, 13901).
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Cell Line Immunofluorescence
For quantitative nuclear HIF1 analysis, HIF2 WT and HIF2 KO CAFs were seeded in cell
imaging 8 chamber cover glass slides (Cellvis, C8-1.5H-N) and allowed to attach for 24 h. Cells
were subsequently treated with DMSO or FG4592 (50 μM) for 48 hrs. After 48 h, cells were fixed
with a 4% solution of PFA in cytoskeleton stabilizing buffer (PEM, 80 mM PIPES pH 6.8, 5 mM
EGTA, 2 mM MgCl2) for 15 min at room temperature,176, 177 permeabilized with 0.3% Triton X100 for 10 min, blocked with 10% goat serum (Millipore Sigma, S26-100ML) for 1h and
incubated with primary anti-HIF1α (1:500, Abcam ab179483, RRID:AB_2732807) in
dilution/wash buffer (PBS, 1% BSA, 0.1% Tween-20) for 1h at room temperature. Cells were
then washed with washed buffer 3 times, incubated with secondary (1:1000, Goat anti-Rabbit
640R, Biotium 20176-1) for 1h at room temperature, rinsed with wash buffer twice, counter
stained with membrane (2 μg/ml, WGA-640R, Biotium 29026-1) and nuclear (1:2000, Hoechst
33342, ThermoFisher, H3570) stain and rinsed with PBS twice before imaging. Cells were imaged
with a Ziess LSM 880 confocal microscope using a 63x oil objective. For quantitative nuclear
HIF1α analysis, confocal images were opened in NIH’s ImageJ software (ImageJ,
RRID:SCR_003070; Fiji, RRID:SCR_002285), and a custom macro was used to quantify relative
fluorescent intensity of HIF1α in nuclei. Briefly, Hoechst signal was used to define a binary
nuclear mask that was applied to HIF1α images. Average fluorescent intensity of the mask images
was subsequently recorded.

Epithelial HIF1 and HIF2 KO
We isolated epithelial PDAC cells from KPF-HIF1fl/fl or KPF-HIF2fl/fl mice and induced
recombination ex vivo via infection with Adeno-Cre or control Adeno-GFP. Recombined KPF
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cells were resuspended in PBS and Matrigel in a 1:1 ratio and orthotopically implanted into the
pancreata of immunocompromised mice.

Bulk RNA Sequencing
Frozen tumors from KPF CAF-HIF2 WT and KO mice were homogenized and RNA was
purified using an RNeasy mini kit (QIAGEN, 74106). Library preparation and sequencing were
performed in the Sequencing and Microarray Facility at MD Anderson. RSEM software package
(RRID:SCR_013027) was used to quantitate transcript abundance from RNA-seq data.178
Differential

expression

analysis

was

performed

using

DESeq2

software

package

(RRID:SCR_015687). Gene Set Enrichment Analysis was performed to identify significantly
enriched pathways (FDR < 0.15). This dataset can be accessed in NCBI’s GEO repository
(https://www.ncbi.nlm.nih.gov/geo/) using accession number GSE191474.

CAF Conditioned Media Harvest
CAFs isolated from KPC tumors and immortalized normal fibroblasts isolated from
EGLN1/2/3fl/fl mice were seeded in DMEM with 10% FBS and 1% Pen/Strep at 5 x105 density in
60-mm cell plates and cultured overnight. The media was replaced with DMEM containing 0.5%
FBS, and cells were transferred to a hypoxia chamber (InvivO2, Baker Ruskinn) set at 1% O2 and
treated with increasing concentrations of PT2399 (Peloton Therapeutics/Merck) for 48 hours.179
Cell media was collected and centrifuged at 3,000 rpm for 5 minutes, and the supernatant was
filtered through a 40 µm strainer (Corning, 352340) and stored as conditioned media (CM) at 80°C. CM was diluted 1:1 with DMEM plus 10% FBS before experimental use to replenish
nutrients depleted during media conditioning.
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Macrophage Culture and Activation
Authenticated RAW 264.7 murine macrophages were purchased from ATCC (TIB-71,
RRID:CVCL_0493) and maintained in DMEM with 10% FBS at 37°C with 5% CO2. For
activation, macrophages were treated with 10 ng/ml IL4 (Peprotech, 214-14) and 10 ng/ml IL13
(Peprotech, 210-13) for 48h. Early passages were used for all experiments.

Macrophage Transwell Migration Assay
Migration was tested in 24-well Transwell permeable plates with 8-µm-pore polyester
membrane inserts (Corning, 3464). Macrophages were resuspended in DMEM with 0.5% FBS at
a concentration of 5x104 cells/mL and 100 µL of cell suspension was added to the upper chamber,
while 600 µL of CM from CAFs or normal fibroblasts was added to the lower chamber as a
chemoattractant. Cells were allowed to migrate through the membrane insert at 21% O2. After 22
hours, nonmigrating macrophages were gently removed from the top of the insert membrane with
a cotton swab. Migrated macrophages were fixed with 4% paraformaldehyde in PBS for 2
minutes, permeabilized with 100% methanol for 20 min at room temperature, stained with 0.5%
crystal violet solution in 70% ethanol for 15 minutes, and rinsed with DI water. Inserts were left
drying overnight before imaging. At least 3 random nonoverlapping fields (10x) were imaged
with a Leica DMi1 or a BioTek Cytation 5. ImageJ software (ImageJ, RRID:SCR_003070; Fiji,
RRID:SCR_002285) was used for analysis with a custom macro to identify, mask, and determine
percent macrophage coverage. Macrophage migration was normalized to the control condition in
each experiment and data from independent experiments were pooled.
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Reverse Transcription Quantitative Real-Time Polymerase Chain Reaction
Frozen tumors from KPF CAF-HIF2 WT and KO mice were homogenized and RNA was
purified using an RNeasy mini kit (QIAGEN, 74106) and reverse transcription was performed
with the QuantiTect reverse transcription kit (QIAGEN, 205313). Quantitative real-time
polymerase chain reaction (qPCR) was carried out using a QuantiFast SYBR Green PCR kit
(QIAGEN, 204056) on a StepOnePlus real-time PCR system (Applied Biosystems). RT-qPCR
analysis was also performed on RAW 264.7 murine macrophages and CAFs treated with the
indicated conditions; reverse transcription was performed with the iScript cDNA synthesis kit
(Bio-Rad, 170-8891) and RT-qPCR was carried out using iTaq Universal SYBR Green Supermix
(Bio-Rad, 172-5124). Hprt and Vcp were used as reference genes for CAFs; Ddx54 and Hsp90b1
were used as reference genes for macrophages. Primers used are listed in Table 3.
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Table 3. PCR and RT-qPCR Primer List, Chapter 2.
Gene Target

Primer Sequence or Catalog #

Acta2 F

GACTACTGCCGAGCGTGAG

Acta2 R

GTCAGCAATGCCTGGGTACA

Arg1 F

ACAAGACAGGGCTCCTTTCAG

Arg1 R

CTTGGGAGGAGAAGGCGTTT

C3ar1 F

TGCTCAGCAACTCGTCCAAT

C3ar1 F

ATGGAGGCAATGTCTTGGGG

Cd74 F

CTCCTTGGGCCTGTGAAGAA

Cd74 R

GTTACCGTTCTCGTCGCACT

Col1a1

Bio-Rad, Cat#10025636 (qMmuCED0044222)

Ctgf

Bio-Rad, Cat#10025636 (qMmuCED0003632)

Ddx54 F

ACGCGCACAACCATCTT

Ddx54 R

AGCTTTCCGGTCCCTCT

Fn1

Bio-Rad, Cat#10025636 (qMmuCID0045687)

Hif1a

Bio-Rad, Cat#10025636 (qMmuCID0005501)

Hif2a F

CAGGCAGTATGCCTGGCTAATTCCAGTT

Hif2a R-flox

CTTCTTCCATCATCTGGGATCTGGGACT

Hif2a R-KO

GCTAACACTGTACTGTCTGAAAGAGTAGC

Hsp90b1 F

AAAGGACTTGCGACTCGCC

Hsp90b1 R

ATCAGCTCTGACGAACCCGA

Itgam F

GGCAGCCAGATTGGCTCTTA

Itgam R

GCTTCACACTGCCACCGT

Mmp9 F

CAGCCGACTTTTGTGGTCTTC

Mmp9 R

GTACAAGTATGCCTCTGCCA

Tgfb-1 F

ACCGCAACAACGCCATCTAT

Tgfb-1 R

TGCCGTACAACTCCAGTGAC

Vcp F

TCGGCTATGGAGGTAGAAGA

Vcp R

ATCGCTGACAGAACGTCG

Vegfa F

TTCGTCCAACTTCTGGGCTC

Vegfa R

CTGGGACCACTTGGCATGG
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Single-Cell RNA Sequencing
Single-cell suspensions were prepared by mincing KPF CAF-HIF2 WT and KO tumors,
digesting them with 0.5 mg/mL Liberase (Sigma, LIBTH-RO 5401135001) for 30 minutes at 130
rpm, and passing them through a 100-µm cell strainer. Samples were then incubated with
Accutase (Sigma, A6964) for 10 minutes at 37°C in a shaker, followed by treatment with ACK
lysing buffer (ThermoFisher, A1049201) to eliminate erythrocytes. Samples were filtered through
a 30-µm cell strainer and single cells were resuspended in PBS (GE Healthcare Life Sciences,
SH30256.01) with 0.1% BSA. Cell viability was measured using Trypan Blue (Bio-Rad,
1450021). Single-cell suspensions were loaded into a 10x Genomics Chromium instrument to
generate gel beads in emulsion. Approximately 5,000 cells were loaded per channel. Single-cell
complementary DNA (cDNA) libraries were prepared using a Chromium Single Cell 3’ Library
& Gel Bead kit v2 (10x Genomics, PN-120237) and sequenced using a NextSeq 500 (Illumina).
The mean number of reads per cell was approximately 25,000 and the median number of genes
detected per cell was approximately 2,000.
The raw data were processed using cellranger count (Cell Ranger v2.1.1, 10x Genomics)
based on the mm10 mouse reference genome. Subsequent data analysis was done in R using the
Seurat package v3.1 (RRID:SCR_007322) with default parameters.180 Dead cells were excluded
by retaining cells with less than 20% mitochondrial reads, leaving 20,802 cells for downstream
analysis. We performed batch correction using the scMC algorithm with default parameters.181
Log normalization, variable feature identification (FindVariableFeatures), and z-scoring
(ScaleData) were applied to the merged object of all cells, and principal component analysis
(RunPCA, npcs = 30) with subsequent Uniform Manifold Approximation and Projection (UMAP)
dimensionality reduction and graph-based clustering of cells were performed. Markers for each
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cluster were identified using Seurat’s FindMarkers command and clusters were assigned to cell
populations using published signature genes.182 Gene expression for genes of interest was then
quantified across cell type groupings.

Immunotherapy Experiments
We obtained KPC cells from Dr. Anirban Maitra that were authenticated by short tandem
repeat profiling and were confirmed to be Mycoplasma free by real-time PCR (CellCheck Mouse
19 Plus, IDEXX Laboratories, Inc.). For the flank model, 1 x 106 KPC cells were resuspended in
PBS and Matrigel (Corning) in a 1:1 ratio and subcutaneously implanted into the right flanks of
syngeneic 10-week-old C57BL/6 female mice. Murine aCTLA4 (BioXCell, BE0164) or isotype
control was administered intraperitoneally (IP) every 3-4 days at 250 µg/mouse beginning 13 days
after implantation. PT2399 was resuspended in 10% ethanol, 30% PEG400, and 60%
methylcellulose/water/Tween 80 and administered 5 days per week (Monday-Friday), twice daily,
at 50 mg/kg via oral gavage. Treatments lasted 2 weeks, and tumor dimensions were measured
with a caliper to calculate approximate volumes.
For the orthotopic model, 2 x 105 KPC cells were resuspended in PBS and Matrigel in a
1:1 ratio and injected into the tail of the pancreas of syngeneic 12-week-old C57BL/6 male mice.
After 2 weeks of recovery, murine aCTLA4 (clone 9D9, Merck) and murine aPD1 (muDX400,
Merck) or isotype control were administered IP every 4 days at 20 µg/mouse, 200 µg/mouse, and
220 µg/mouse, respectively, for 2 weeks. PT2399 was administered 5 days per week, twice daily
for 3 weeks, at 50 mg/kg via oral gavage. Tumor burden was monitored by ultrasound as
previously described. Mice were age-matched, but group assignment was unblinded.
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Hematopoietic Toxicity Study
For the hematopoietic toxicity study, 1 x 105 KPC cells were resuspended in PBS and
Matrigel in a 1:1 ratio and injected orthotopically into the tail of the pancreas of syngeneic 12week-old C57BL/6 male mice. After 2 weeks of recovery, we began treatment with PT2399 5
days per week, twice daily for 7 weeks, at 50 mg/kg via oral gavage. Terminal blood collection
via cardiac puncture was performed at the study endpoint and complete blood count analysis was
done at the MD Anderson Department of Veterinary Medicine & Surgery Pathology Core.

Statistical Methods
Survival was analyzed by the Kaplan-Meier method and log-rank test. Student‘s t test and
one-way ANOVA were used to analyze parametric data sets with two groups and more than three
experimental groups, respectively, unless otherwise noted on the figure legend. The Mann–
Whitney U test was used to analyze non-parametric data sets. All statistical analyses were
performed using GraphPad Prism V.8 (RRID:SCR_002798), with a significance level of a = .05.

2.4 Results
Deletion of Stromal HIF2 Delays Pancreatic Cancer Progression and Enhances
Survival
We used a dual recombinase system to constrain the deletion of Hif1a or Hif2a to CAFs
within autochthonous PDAC tumors. Mice with FlpO-responsive alleles of both oncogenic Kras
(FSF-KrasG12D/+)170 and homozygous Trp53 (Trp53frt/frt)171 were crossed with mice expressing
FlpO in pancreatic tissue (Pdx1-FlpO)172 to generate KPF mice. These mice developed
spontaneous PDAC over a timeframe and with a penetrance similar to those in KPC mice (Cre-
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Figure 6. Dual recombinase genetic strategy to develop a PDAC model with HIF1 or HIF2
knockout in aSMA+ cells in a tamoxifen-induced manner using KPF mice. Created with
BioRender.com

driven model), and both models recapitulate human PDAC172. KPF mice were subsequently bred
with mice harboring conditional null alleles of Hif1a (Hif1afl/fl)183 or Hif2a (Hif2afl/fl),23 driven
by expression of the Cre-ERT2 transgene under the control of the αSMA (also known as Acta2)
promoter which marks CAFs (Figure 6).173 We confirmed aSMA-Cre-ERT2– mediated deletion
of Hif1α or Hif2α through ex vivo analyses of activated fibroblasts isolated from tdTomato
reporter mice (Figure 7A-B). Moreover, both immunofluorescence and immunohistochemical
analyses of tumor sections showed a reduction of HIF2 expression in αSMA+ CAFs (Figure 7CD).
Once weaned, mice were fed normal chow or tamoxifen chow to generate KPF CAF-HIF1
and -HIF2 WT mice, or KPF CAF-HIF1 and -HIF2 KO mice respectively (Figure 8A). Mice
were screened for tumors weekly by ultrasound. The median age at tumor onset was 10.3 weeks
(range: 7.1–21.1) in both the WT and KO groups. Surprisingly, loss of stromal HIF1 had no effect
on tumor growth or survival tumor growth or survival (median survival, 91 days for KO versus
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Figure 7. Validation of dual recombinase model to generate KPF CAF-HIF2 mice. (A and B)
Fibroblasts isolated from the pancreata of Hif2αfl/fl; αSMACreERT2/+; LSL-tdTomato mice were treated with
vehicle DMSO (veh), adenovirus-Cre (Ad-Cre) as a positive control, or 4-hydroxytamoxifen (4-OHT)
ex vivo. (A) Bright-field (BF) and fluorescent microscopy confirmed activation of the Cre-ERT2 fusion
protein in activated αSMA+ fibroblasts. Scale bars, 100 µm. (B) PCR genotyping confirmed Hif2α KO.
(C) Representative IHC images of KPF CAF-HIF2 WT and KO tumors stained for HIF2 (n = 5/group).
Scale bars, 20 µm. (D) Left: Representative IF images of KPF CAF-HIF2 WT (continued in next page)
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Figure 8. Deletion of stromal HIF2, but not HIF1, delays PDAC progression and enhances
survival. (A) Experimental design to generate KPF CAF-HIF1/2 wildtype (WT) control and KPF early
CAF-HIF1/2 KO mice. Created with BioRender.com. (B) Left: Kaplan-Meier curves showing
percentage survival for KPF CAF-HIF1 WT (n = 16) and KO mice (n = 13). Right: Corresponding tumor
weights for KPF CAF-HIF1 WT (n = 9) and KO mice (n = 7). (C) Left: Kaplan-Meier curves showing
percentage survival for KPF CAF-HIF2 WT (n = 21) and KO (n = 23) mice. Right: Corresponding tumor
weights for KPF CAF-HIF2 WT (n = 21) and KO (n = 15) mice. P, by log-rank test for percentage
survival and by Student’s t test for tumor weights; ns, not significant. All error bars are mean ± SEM.

100 days for WT; Figure 8B). In contrast, HIF2 ablation in CAFs significantly decreased tumor
growth and improved survival (median survival, 120 days for KO versus 80 days for WT; n = 2123 mice/group, Log-rank P = .0009; Figure 8C). Histological analyses of the pancreata revealed
well-differentiated PDAC foci in both CAF-HIF2 WT and CAF-HIF2 KO groups, yet remarkably,
(Continued Figure 7 legend) and KO tumors stained for αSMA and HIF2 (n = 3-5 fields of view/group).
Scale bars, 50 µm and 10 µm. Right: Quantitative analysis of mean αSMA-specific HIF2 intensity per
field of view (FOV).
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Figure 9. Histopathological analyses of PDAC tumors with CAF-specific HIF2 ablation. (A)
Representative images of H&E-stained KPF CAF-HIF2 WT (n = 12) and KO (n = 14) tumors. Scale
bars, 50 µm. (B and C) Quantification of the differentiation state of the tumors in (A). The fractions of
each pancreas that were necrotic tissue, poorly differentiated PDAC (PD-PDAC), well-differentiated
PDAC (WD-PDAC), pancreatic intraepithelial neoplasia (PanIN), or normal tissue were scored in a
blinded manner, and values are shown averaged per group (B) or shown per individual mouse (C). (D)
Left: Representative images of Masson’s trichrome staining in KPF CAF-HIF2 WT (n = 12) and KO (n
= 8) tumors; scale bars, 50 µm. Right: Fibrotic score; median ± interquartile range; P, by Mann–Whitney
U test. (E) Proportion of KPF CAF-HIF2 WT and KO mice presenting distant (continued in next page)
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we found no gross or microscopic evidence of tumor tissue in the sections analyzed from six of
the HIF2-depleted mice, suggesting that deletion of stromal HIF2 may also influence PDAC
oncogenesis and/or progression (Figure 9A-C).83 Importantly, there were no statistically
significant differences in tumor fibrosis associated with KPF CAF-HIF2 KO (n = 8-12
tumors/group, P = .051; Figure 9D), indicating that this approach does not physically disrupt the
tumor stroma.97 Because stromal modulation, particularly of αSMA+ CAFs, impacts PDAC
metastasis,125, 131 we evaluated metastatic burden at the time of death and found no statistically
significant differences in the proportion of KPF CAF-HIF2 WT and KO mice that presented with
distant metastasis (0.45 for WT versus 0.32 for KO; n = 19-20 mice/group, P = .514; Figure 9E).
These results indicate that survival in KPF CAF-HIF2 KO mice was driven by lower primary
tumor burden.
Moreover, the survival advantage seen in mice with deletion of HIF2 in CAFs was not
dependent on Trp53 gene dosage, as CAF-specific loss of HIF2 in KPF mice heterozygous for
Trp53 also exhibited significantly improved survival compared to CAF-HIF2 WT littermates
(median survival, 375 days for KO versus 237 days for WT; n = 5-10 mice/group, Log-rank P =
.0103; Figure 10A). The tumor weights, histopathological quantification, and metastasis rate for
Trp53het KPF CAF-HIF2 WT and KO mice are shown in Figure 10B-E.
We next assessed how stromal HIF2 deletion after PDAC onset impacted survival, as this
would more closely reflect the timeline of therapeutic HIF2 targeting in patients. We generated
another cohort of KPF αSMA-HIF2fl/fl mice and fed them normal chow or tamoxifen chow after
tumors were diagnosed by ultrasound (Figure 11A). This late abrogation of HIF2 in CAFs still
improved survival by 37.3% compared to the survival of control mice (median, 114 days versus
(Continued Figure 9 legend) metastasis; P, by Fisher’s exact test.
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Figure 10. Histopathological analyses of Trp53 heterozygous PDAC tumors with CAF-specific
HIF2 ablation. (A) Kaplan-Meier curves showing percentage survival for Trp53 heterozygous
(Trp53het) KPF CAF-HIF2 WT (n = 5) and KO mice (n = 10). P, by log-rank test. (B) Corresponding
tumor weights for KPF CAF-HIF2 WT (n = 5) and KO mice (n = 4). Mean ± SEM; P, by Student’s t
test. (C and D) Quantification of the differentiation state of the tumors in (A and B). The fractions of
each pancreas that were necrotic tissue, poorly differentiated PDAC (PD-PDAC), well-differentiated
PDAC (WD-PDAC), pancreatic intraepithelial neoplasia (PanIN), or normal tissue were scored in a
blinded manner, and values are shown averaged per group (C) or shown per individual mouse (D); n =
4-6 mice/group. (E) Proportion of KPF CAF-HIF2 WT and KO mice presenting distant metastasis; P,
by Fisher’s exact test.
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Figure 11. Late deletion of stromal HIF2 delays PDAC progression and enhances survival. (A)
Experimental design to generate post-diagnosis (post-Dx) KPF CAF-HIF2 WT and KO mice. Created

with BioRender.com. (B) Kaplan-Meier curves showing percentage survival for post-Dx KPF CAFHIF2 WT (n = 10) and KO (n = 7) mice. P, by log-rank test.

83 days; P = .002; Figure 11B), which was similar to the median survival of mice receiving
tamoxifen chow at weaning. Together, these data suggest that stromal HIF2, but not HIF1, plays
a critical role in PDAC development and progression.
To confirm that this survival advantage was mediated by HIF2 depletion in CAFs, and not
in tumor cells, we isolated cancer cells from KPF tumors with Hif1afl/fl or Hif2afl/fl alleles and
induced ex vivo recombination by infection with Cre or control GFP adenovirus. These KPF cells
were orthotopically implanted into the pancreata of immunocompromised mice (Figure 12A).
We found that deletion of HIF1 or HIF2 in tumor cells had no impact on tumor growth (Figure
12B-C), confirming cell non-autonomous functions of HIF in PDAC.
Moreover, to confirm that our phenotype was due to abrogation of HIF2 in CAFs, and not
due to a potential compensatory increase in HIF1 expression, we analyzed CAFs from KPF
tumors ex vivo. Hif2αfl/fl CAFs were harvested from KPF tumors using a combination of enzymatic
digestion, outgrowth, and clonal isolation (Figure 13A-B). CAF identity was validated at the
RNA level via RT-qPCR for fibroblast and epithelial markers, and the clones with the highest
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Figure 12. KPF pancreatic cancer cell-specific HIF1 or HIF2 knockout does not affect PDAC
progression. (A) Cancer cells from KPF Hif1afl/fl or Hif2afl/fl tumors were isolated and infected ex vivo
with adenovirus-GFP (Ad-GFP) or adenovirus-Cre (Ad-Cre) and subsequently injected into the
pancreata of immunocompromised mice. Created with BioRender.com. (B and C) Comparison of the
orthotopic tumors showed no significant difference in tumor size between tumors with (B) Hif1a or (C)
Hif2a deletion and the respective WT controls. Mean ± SEM; ns, by Student’s t test.
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Figure 13. Isolation and characterization of KPF tumor-derived CAFs. (A) Hif2αfl/fl CAFs were
isolated from KPF tumors using a combination of enzymatic digestion, outgrowth, and clonal isolation.
CAF clones were validated prior to being infected with Ad-GFP or Ad-Cre to generate HIF2 WT and
HIF2 KO CAFs, respectively, which were then enriched via subclonal expansion and validated. Created

with BioRender.com. (B) Representative images of CAF clones showing spindle morphology (4X).
(C) CAF identity was validated at the RNA level via RT-qPCR. Murine duodenum was used as an
epithelial control as indicated. Mean ± SEM; P, by one-way ANOVA; *P ≤ .05, **P ≤ .01, ***P ≤
.001, ****P ≤ .0001; ns, not significant.
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Figure 14. Validation of HIF2 KO in KPF-derived CAF subclones. (A) HIF2 WT and HIF2 KO CAF
subclones were validated at the DNA level via PCR genotyping. (B) Pure subclones were treated with
DMSO or 50 µM FG-4592 for 48h at normoxia, and HIF2KO was validated at the protein level via
western blot analysis.

expression of αSMA (Acta2) were chosen for subsequent analyses (Figure 13A and 13C).
Hif2αfl/fl CAFs were infected with Ad-GFP or Ad-Cre to generate HIF2 WT and HIF2 KO CAFs,
respectively, which were then enriched via subclonal expansion. (Figure 13A). Pure HIF2 WT
and HIF2 KO CAF subclones were validated via DNA genotyping and western blots (Figure 14).
We found that HIF2 KO in CAFs did not cause a compensatory increase of HIF1 expression at
the mRNA or nuclear protein levels (Figure 15), suggesting that the survival advantage seen in
CAF HIF2-KO mice was specifically due to loss of HIF2 in CAFs.

Stromal HIF2 Regulates Macrophage Recruitment to Pancreatic Tumors
We performed bulk RNA sequencing (RNA-seq) to understand the mechanism by which
loss of HIF2 in CAFs suppressed tumor growth. Transcriptomic analysis revealed a stromal HIF2dependent gene downregulation signature (Figure 16) with the most conspicuous changes being
in pathways related to myeloid/macrophage biology (Figure 17A-B). Deletion of HIF2 in CAFs
led to downregulation of genes involved in macrophage migration, differentiation, and activation,
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Figure 15. HIF2 KO in KPF-derived CAFs does not affect HIF1 expression. (A) Representative IF
images of HIF2 WT and HIF2 KO CAFs treated with vehicle or FG-4592 showing merged maximum
intensity projection (top) and masked nuclear HIF1 (bottom). Scale bars, 20 µm. (B) Quantitative
analysis of mean nuclear HIF1 intensity FOV (n = 5 FOVs/group). (C) Hif1α expression was measured
by RT-qPCR. Data is representative of two independent experiments. All error bars represent mean ±
SEM; P, by Student’s t test.

including Mmp9, Cd74, Tgfb1, Itgam, and C3ar1; these results were validated by RT-qPCR
(Figure 17B-C). GSEA analysis did not reveal any upregulated gene sets that achieved statistical
significance. We next compared tumor-associated macrophage (TAM) infiltration by F4/80 IHC
and observed significantly fewer TAMs in KPF CAF-HIF2 KO tumors than in controls (n = 5
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Figure 16. Bulk tumor RNA-sequencing reveals a stromal HIF2-dependent gene signature. (A)
Heatmap of the top expressed genes using bulk RNA-seq data from KPF CAF-HIF2 tumors (n =
4/group). (B) Volcano plot illustrating total differential gene expression analysis from (A).

tumors/group, P = .028; Figure 17D). These results suggest that HIF2 signaling in CAFs regulates
macrophage recruitment to PDAC tumors.
To evaluate this hypothesis, we established CAF and normal fibroblast lines from
spontaneous KPC pancreatic tumors and normal pancreata, respectively. Both cell lines were
cultured in hypoxia to stabilize HIF2 and to approximate in vivo TME conditions, and were then
treated with either vehicle or the clinical HIF2 inhibitor PT2399.179 We found that conditioned
media from hypoxic CAFs stimulated RAW 264.7 macrophage migration in a HIF2-dependent
fashion (Figure 18A-B). Stimulation of RAW 264.7 macrophage migration by CAFs appears to
be specific to fibroblasts reprogrammed in the PDAC TME, as fibroblasts isolated from normal
pancreata lacked the ability to stimulate migration (Figure 18C-D). To confirm that the reduction
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Figure 17. Stromal HIF2 downregulates macrophage recruitment to PDAC tumors. (A) Gene sets
enriched in KPF CAF-HIF2 WT tumors compared to KO tumors ranked by normalized enrichment score
(NES; n = 4/group). Nom., nominal; FDR, false discovery rate. (B) Gene set enrichment analysis of
tumors in (A) correlates CAF-HIF2 function with macrophage migration, (continued in page 62)
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Figure 18. Hypoxic CAFs promote RAW 264.7 macrophage migration in a HIF2-dependent
paracrine fashion. (A) Conditioned media (CM) was collected from hypoxic KPC-derived CAFs
treated with veh or PT2399, and was then placed in the bottom chamber of a (continued in page 63)
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in migration that occurred with HIF2-inhibited CAF conditioned media was not due to biological
repercussions of carryover of residual PT2399, we directly added the drug to processed
conditioned media made from untreated hypoxic CAFs and found no differences in RAW 264.7
macrophage migration (Figure 18E-F). Moreover, direct treatment of RAW 264.7 macrophages
with PT2399 had no effect on transwell migration (Figure 18G-H). These results strongly suggest
that HIF2 coordinates CAF-TAM crosstalk and induces macrophage migration in a paracrine
fashion.

Hypoxic CAFs Promote Macrophage Polarization in a HIF2-Dependent Paracrine
Fashion
In many cancers, including PDAC, M2 macrophages are associated with worse outcomes
because they promote metastasis and suppress anti-tumor immune responses by expressing
checkpoint ligands and by inducing Tregs.104, 105 CAFs have been linked to M2 repolarization of
TAMs in PDAC,105 yet the roles of hypoxia and HIF2 in this context remain unclear. To
understand whether HIF2 signaling in CAFs drives macrophage M2 repolarization, we stimulated
RAW 264.7 macrophages with conditioned CAF media and assessed expression of Arg1, an M2
polarization marker (Figure 19A). We found that hypoxia in CAFs, and therefore HIF2
expression, increased Arg1 levels in RAW 264.7 macrophages by 4-fold compared to normoxic
CAFs (Figure 19B). Moreover , HIF2 inhibition via PT2399 in hypoxic CAFs impaired the ability
(Continued Figure 17 legend) differentiation, and activation. GO, gene ontology; NES, normalized
enrichment score. (C) RT-qPCR confirmed the downregulation of genes involved in the pathways in
(B). (D) Left: Representative IHC images of CAF-HIF2 tumors stained for F4/80 and counterstained
with Hematoxylin QS (n = 5/group). Scale bar, 50 µm. Right: Quantification of F4/80+ macrophages
per field. All error bars represent mean ± SEM and each dot denotes a biological replicate. P, by
Student’s t test.
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of conditioned media from these cells to induce M2 polarization, indicating that the paracrine
CAF signal is HIF2-dependent (Figure 19C). To confirm that this polarization was specific to
HIF2 function in CAFs and not an off-target effect of PT2399,184 we developed HIF2 WT and
HIF2 KO CAFs from KPF tumors and deleted Hif2α ex vivo with Cre or control GFP adenovirus
(Figures 13 and 14). We found that conditioned media from CAFs lacking Hif2a expression did
not enhance Arg1 expression in RAW 264.7 macrophages, confirming that our phenotype is
driven by abrogation of intrinsic HIF2 signaling in CAFs (Figure 19D-E). Conditioned media
from hypoxic normal pancreatic fibroblasts failed to induce M2 polarization (Figure 19F-G),
confirming that stimulation of macrophages by CAFs is specific to fibroblasts reprogrammed in
the PDAC TME. Furthermore, direct treatment of hypoxic or normoxic RAW 264.7 macrophages
with PT2399 did not affect their Arg1 levels (Figure 19H-K). Taken together, these findings
support the notion that hypoxic CAFs regulate TAMs in a HIF2-dependent paracrine fashion.
To assess whether HIF2 signaling regulates M2 polarization in non-transformed macro(Continued Figure 18 legend) transwell as a chemoattractant. (B) Representative bright-field images
(10x; left) and quantification of macrophage migration relative to macrophages treated with CM from
hypoxic veh-treated CAFs (right; n = 8/group pooled from 3 independent experiments). (C) CM was
collected from hypoxic normal fibroblasts and used in the same manner as in (A). (D) Representative
bright-field images (stitched whole well; left) and quantification of macrophage migration relative to
macrophages treated with CM from hypoxic veh-treated normal fibroblasts (right; n = 5/group pooled
from 2 independent experiments). (E) CM was collected from hypoxic CAFs, and then veh or PT2399
was added exogenously to the processed CM, which was subsequently used like in (A). (F)
Quantification of macrophage migration relative to macrophages treated with CM from hypoxic CAFs
that was supplemented exogenously with veh (n = 3/group pooled, 1 experiment). (G) 5%FBS/DMEM
with veh or PT2399 was used as chemoattractant for macrophage migration. (H) Representative brightfield images (stitched whole well; left) and quantification of macrophage migration relative to
macrophages treated with veh. All error bars represent mean ± SEM; P, by one-way ANOVA; ns, not
significant. Panels (A), (C), (E), and (G) were created using BioRender.com
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Figure 19. Hypoxic CAFs promote RAW 264.7 macrophage M2 polarization in a HIF2-dependent
paracrine fashion. (A) Macrophages were incubated under normoxic conditions with conditioned
media collected from hypoxic KPC-derived CAFs treated with veh or PT2399 and Arg1 expression was
measured by RT-qPCR. (B) Macrophages were incubated under normoxic (continued in next page)
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phages (like RAW 264.7 macrophages), I established primary murine bone marrow-derived
macrophage (BMDM) cultures (Figure 20A). Upon six days of treatment with monocyte colony
stimulating factor (CSF1), bone marrow progenitor cells developed spindle morphology and
upregulated macrophage markers (Figure 20B-C), indicating differentiation into macrophages.
Similar to unstimulated RAW 264.7 macrophages, unstimulated BMDMs do not express Arg1
under normoxia. However, exposing BMDMs to hypoxia led to a significant upregulation of Arg1
in a HIF2-dependent manner (Figure 20D-E), as has been reported previously106. Moreover,
hypoxia modestly increased Pdl1 (ligand for PD-1 immune checkpoint), but this was unaffected
by treatment with PT2399 (Figure 20E). A previous study showed that HIF1, but not HIF2,
directly upregulates Pdl1 in macrophages and BMDMs.110, 185-187 Interestingly, conditioned media
(Continued Figure 19 legend) conditions with CM collected from CAFs grown in normoxic or hypoxic
conditions and Arg1 expression was measured by RT-qPCR. Arg1 fold change over macrophages
incubated with CM from normoxic CAFs is shown. (C) Arg1 fold change over macrophages incubated
with CM from veh-treated hypoxic CAFs is shown. Data is representative of 4 independent experiments.
(D) Macrophages were incubated under normoxic conditions with CM collected from normoxic or
hypoxic HIF2 WT and HIF2 KO CAFs and Arg1 expression was measured by RT-qPCR. (E) Arg1 fold
change over macrophages incubated with CM from normoxic HIF2WT CAFs is shown. (F)
Macrophages were incubated under normoxic conditions with CM collected from hypoxic normal
fibroblasts treated with vehicle or PT2399 and Arg1 expression was measured by RT-qPCR. (G) Arg1
fold change over macrophages incubated with CM from vehicle-treated normoxic normal fibroblasts is
shown. (H) Macrophages were incubated under hypoxic conditions and directly treated with veh or
PT2399 and Arg1 expression was measured by RT-qPCR. (I) Arg1 fold change over veh-treated hypoxic
macrophages is shown. (J) M2-polarized macrophages were incubated under normoxic conditions and
directly treated with veh or PT2399 and Arg1 expression was measured by RT-qPCR. (K) Arg1 fold
change over vehicle-treated normoxic M2 macrophages is shown. Data is representative of 3
independent experiments. All error bars represent mean ± SEM; P, by Student’s t test; *P ≤ .05, **P ≤
.01, ***P ≤ .001, ****P ≤ .0001; ns, not significant. Panels (A), (D), (F), (H), and (J) were created
using BioRender.com.
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Figure 20. Isolation, validation, and polarization studies in BMDMs. (continued in next page)
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from normoxic normal pancreatic fibroblasts led to significant Arg1 upregulation in hypoxic
BMDMs, and conditioned media from hypoxic normal pancreatic fibroblasts further stimulated
BMDMs in a HIF2-dependent manner (Figure 20F-G). Together, these data suggest that hypoxia
activates macrophages directly in a HIF2-independent manner, and indirectly, via fibroblast-HIF2
signaling. Future studies will need to evaluate the effects of conditioned CAF media in BMDM
polarization.
VEGF is a potent immunosuppressive factor known to induce M2 repolarization in
TAMs.188 Since Vegf is a hypoxia-inducible gene,84 we measured Vegf expression in hypoxic
CAFs treated with PT2399 and found modest to no difference compared to vehicle-treated CAFs
(Figure 21A). Moreover, IHC staining of tumor sections for the endothelial marker Meca32
showed no differences in vessel density between CAF-HIF2 WT and KO mice (n = 5
tumors/group, P = .556; Figure 21B-C). These data suggest that HIF2-regulated CAF-TAM
crosstalk is independent of angiogenic signaling pathways.

(Continued Figure 20 legend) (A) Hematopoietic stem cells were isolated from C57BL/6J mice and
differentiated into bone marrow-derived macrophages (BMDMs) using human CSF1 (hCSF1). (B)
Representative images of hematopoietic stem cells differentiating into BMDMs (4X). (C) BMDM
differentiation was verified via RT-qPCR. (D) BMDMs were cultured in normoxia or hypoxia, and
directly treated with veh or 2µM PT2399, and RT-qPCR was performed. For M1 and M2 polarization
controls, normoxic BMDMs were treated with IFNy + LPS or IL-4 + IL-13, respectively. (E) Arg1 and
Pdl1 relative expressions are shown. (F) BMDMs were incubated under hypoxic conditions with CM
collected from normoxic or hypoxic normal fibroblasts treated with veh or PT2399, and Arg1 expression
was measured by RT-qPCR. (G) Arg1 relative expression is shown. Mean ± SEM; P, by Student’s t

test (C and D) or one-way ANOVA (G); *P ≤ .05, **P ≤ .01, ***P ≤ .001, ****P ≤ .0001; ns, not
significant. Panels (A), (D), and (F) were created using BioRender.com.
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Figure 21. Assessment of CAF-HIF2 signal abrogation on Vegf levels and tumor vessel density.
(A) KPC-derived CAFs were grown in normoxic or hypoxic conditions and treated with PT2399 at the
indicated doses, then Vegfa expression was measured by qRT-PCR. (B) Representative IHC (top) and
masked images (bottom) of KPF CAF-HIF2 tumors stained for Meca32 (n = 5/group); scale bars, 100
µm. (C) Quantification of Meca32+ percent area per field. Each data point represents one mouse, with
two random fields of view analyzed and averaged per mouse. All error bars represent mean ± SEM; P,
by Student’s t test (C) or one-way ANOVA (A); *P ≤ .05, **P ≤ .01.

Deletion of Stromal HIF2 Reduced Pancreatic Cancer Immunosuppression
We performed single-cell RNA sequencing (scRNA-seq) to interrogate the impact of
CAF-specific HIF2 signaling on other cell compartments in the PDAC TME. We analyzed the
transcriptomes from 20,802 single cells isolated from three KPF CAF-HIF2 WT tumors (9,774
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Figure 22. Single-cell RNA sequencing (scRNA-seq) reveals the cellular landscape of KPF CAFHIF2 WT and KPF CAF-HIF2 KO tumors. (A) UMAP of scRNA-seq analysis of 20,802 cells sorted
from 6 mice (3/group). Graph-based clustering identified 15 clusters, indicated by color. (B) UMAP of
scRNA-seq dataset from KPF CAF-HIF2 WT tumors (9,774 cells; n = 3 mice) and KPF CAF-HIF2 KO
tumors (11,028 cells; n = 3 mice). Cell types were identified through graph-based clustering followed
by manual annotation using known marker genes. (C) Bubble plots showing the relative average
expression of selected cell-type-specific markers across all major cell populations identified. The size
of the dots indicates the percentage of the cell population that expressed the marker, and the intensity of
color indicates the average expression level. (D) Proportions of cell types in CAF-HIF2 WT and KO
tumors, quantified as an average per group.

cells) and three KPF CAF-HIF2 KO tumors (11,028 cells). Graph-based clustering of all viable
cells after UMAP dimensionality reduction identified 15 clusters that were assigned to six major
cell types using signature genes (Figure 22A-C).182 All the cell populations identified were
represented in both experimental groups and in all six mice, with 48.7% of the cells analyzed
being identified as epithelial/tumor cells, 25.4% as myeloid cells, 21.4% as fibroblasts, and the
remaining cells as endothelial cells, B cells and T cells, and neutrophils (Figure 22D).
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Figure 23. Fibroblast subtype analysis in scRNA-seq datasets of KPF CAF-HIF2 WT and KPF
CAF-HIF2 KO tumors. (A) UMAP of scRNA-seq analysis of 20,802 cells sorted from 6 mice
(3/group). Inset: Graph-based reclustering of broad fibroblast population (4,450 cells) identified 5
subtypes, indicated by color. (B) Average percentage of fibroblast subtypes over total fibroblasts
sequenced per tumor. Mean ± SEM; P, by Student’s t test; ns, not significant.

Quantification of the relative proportions of each cell type within tumors showed that
HIF2 deletion in aSMA+ CAFs did not affect the total number of fibroblasts within tumors
(Figure 22D), which goes in hand with the observation that fibrosis levels were almost unaltered
(Figure 9D). As mentioned in the introductory chapter, pancreatic CAFs are a heterogenous
population with both tumor supportive and suppressive functions, broadly classified as myCAFs,
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iCAFs, and apCAFs.120 Though antigen-presenting, apCAFs don’t express T cell costimulatory
molecules, and are therefore proposed to function as decoy antigen-presenting cells that promote
T cell anergy and/or Treg induction.122 In our KPF CAF-HIF2 model, we targeted aSMA+
cells, which largely includes myCAFs,121 but also possibly apCAFs. 122 Thus, to evaluate if loss
of HIF2 in aSMA+ cells changed the composition of pancreatic CAFs, we isolated the broad
fibroblast population from our scRNA-seq dataset and reclustered it (Figure 23A). UMAP
dimensionality reduction identified 12 clusters (data not shown) that were assigned to five
fibroblast subset categories using signature genes182: normal (quiescent) fibroblasts, activated
fibroblasts, myCAFs, iCAFs, and a mixed iCAF and apCAF population (Figure 23A). All
fibroblast categories were represented in both experimental groups and in all tumors (data not
shown), with approximately 60% identified as myCAFs and ~20% as iCAFs (Figure 23B). These
proportions are in agreeance with the CAF proportions found in late-stage PDAC tumors by other
groups.135 Loss of HIF2 in aSMA+ CAFs resulted in fewer iCAFs, but this was not statistically
significant. Moreover, there was no change in terms of proportion in the mixed iCAF and apCAF
population (Figure 23B), but there is a possibility that HIF2-dependent changes in absolute
apCAF and iCAF numbers are masked within this mixed –and plastic122, 123– population.
Thus, I decided to further investigate how hypoxia and HIF2 inhibition influence the
expression of myCAF, iCAF, and apCAF markers. We cultured two KPF-derived CAF clones
(Figure 13A-C) and one normal murine pancreatic fibroblast line in hypoxia with or without
PT2399 (Figure 24A). In KPF-derived CAFs, hypoxia decreased the levels of myCAF markers
Acta2 (aSMA) and Tgfb2, while it increased the levels of iCAF markers Fn1 and Lif (Figure
24B). Interestingly, upregulation of Lif expression was HIF2-dependent, whereas changes in the
other markers were independent of HIF2 (Figure 24B), and thus probably driven by HIF1.
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Figure 24. Hypoxia downregulates myCAF markers and upregulates iCAF markers. (A) KPFderived CAFs with intact HIF2 were incubated under normoxic or hypoxic conditions with veh or
PT2399 and RT-qPCR was performed. Ceated using BioRender.com. (B) Relative gene expression of
myCAF and iCAF markers normalized to a reference gene is shown. Data is representative of two KPFderived CAF clones. Mean ± SEM; P, by one-way ANOVA; *P ≤ .05, **P ≤ .01, ***P ≤ .001, ****P
≤ .0001; ns, not significant.

Moreover, HIF1 seems to activate CAFs, as it increased the pan-CAF marker Col1a1 (Figure
24B), which is highly expressed in myCAFs, but also in iCAFs and apCAFs. Furthermore,
hypoxia, as well as HIF2 inhibition, caused significant downregulation of Ccl2 (a monocyte
chemoattractant) in a synergistic manner (Figure 24B), which could indicate that HIF1, which
becomes acutely stabilized upon EGLN inhibition (Figure 15A-B), represses Ccl2 expression,
whereas HIF2, which appears to be chronically stabilized in KPF-derived CAFs even in normoxic
conditions (Figure 14B), might somehow sustain Ccl2 expression. This could be verified in KPFderived HIF2 KO CAFs or in KPC-derived CAFs, which have lower baseline HIF2 levels (data
not shown). Importantly, the apCAF marker Cd74 was also evaluated, but its expression was
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Figure 25. scRNA-seq reveals that stromal HIF2 ablation reduces immunosuppressive M2
macrophages in PDAC tumors. (A) Average percentage of myeloid cells over immune cells sequenced
per tumor. Mean ± SEM; P, by Student’s t test. (B) M2-polarized TAMs were identified within the
myeloid cell population via expression of Arg1 and Mrc1. Immunosuppressive TAMs were identified
within the myeloid cell population via expression of Cd274 (Pdl1) and Cd86 (B7-2). (C) Bubble plots
showing the relative average expression of macrophage markers across all myeloid cells identified in
the scRNA-seq analysis. The size of the dots indicates the percentage of the cell population that
expressed the marker, and the intensity of color indicates the average expression level.

undetectable in both KPF-derived CAF lines that were assessed. This may be secondary to ex vivo
2-D culturing, which promotes apCAF interconversion to myCAF phenotype.122 Thus, more
optimal culture conditions123 are required to further assess iCAF and apCAF phenotypes and
functional status.
Single-cell analyses were largely concordant with the bulk RNA-seq and IHC data (Figure
17A-B and 17D), showing that CAF-HIF2 KO tumors had a significantly lower proportion of
myeloid immune cells than CAF-HIF2 WT tumors (66.9% versus 83.24%; n = 3 tumors/group, P
= .018; Figure 25A). Further interrogation of the myeloid cell population revealed high
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Figure 26. Deletion of HIF2 in CAFs reduces the PDAC immunosuppressive TME. (cont in p.75)
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expression of Arg1, Mrc1, Cd11b (Itgam), Cd68, Adgre1 (F4/80), indicating a predominance of
M2-polarized TAMs, which were reduced in CAF-HIF2 KO tumors (Figure 25B-C). A
substantial proportion of these TAMs expressed the immunosuppressive checkpoint ligands
Cd274 (Pdl1), Cd80 and Cd86 (both ligands for CTLA-4; Figure 25B-C). To further assess how
HIF2 deletion in aSMA+ CAFs altered the immune TME of PDAC, we isolated the broad myeloid
population, the B + T cell population, and the neutrophils from our scRNA-seq dataset and
reclustered them (Figure 26A). UMAP dimensionality reduction identified 16 clusters (data not
shown) that were assigned to thirteen immune subset categories using signature genes (Figure
26A).182 All immune subsets were represented in both experimental groups and in all tumors (data
not shown), with the majority of cells being from the myeloid lineage, but also with a significant
portion of innate immune cells, including NK T cells, CD56+ NK cells, and DCs, and a smaller
portion of lymphoid cells, including B cells, naïve CD4+ T cells, naïve CD8+ T cells, Tregs, and
effector CD8+ T cells (Figure 26B). From the myeloid lineage, monocytes were reduced in CAFHIF2 KO tumors compared to CAF-HIF2 WT tumors (Figure 26B), supporting our observations
that HIF2 deletion and inhibition downregulates myeloid/monocyte/macrophage chemotaxis into
(Continued Figure 26 legend) (A) UMAP of scRNA-seq analysis of 20,802 cells sorted from 6 mice
(3/group). Inset: Graph-based reclustering of immune subsets (5,612 cells) identified 13 subsets,
indicated by color. (B) Average percentage of immune subsets over total immune cells sequenced per
tumor. (C) Bubble plots showing the relative average expression of immunosuppressive markers across
all immune cell subtypes identified in the scRNA-seq analysis. The size of the dots indicates the
percentage of the cell population that expressed the marker, and the intensity of color indicates the
average expression level. (D) Left: Representative IHC images of CAF-HIF2 WT and KO tumors
stained for FoxP3 and counterstained with Hematoxylin QS (n = 5-6/group); scale bars, 50 µm. Right:
Quantification of FoxP3+ Tregs per field. All error bars represent mean ± SEM; P, by Student’s t test.
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tumors (Figures 17 and 18A-B). Moreover, the total percentage of macrophages was greatly
reduced (Figure 26B), suggesting that stromal HIF2 regulates macrophage differentiation
(Figures 17). However, it is not clear whether this reduced macrophage population originates
from circulating monocytes or pancreas tissue resident macrophages.109 Further analysis showed
that this reduced macrophage population highly expresses Ccl17 (data not shown), which could
indicate it originates from circulating monocytes.109 There were no significant changes in the
proportion of Mrc1+ macrophages or Arg1+ macrophages (Figure 26B), but their absolute cell
numbers were lower in CAF-HIF2 KO tumors (data not shown), which is likely due to a lower
supply pool of monocytes and macrophages. MDSCs were higher in CAF-HIF2 KO tumors, but
they expressed lower levels of Arg1 and Mrc1 (Figure 26B-C). Interestingly, MDSCs, Mrc1+
macrophages, and Arg1+ macrophages had high expression of Hif2a (Epas1; Figure 26C), which
could be targeted with global HIF2 inhibition using PT2399.
Single-cell analysis also revealed that CAF-HIF2 KO tumors had higher infiltration with
NK T cells, CD56+ NK cells, and naïve CD8+ T cells (Figure 26B), which suggests that these
tumors were less immunosuppressed. However, there were no appreciable differences in the
proportions of effector CD8+ T cells or Tregs (Figure 26B), but the number of cells were too low
to draw conclusions from, possibly due to tissue dissociation bias. Moreover, both CD8+ T cells
and Tregs displayed high expression of Ctla4 (Figure 26C), which can be targeted with
checkpoint immunotherapy. Additionally, IHC staining of tumor sections for the Treg marker
FoxP3 showed that CAF-HIF2 KO tumors had significantly fewer Tregs than CAF-HIF2 WT
tumors (n = 5-6 tumors/group, P = .014; Figure 26D). Taken together, our data strongly suggest
that deletion of HIF2 in CAFs reduces the PDAC immunosuppressive landscape. Of note, this
scRNA-seq was performed on end-stage tumors. Thus, it would be interesting to evaluate how the
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Figure 27. Inhibition of HIF2 signaling enhances response to anti-CTLA-4 immunotherapy in a
flank PDAC model. (A) Schematic for administration of PT2399 + αCTLA4 in a syngeneic flank KPC
model. i.p., intraperitoneal; o.g., oral gavage; b.i.d., bid in die (twice a day). Created using
BioRender.com. (B) Tumor growth curve (n = 10/group). Veh, vehicle; All error bars represent mean ±
SEM; P, by Mann–Whitney U test.

immune landscape evolves throughout tumor progression when HIF2 is targeted genetically and
pharmacologically.

Inhibition of HIF2 Signaling Enhances Responses to Immunotherapy in Pancreatic
Cancer
PDAC is highly resistant to immunotherapy,68 but recent studies have suggested that
targeting non-redundant pathways with a combined anti-CTLA-4 and anti-PD-1 approach may
overcome inherent TME immunosuppression.189 Since HIF2 deletion in CAFs reduced the PDAC
immunosuppressive landscape, we reasoned that PT2399 might improve response to checkpoint
immunotherapy. To test this hypothesis, we implanted KPC cells subcutaneously into syngeneic
C57BL/6 mice and assigned them to one of four treatments: vehicle plus IgG control, vehicle plus
anti-CTLA-4 antibody (aCTLA4), PT2399 plus IgG, or PT2399 plus aCTLA4 (Figure 27A).
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Figure 28. Inhibition of HIF2 signaling enhances response to dual checkpoint immunotherapy in
an orthotopic PDAC model. (A) Schematic for administration of PT2399 + αCTLA4/αPD1 in a
syngeneic orthotopic KPC model. Created using BioRender.com. (B) Kaplan-Meier curves showing
percentage survival (n = 10/group); P, by log-rank test; P values specified in the panel. (C)
Corresponding tumor growth curve, measured by ultrasound. Mean ± SEM; P, by Mann–Whitney U
test; *P ≤ .05, **P ≤ .01. (D) Tumor volumes measured by caliper at the time of sacrifice. Mean ± SEM;
P, by one-way ANOVA; ****P ≤ .0001. (E) Proportion of mice with metastasis. P, by Fisher’s exact
test.

78

Figure 29. Immune landscape of orthotopic PDAC model treated with combined PT2399 and dual
checkpoint immunotherapy. (A) Quantification of percent collagen area per field. (C-D)
Quantification of F4/80+ macrophages (A), CD4+ T cells (B), and CD8+ T cells (C) percent area per
field. Each data point represents one mouse. All error bars represent mean ± SEM; P, by one-way
ANOVA; *P ≤ .05, **P ≤ .01.

We found that the combination of PT2399 with aCTLA4 significantly slowed tumor growth (n =
10 mice/group, P = .038), while treatment with either drug alone had no discernible effect (Figure
27B).
We next implanted KPC cells orthotopically into syngeneic C57BL/6 mice to test whether
HIF2 inhibition enhanced response to dual checkpoint blockade (DCB) with aCTLA4 and antiPD-1 antibody (aPD1). Mice were assigned to one of four treatments: vehicle plus IgG, vehicle
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Figure 30. On-target bone marrow toxicity of pharmacological HIF2 inhibition with PT2399 in
tumor bearing mice. A syngeneic orthotopic KPC mouse model was used to assess bone marrow
toxicity related to systemic HIF2 inhibition. Mice were treated with treated with veh or PT2399 and
non-tumor bearing C57BL/6 mice were used as a control. (A) Hemoglobin and hematocrit levels (B) are
shown (n = 2-7 mice/group). All error bars represent mean ± SEM; P, by Student’s t test; ns, not
significant.

plus DCB, PT2399 plus IgG, or PT2399 plus DCB, with the goal to assess 60-day survival (Figure
28A). The experiment was prematurely terminated due to institutional mandates related to
COVID-19, yet the survival rate at 45 days in mice that received combined PT2399 and DCB was
100%, significantly higher than the survival rate in the groups treated with IgG control (n = 10
mice/group, P ≤ .0005), and trending toward improved survival compared to mice treated with
DCB and vehicle (n = 10 mice/group, P = .067; Figure 28B). Both groups treated with DCB had
slower growing tumors, and there were no statistically significant differences in metastasis rate
between any groups (Figure 28C-E). These orthotopic tumors had a lower stromal component
than spontaneous tumors, as has been previously reported,190 and we found no differences in
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fibrosis between treatment groups (Figure 29A). Moreover, tumors of mice treated with DCB,
with or without PT2399, had fewer macrophages and more CD4+ T cells and CD8+ T cells (Figure
29B-D). However, because these tumors were also quite advanced, it is hard to extrapolate how
the immune responses changed with HIF2 inhibition and/or DCB. Thus, future studies should
evaluate these parameters in earlier timepoints. Lastly, PT2399 induced modest anemia in a
separate cohort of tumor-bearing mice (Figure 30), which is an expected on-target effect that can
be best evaluated in Phase I clinical trials.179 Taken together, these results suggest that HIF2
inhibition might enhance anti-tumor immune responses and improve survival.

2.5

Discussion
Our study addresses a long-standing knowledge gap about the relative roles of HIF

signaling in the PDAC microenvironment. Here we show that CAF-specific expression of HIF2,
but not HIF1, drives paracrine signals that increase the presence of immunosuppressive cells like
TAMs and Tregs in a HIF2-dependent fashion. Furthermore, both genetic and pharmacologic
inhibition of HIF2 improved survival in spontaneous and syngeneic mouse models.
Our study identifies HIF2 signaling in CAFs as a critical component of hypoxia-related
immunosuppression in pancreatic cancer. We demonstrate that HIF2 signaling orchestrates
immunosuppression within pancreatic tumors by shifting the immune cellular composition of the
TME rather than by altering fibrosis, which was unchanged in our model. We observed more
TAMs and Tregs in tumors from mice with intact CAF HIF2 function compared to mice with
HIF2 deletion. These data contrast with findings from a previous study in which depletion of
aSMA+ CAFs reduced fibrosis, increased Tregs, and drove cancer progression.131 These
phenotypic differences are most likely explained by the different approaches of the two studies:
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we targeted CAF functionality under hypoxia, while the former study ablated CAFs altogether.
Our dual recombinase system specifically interrogated HIF2 function in aSMA+ CAFs within
autochthonous tumors, but did not address the potential role of HIF2 in other CAF subtypes that
do not express aSMA.122 These other subtypes could be studied in future experiments using
different Cre drivers, such as Fap124 or Fsp1,191 to address the dynamic relationships between
CAF populations.
Hypoxia, and therefore HIF signaling, affects every cell type within a pancreatic tumor,
but our data suggests that the detrimental effects of tumor hypoxia are mediated largely by HIF2dependent crosstalk between CAFs and macrophages, which has not been previously reported.
Using single-cell approaches, we found that M2-polarized TAMs were a major source of
immunosuppressive CD86 and PD-L1, and this was reversed by the CAF-specific ablation of
HIF2. Thus, we infer that these TAMs may be partially responsible for the subsequent
reprogramming of effector T cells in the pancreatic TME. Like the findings in several clinical
reports, reduced TAM density correlated with improved survival from pancreatic cancer104, 105 in
mice in the setting of CAF-HIF2 deletion. Furthermore, we demonstrate via ex vivo experiments
that hypoxic CAFs stimulate the migration and M2 polarization of macrophages in a HIF2dependent fashion. In contrast, normal pancreatic fibroblasts did not alter macrophage migration
or polarization. It is not yet known if this novel crosstalk is mediated by a single soluble factor or
by a combination of cytokines/growth factors,105 metabolites,192 lipids,193 and/or exosomes.194
Although we focused on CAF-TAM crosstalk, we note that other HIF2-dependent
pathways may be contributing to the overall phenotype. Hypoxia, and particularly HIF2, have
also been shown to induce TGF-β signaling,195, 196 which could modulate the immune landscape
in the TME. Notably, we found that Tgfb1 expression was reduced in CAF-HIF2 KO tumors, thus
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changes in TGF-β signaling could potentially have a role in HIF2-dependent CAF-mediated TME
reprogramming. However, since HIF2 modulates multiple homeostatic pathways, our data does
not rule out the contribution of HIF2-dependent metabolic192 or epigenetic197 changes within
CAFs that could mediate immune crosstalk.
We note that since our experimental system was designed to interrogate HIF2 function in
CAFs, we cannot exclude the possibility that HIF2 signaling may also be critical in other cell
types in the TME. Previous knockout studies have shown that HIF2 has tumor supporting roles in
macrophages106 and Tregs111 in colorectal and hepatocellular cancer models, suggesting a
potential therapeutic benefit with HIF2 inhibition. Pharmacologic HIF2 inhibition is global and
affects all cells in the TME. Therefore, it was reassuring to demonstrate that HIF2 inhibition with
PT2399 enhanced immune responses in our syngeneic pancreatic cancer models. It will be
important to evaluate immune responses in autochthonous tumor models that contain higher
stromal abundance,198 and we posit that with higher CAF content, the immune responses to HIF2
inhibition will be more robust. Belzutifan (PT2977, MK-6487) is a second-generation HIF2
inhibitor that recently received FDA approval for use in VHL-associated renal cell carcinoma.179,
199

Thus, our approach of using HIF2 inhibition to prime immune responses could potentially be

repurposed to treat pancreatic cancer.
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Chapter III: The Role of HIF2 in Normal Tissue Biology: Mechanisms of HIF2
Radioprotection of the Small Intestine

This chapter is based upon “García García CJ, Acevedo Diaz AC, Kumari N, Govindaraju S,
de la Cruz Bonilla M, San Lucas FA, Nguyen ND, Jiménez Sacarello I, Piwnica-Worms H, Maitra
A, Taniguchi CM. HIF2 Regulates Intestinal Wnt5a Expression. Frontiers in Oncology.
2021;11:769385. doi: 10.3389/fonc.2021.769385. eCollection 2021.” This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY), which establish that the original author(s) retain copyrights.
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4.1 Abstract
Radiation therapy for abdominal tumors is challenging because the small intestine is
exquisitely radiosensitive. Unfortunately, there are no FDA-approved therapies to prevent or
mitigate GI radiotoxicity. The EGLN protein family are oxygen sensors that regulate cell survival
and metabolism through the degradation of the HIFs. Our group has previously shown that
stabilization of HIF2 through genetic deletion or pharmacologic inhibition of the EGLNs
mitigates and protects against GI radiotoxicity in mice by improving intestinal crypt stem cell
survival. Here we aimed to elucidate the molecular mechanisms by which HIF2 confers GI
radioprotection. We developed duodenal organoids from mice, transiently overexpressed nondegradable HIF2, and performed bulk RNA sequencing. Interestingly, HIF2 upregulated known
radiation modulators and genes involved in GI homeostasis, including Wnt5a. Non-canonical
Wnt5a signaling has been shown by other groups to improve intestinal crypt regeneration in
response to injury. Here we show that HIF2 drives Wnt5a expression in multiple duodenal
organoid models. Luciferase reporter assays performed in human cells showed that HIF2 directly
activates the WNT5A promoter via a hypoxia response element. We then evaluated crypt
regeneration using spheroid formation assays. Duodenal organoids that were pre-treated with
recombinant Wnt5a had a higher cryptogenic capacity after irradiation, compared to vehicletreated organoids. Conversely, we found that Wnt5a knockout decreased the cryptogenic potential
of intestinal stem cells following irradiation. Treatment with recombinant Wnt5a prior to
irradiation rescued the cryptogenic capacity of Wnt5a knockout organoids, indicating that Wnt5a
is necessary and sufficient for duodenal radioprotection. Taken together, our results suggest that
HIF2 radioprotects the GI tract by inducing Wnt5a expression.
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Figure 31. Schematic abstract of Chapter 3.

4.2 Introduction and Rationale
Radiation is one of the four pillars of cancer care, with approximately half of cancer
patients receiving radiotherapy at some point of their treatment regimen.200 Similar to
chemotherapy, the efficacy of radiotherapy is limited by normal tissue toxicity. This toxicity is
especially limiting in the case of abdominal and pelvic cancers, which are surrounded by the
exquisitely radiosensitive GI tract, and they require high doses of radiation to achieve tumoricidal
effects.139 Multiple studies have highlighted how common GI radiotoxicity is among cancer
patients.140-142 Results from a Phase 3 clinical trial showed that over a third of patients treated
with 45 Gy or 50.4 Gy four-field pelvic radiotherapy or pelvic intensity-modulated radiotherapy
reported GI symptoms following radiation treatment.201 Consequently, abdominal radiotherapy
for cancers of the hepatobiliary tract and pancreas are administered at sub-curative doses to avoid
GI radiotoxicity. Recent clinical trials have shown that dose-escalated radiotherapy using highly
precise 3D conformal radiation techniques, such as SBRT and intensity-modulated radiotherapy,
can improve outcomes,138, 148, 149 but these techniques still cannot fully avoid the small intestines.
Furthermore, these sophisticated techniques are not widely accessible, as they require specialized
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expertise that is limited to some academic centers. Thus, an alternative to reduce GI radiotoxicity
in cancer patients is to use a radioprotector to prevent radiation-induced damage and/or to improve
GI repair following radiotherapy.148
There are currently no FDA-approved radioprotectors of the GI tract. The intestine has a
physiological hypoxia gradient that arises due to its vascular anatomy, and the HIFs regulate
various genes required for intestinal barrier function.163 The HIFs are transcription factors which
are hydroxylated by the EGLN family of prolyl hydroxylases, allowing the von Hippel-Lindau
E3 ubiquitin ligase complex to bind and tag HIFs for proteasomal degradation.20-22, 24-28 The
stabilization of HIFs through hypoxia or EGLN inhibition allows them to regulate cell metabolism
and survival,22 induce tissue remodeling,160 increase epithelial integrity,161 and promote stem cell
survival.20 Our group has previously shown that stabilization of HIF2, but not HIF1, significantly
reduces GI radiotoxicity without sparing hypoxic pancreatic tumors.164,

165

However, the

mechanisms by which HIF2 confers radioprotection to the small intestine remain unclear.
In the current study, we generated a 3D murine small intestinal organoid model system,202
transiently overexpressed a non-degradable HIF2 allele,203 and performed whole transcriptomic
analysis to gain insight in this regard. We found that HIF2 directly induces Wnt5a expression, a
non-canonical Wnt family glycoprotein, in both murine and human cell lines, by activating its
promoter. Like other Wnt family members, Wnt5a plays an important role in the in the embryonic
development and subsequent homeostasis GI tract, and enhances regeneration following injury.204,
205

Here, we show that Wnt5a is necessary for small intestinal crypt regeneration following

radiation and that addition of exogenous Wnt5a to duodenal 3D organoid cultures improves their
cryptogenic capacity. Together, our data indicate that HIF2 radioprotects the small intestine, at
least in part, by inducing Wnt5a expression.
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4.3 Materials and Methods
Cell Lines and Reagents
L-WRN cells were obtained from the ATCC (CRL-3276). HEK293-derived Adherent293 (AD-293) cells were obtained from Stratagene (240085). CBRLuc-mCherry reporter murine
duodenal organoids were a gift from Dr. Helen Piwnica-Worms.206 Murine duodenal organoids
were cultured at 37°C in 5% CO2 and 5% O2, while all other cell lines were cultured at 37°C in
standard 5% CO2 incubators. All cell lines were authenticated by short tandem repeat profiling
and were confirmed to be Mycoplasma free. Recombinant human/mouse Wnt5a was purchased
from R&D Biosystems (645-WN-010-CF).

Mice
All experimental mouse work adhered to the standards articulated in the Animal Research:
Reporting of In Vivo Experiments guidelines. Additionally, all mouse work was approved by the
Institutional Animal Care and Use Committee of The University of Texas MD Anderson Cancer
Center. Mice were maintained on a 12-hour light/dark cycle and were provided with sterilized
water and standard rodent chow (Prolab Isopro RMH 3000 irradiated feed) ad libitum. C57BL/6
mice (RRID:IMSR_JAX:000664), Wnt5afl/fl mice (RRID:IMSR_JAX:026626)207, and R26-LSLhHIF2adPA mice (RRID:IMSR_JAX:009674)203 were obtained from Jackson Laboratories.

Generation of 3D Small Intestinal Organoids
L-WRN conditioned media was prepared as previously described.202, 206 Briefly, L-WRN
cells were maintained in DMEM high glucose media (Sigma, D6429) supplemented with 10%
(v/v) FBS (Sigma, F4135, 1% (v/v) Penicillin/Streptomycin (Sigma, P4333), 500 µg/ml
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Hygromycin B Gold (InvivoGen, ant-hg-1), and 500 µg/ml G418 (Sigma, G8168). Once cells
were confluent, the media was replaced with Advanced DMEM/F12 media (Gibco, 12634010)
supplemented with 10% (v/v) FBS, 1% (v/v) Penicillin/Streptomycin, and 2 mM L-glutamine
(Sigma, G7513). Conditioned media was collected for six days, centrifuged at 3,000 rpm for 5
minutes, vacuum filtered through a 20 µM PES membrane (Thermo Scientific, 567-0020), and
stored at -80°C.
Duodenal crypts were isolated from C57BL/6 mice, R26-LSL-hHIF2adPA mice, and
Wnt5afl/fl mice, and 3D organoid cultures were established as previously described.202, 206 For all
steps in this protocol, EDTA (Sigma-Aldrich, E7889) was added fresh to both PBS (Cytiva,
SH30256.LS) and HBSS without calcium and magnesium (Gibco, 14025092) to a final
concentration of 2 mM, and kept on ice. Mice were humanely euthanized by CO2 inhalation
followed by cervical dislocation. The duodenum was measured 1 cm below the pylorus, and 4 cm
were resected and flushed with PBS/EDTA, then incubated on fresh PBS/EDTA for 10 min on
ice, and finally transferred to ice-cold HBSS/EDTA. Duodenal samples were then serially
vortexed at 1,600 rpm at 4°C, in fresh HBSS each time, for 5 min, 3 min, and 8 min. Supernatants
from the second and third vortexes were combined and passed through 70-µm strainers (Corning,
431751) to isolate crypts and remove any villi that might remain after the washes. Duodenal crypts
were pelleted at 1,000 rpm at 4°C, then washed in Advanced DMEM/F12 supplemented with 10%
(v/v) FBS, 1% (v/v) Penicillin/Streptomycin, and 2 mM L-glutamine, and re-centrifuged as
before. The pelleted crypts were resuspended in 50% (v/v) Matrigel (Corning, 354234) diluted
with the crypt washing media, and then were seeded as domes into 24-well plates (Corning, 3524).
After Matrigel solidification at 37°C, the duodenal organoids were cultured in 50% (v/v) L-WRN
conditioned media supplemented with 10 mM Y27632 (ROCK inhibitor; Sigma-Aldrich, Y0503)
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and 10 µM SB431542 (TGF-β RI Kinase Inhibitor VI; Sigma-Aldrich, 616461). The culture
media was refreshed every other day and the organoids were passaged every third day.

Adenoviral Transduction
Ad-GFP (VVC-U of Iowa-4, Ad5CMVeGFP), Ad-Cre (VVC-U of Iowa-5,
Ad5CMVCre), and Ad-Cre-GFP (VVC-U of Iowa-1174, Ad5CMVCre-eGFP) viral vectors were
provided

by

the

University

of

Iowa

Viral

Vector

Core

(http://www.medicine.uiowa.edu/vectorcore). Ad-human HIF1 and Ad-human HIF2 viral vectors
were previously produced208 using hHIF1 (Addgene #18955) and hHIF2 plasmids (Addgene
#18956) that contain double proline-to-alanine substitutions which render them nondegradable by
VHL.209 Duodenal organoids were transduced after at least three passages. First, organoids were
harvested by incubation with Cell Recovery Solution (Corning, 354253) for 30 min on ice, then
centrifuged at 1,000 rpm for 5 min at 4°C, and then washed with cold PBS. Organoids were then
digested into single ISCs via mechanical digestion while incubating in TrypLE (Gibco, 12605010)
supplemented with 10 µM Y27632 and 500 µM N-acetylcysteine (Sigma-Aldrich, A0737) for 5
min at 37°C. To neutralize TrypLE, cold Advanced DMEM/F12 media supplemented with 10%
(v/v) FBS, 1% (v/v) Penicillin/Streptomycin, 2 mM L-glutamine, 10 μM Y27632, and 10 μM
SB431542 was added and the ISC suspension was centrifuged at 1,500 rpm for 5 min at 4°C.
Single ISCs were resuspended in Advanced DMEM/F12 supplemented as described above and
passed through a 35-μM strainer (Corning, 352235). Single ISCs were stained with Trypan Blue
(Bio-Rad, 1450021) and counted on a TC20 Automated Cell Counter (Bio-Rad). Duodenal ISCs
were transduced with adenoviral particles at MOI rates of 50 particles per cell for 1.5 h at 37°C.
Afterwards, transduced ISCs and leftover adenoviral particles were resuspended in 50% (v/v)
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Matrigel, seeded into 24-well plates, and cultured in 50% (v/v) L-WRN conditioned media
supplemented with 10 µM Y27632, 10 µM SB431542, and 10 mM Nicotinamide (Sigma-Aldrich,
N3376). RNA purification of duodenal organoids was done approximately 72 hours posttransduction.

Western Blotting
Duodenal organoids were released from Matrigel by incubation with Cell Recovery
Solution for 30 min on ice, then centrifugation at 1,000 rpm for 5 min at 4°C, followed by washing
with cold PBS. Organoids were then lysed in M-PER mammalian protein extraction reagent
(Thermo Fisher Scientific, 78501) supplemented with protease inhibitor (Roche Life Science,
11836170001) and phosphatase inhibitor (Roche Life Science, 4906837001), and then denatured
with 4x Laemmli sample buffer (Bio-Rad, 1610747). Equal cell protein lysate amounts were
resolved on SDS-PAGE gel (Bio-Rad, 4568034) and transferred onto a nitrocellulose membrane
(Bio-Rad, 1620215) using a Trans-Blot Turbo transfer system (Bio-Rad). After blocking with 5%
(w/v) skim milk powder (Bio-Rad, 1706404XTU) in TBS-T for 1h at room temperature, the
membrane was probed with primary antibodies diluted in Superblock T20 (ThermoFisher
Scientific, 37536) at 4°C overnight. Anti-HIF2α rabbit (Novus Biologicals, NB100-122) was
used at 1:500 and anti-β-actin rabbit (Cell Signaling Technology, 4970S) was used at 1:1,000.
The membrane was then washed and incubated with HRP-conjugated secondary antibody for 1h.
The membrane was developed with Clarity Western ECL Substrate kit (Bio-Rad, 1705061) and
visualized using a ChemiDoc imaging system (Bio-Rad). Relative protein expression was
quantified based on band intensity using ImageJ software (RRID:SCR_003070) and normalized
to control group.
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RNA Purification and RT-qPCR Analysis
Duodenal organoids were released from Matrigel as indicated above, then homogenized
by vortexing and vigorously pipetting, and then RNA was purified using an RNeasy mini kit
following the manufacturer’s handbook (Qiagen, 74106). Reverse transcription was performed
with a mix of random primers and oligos using an iScript cDNA Synthesis kit (Bio-Rad,
1708891). Next, qPCR was performed using SYBR Green Master mix (Bio-Rad, 1725124) and
the primer assays listed on Table 4 on a CFX384 Real-time system (Bio-Rad). Relative gene
expression and fold change was calculated using Hprt and Tbp as reference genes.

Table 4. RT-qPCR Primer Assay List, Chapter 3.
Gene Target

Vendor

Unique Assay ID

Aqp8

Bio-Rad

qMmuCID0007218

Egr1

Bio-Rad

qMmuCED0039815

Hif2a

Bio-Rad

qMmuCID0005755

Hprt

Bio-Rad

qMmuCED0045738

Nos2

Bio-Rad

qMmuCID0023087

Stat6

Bio-Rad

qMmuCID0006404

Tbp

Bio-Rad

qMmuCID0040542

Wnt4

Bio-Rad

qMmuCID0006529

Wnt5a

Bio-Rad

qMmuCED0046181

RNA Sequencing and Analysis
Duodenal organoids from C57BL/6 mice transduced with either Ad-GFP, Ad-hHIF1, or
Ad-hHIF2 were harvested and and RNA was purified using an RNeasy mini kit. RNA purity and
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concentration were measured using a Epoch Microplate Spectrophotometer with a Take3 MicroVolume Plate, and Gen5 software (v2), all from BioTek Instruments, Inc. Library preparation and
sequencing were performed in the Sequencing and Microarray Facility at MD Anderson Cancer
Center. The raw sequencing data was downloaded from the core server and low-quality reads
were removed and Q20 and GC contents were calculated. Transcript abundance was quantified
using the RSEM software package (RRID:SCR_013027).178 Differential expression analysis was
performed using EBSeq software package (RRID:SCR_003526).210 The raw and processed data
are publicly available in NCBI’s GEO repository and can be accessed under number GSE186927.

WNT5A Promoter Analysis and Dual Luciferase Assays
The human WNT5a promoter from −2000 to +200 nucleotides from the +1 transcriptional
start site211 was synthesized directly into the KpnI- and XhoI-flanked region of the pUC57 vector
(Genscript, SD1176). All mutant promoters were synthesized in a similar fashion. The specific
sequences of the mutations can be found in the results section of this chapter. The KpnI- and
XhoI-flanked fragments of each of the promoter constructs were excised and then ligated into the
compatible BglII- and HindIII-flanked sites in the pGL4.10[luc2] vector (Promega, E6651). AD293 cells were cultured in DMEM supplemented with 10% FBS and 2 mM L-Glutamine. Cells
were transfected using Xfect Transfection Reagent (TakaraBio, 631318) using the manufacturer's
standard protocol. For instance, a 96-well opaque plate was seeded with 9.5 x 103 cells/well and
transfected with 0.08 µg of hHIF1 plasmid, hHIF2 plasmid, or control GFP plasmid (Addgene
#26822), 0.09 µg of WNT5A-luciferase construct, and 9 ng of Renilla luciferase, along with Xfect
polymer. The transfected cells were incubated for 48 h in Opti-MEM media (Gibco, 31985070).
Dual luciferase assays were performed using the Dual-Glo® Reagent (Promega, E2940) kit
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according to manufacturer’s instructions. The luminescence data was measured on a Cytation 3
luminometer (Biotek Instruments, Inc.). Luciferase signal was normalized to Renilla signal, and
then WNT5A promotor transactivation was calculated as a fold change over control GFP plasmid
transfection.

Spheroid Formation Assays
Spheroid Formation Assays were performed as previously described,206 using a murine
duodenal Click Beetle Red Luciferase-mCherry (CBRLuc-mCherry) reporter organoid line and
Wnt5afl/fl duodenal organoids. Briefly, duodenal organoid cultures were exposed to the indicated
pre-radiation treatments and then irradiated using an X-Rad 320 cell irradiator (Precision X-Ray).
Immediately after irradiation, the duodenal organoids were harvested using Cell Recovery
Solution and then digested into single ISCs using TrypLE supplemented with Y27632 and NAcetylcysteine, followed by filtering through a cell strainer as detailed above for Adenoviral
Transduction. Live cells were quantified using ViaStain™ AO/PI Staining Solution (Nexcelom,
CS2-0106) in a Cellometer® Vision CBA Image Cytometer (Nexcelom). Live duodenal ISCs
were seeded in Matrigel in 24-well culture plates at a density of 5,000 cells/well. Organoids were
maintained in 50% L-WRN conditioned media supplemented with 10 μM Y27632 and 10 μM
SB431542 for six days, then surviving cells were assessed via bioluminesce or z-stack imaging.
For quantification of bioluminescence, organoids were incubated with 300 µg/ml of D-Luciferin
Firefly (Gold Biotechnology, L-123) in the media for 20 min at 37°C, and measurements were
taken using a CLARIOstar plate reader (BMG Labtech). Sample wells were first normalized to
blank Matrigel wells, and then to unirradiated controls. Z-stack images covering the entire
Matrigel dome area were taken using a Cytation 3 Cell Imaging Multi-Mode Reader (Biotek
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Instruments,

Inc.). Z-stack

images

were

stitched

using

Photoshop

version

19.1.7

(RRID:SCR_014199) and viable organoids measuring at least 150 μm were manually quantified
using ImageJ version 1.52q (RRID:SCR_003070). For organoids analyzed via z-stack imaging,
the surviving fraction was calculated as described previously using a murine duodenal Click
Beetle Red Luciferase-mCherry (CBRLuc-mCherry) reporter organoid line and Wnt5afl/fl
duodenal organoids. Briefly, duodenal organoid cultures were exposed to the indicated preradiation treatments and then irradiated using an X-Rad 320 cell irradiator (Precision X-Ray).
Immediately after irradiation, the duodenal organoids were harvested using Cell Recovery
Solution and then digested into single ISCs using TrypLE supplemented with Y27632 and NAcetylcysteine, followed by filtering through a cell strainer as detailed above for Adenoviral
Transduction. Live cells were quantified using ViaStain™ AO/PI Staining Solution (Nexcelom,
CS2-0106) in a Cellometer® Vision CBA Image Cytometer (Nexcelom). Live duodenal ISCs
were seeded in Matrigel in 24-well culture plates at a density of 5,000 cells/well. Organoids were
maintained in 50% L-WRN conditioned media supplemented with 10 μM Y27632 and 10 μM
SB431542 for six days, then surviving cells were assessed via bioluminesce or z-stack imaging.
For quantification of bioluminescence, organoids were incubated with 300 µg/ml of D-Luciferin
Firefly (Gold Biotechnology, L-123) in the media for 20 min at 37°C, and measurements were
taken using a CLARIOstar plate reader (BMG Labtech). Sample wells were first normalized to
blank Matrigel wells, and then to unirradiated controls. Z-stack images covering the entire
Matrigel dome area were taken using a Cytation 3 Cell Imaging Multi-Mode Reader (Biotek
Instruments, Inc.).

Z-stack images were stitched using Photoshop version 19.1.7

(RRID:SCR_014199) and viable organoids measuring at least 150 μm were manually quantified

95

using ImageJ version 1.52q (RRID:SCR_003070). For organoids analyzed via z-stack imaging,
the surviving fraction was calculated as described previously.212

Statistical Methods
All statistical analyses were performed using GraphPad Prism® V.8 (San Diego, CA;
RRID:SCR_002798), with a significance level of a = 0.05. Dunnett’s multiple comparisons test
was used to analyze Dual Luciferase Assays.

4.4 Results
Transcriptomic Analysis of HIF2 Overexpression in Small Intestinal Organoids by RNA
Sequencing
To gain insight into how the HIFs regulate GI biology and to understand the mechanisms
by which HIF2 confers radioprotection to the small intestine, we generated a 3D murine small
intestinal organoid model system. We harvested duodenum crypts of wild-type C57BL/6 mice,
seeded them in basement membrane matrix (Matrigel), and cultured them in conditioned media
containing Wnt3a, R-spondin 3, and noggin (Figure 32A).202 These conditions enrich for
intestinal stem cells (ISCs), which self-assemble into crypt-like 3D structures that are able to
recapitulate the small intestinal crypt ex vivo.213 We then transiently overexpressed a nondegradable HIF1 or HIF2 allele,203 which contain mutations in the two key prolyl residues that
are hydroxylated by the EGLN proteins, rendering them stable even under normoxic conditions,
using adenoviral particles (Figure 32A). We confirmed adenoviral-mediated HIF overexpression
by both western blot and RT-qPCR, and then performed RNA sequencing (Figures 32A-C).
Among thousands of coding transcripts assessed, 1,113 genes exhibited significant
differential expression between control GFP- and HIF2-overexpressing duodenal organoids
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Figure 32. HIF2 overexpression in ISC-enriched duodenal organoid cultures. (A) Experimental
design to generate 3D murine small intestinal organoid model system. Duodenal organoids were
transduced with Adenovirus-human HIF1 (Ad-hHIF1), Ad-hHIF2, or Ad-GFP as control, and then RNA
sequencing was performed. Created with BioRender.com. (B) Left: Validation of adenovirus-mediated
gene transfer by Western blot and its quantification (right). (C) Validation of adenovirus-mediated gene
transfer by RT-qPCR. All error bars represent mean ± SEM. ***P < 0.001, by Student’s t test.

(Figure 33A). All the differentially expressed genes with statistical significance were selected
with p < 0.05, False Discovery Rate (FDR) < 0.05, and at least 2-fold change. Hierarchical
clustering analysis revealed a total of 461 upregulated genes and 652 down-regulated genes
(Figure 33A). The entire set of differentially expressed genes can be visualized in a volcano plot
in Figure 33B. To validate our RNA sequencing results, we independently assessed the
expression of 5 genes by RT-qPCR. Our results confirmed that Stat6, Aqp8, and Nos2 were
upregulated and that Wnt4 and Egr1 were downregulated in HIF2-overexpressing duodenal
organoids compared to wild-type duodenal organoids, indicating that the RNA sequencing dataset
is reliable (Figure 33C).
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Figure 33. Differentially expressed gene profile in HIF2-overexpressing duodenal organoids. (A)
Heatmap shows all the differentially expressed genes in duodenal organoids infected with Ad-hHIF2 or
control Ad-GFP evaluated via RNA sequencing (n = 3 biological replicates/group). (B) Volcano plot of
the differentially expressed genes. (C) RT-qPCR validation of the sequencing data in (A). All error bars
represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, by Student’s t test.

We also examined the transcriptome of HIF1-overexpressing organoids to gain more
insight into how the HIFs regulate overall ISC biology. Among the thousands of coding transcripts
assessed, only 55 genes exhibited significant differential expression between control GFP- and
HIF1-overexpressing duodenal organoids, in which 25 genes were upregulated and 30 genes were
downregulated (Figure 34). Interestingly, the only genes commonly upregulated by HIF1 and
HIF2 in our dataset were Nanp, Ppp1r3c, Rasgrf1, Klhl3, Mical2, and Nos2, and the only
transcripts commonly downregulated by both HIFs were Slc18a1, Gm37069, Hr, Gm12480,
Gm13151, Gm21981, Klhl30, Vcp-rs, Gm4204, AY512931, and Gm28037. We then focused our
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Figure 34. Differentially expressed gene profile in HIF1-overexpressing duodenal organoids. (A)
Heatmap shows all the differentially expressed genes in duodenal organoids infected with Adeno-hHIF1
or control Adeno-GFP evaluated via RNA sequencing (n = 3 biological replicates/group). (B) Volcano
plot of the differentially expressed genes.

attention on the HIF2 dataset, as HIF2 and not HIF1, has been shown to be the main HIF isoform
driving GI radioprotection.164

HIF2 Induces Intestinal Non-Canonical Wnt5a Expression
Interestingly, the HIF2-induced transcriptome included known radiation modulators as
well as genes involved in GI healing and homeostasis, as highlighted in Figure 35A in blue and
red, respectively. We identified Wnt5a as a transcriptional target of HIF2, but not HIF1 (Figure
35A), and interestingly, Wnt5a has a known connection to non-canonical intestinal crypt
regeneration.205 Thus, we took a candidate approach to further investigate its transcriptional regu99

Figure 35. Candidate approach identifies Wnt5a as direct HIF2 target. (A) Post-Fold Change
(PostFC) of 20 DE genes identified from the RNA sequencing analysis. (B) RT-qPCR validation of
HIF2-induced Wnt5a upregulation in wild-type duodenal organoids infected with Ad-GFP or Ad-hHIF2.
Data represents 3 biological replicates (3 technical replicates/mouse). (C) RT-qPCR showing HIF2induced upregulation of Wnt5a in LSL-hHIF2 duodenal organoids infected with Ad-GFP or Ad-Cre.
Data represents 3 biological replicates (3 technical replicates/mouse). All error bars represent mean ±
SEM. *P < 0.05, **P < 0.01, by Student’s t test.

lation by HIF2. We verified that Wnt5a was upregulated by HIF2 using two approaches. First, we
performed RT-qPCR to independently evaluate duodenal organoids that transiently organoids that
transiently overexpressed non-degradable HIF2 via Adeno-hHIF2 transduction,203 and found
significantly increased Wnt5a expression by almost 50-fold compared to organoids transduced
with Adeno-GFP (Figure 35B). Second, we generated duodenal organoids from mice that
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conditionally overexpressed non-degradable human HIF2 by knock-in into the Rosa 26 locus
(R26-LSL-hHIF2),203 transduced them with either Adeno-Cre or control Adeno-GFP vectors, and
assessed Wnt5a expression using RT-qPCR. Stable HIF2 overexpression also resulted in
significant upregulation of Wnt5a by 6-fold (Figure 35C). Together, these results suggest that
HIF2 induces intestinal Wnt5a expression.

HIF2 Directly Activates the Wnt5a Promoter
The HIFs are transcription factors that recognize and bind hypoxia response elements
(HREs) in promoter or enhancer regions to induce gene transcription.20 Thus, we analyzed the
WNT5A promoter sequence to determine whether it contained putative HRE motifs and identified
multiple low- and high-stringency HRE consensus sequences (Figure 36A). To determine
whether induction by HIF2 occurs directly or indirectly, we designed luciferase reporter
constructs of the human WNT5A promoter spanning from 2,000 nucleotides upstream of the
transcriptional start site211 to 200 nucleotides downstream, containing five HRE consensus
sequences that are closely associated with HIF ancillary sequences (HAS) and E-box motifs
(Figure 36A). HAS and E-box motifs are cis-element that are required for an HRE to be
functionally active. Both motifs play a role in the recruitment of transcriptional machinery that
together with HIF2 induce promoter activation.30, 214, 215 We transfected this construct into human
embryonic kidney-derived Adherent 293 (AD-293) cells along with an expression vector
encoding GFP or constitutively active human HIF1 or HIF2203 and performed dual luciferase
reporter assays. We found that HIF2 significantly increased WNT5A promoter transactivation by
eight-fold over GFP controls (Figure 36B). HIF1 only modestly affected promoter activity
(Figure 36B).
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Figure 36. HIF2 directly activates the WNT5A promoter via HREs. (A) Human WNT5A promoter
scheme showing distal (-1648, -1548, and -631) and proximal (-296 and +82) HREs identified by
sequence analysis. (B) Dual luciferase reporter assay in AD-293 cells with wild-type human WNT5A
promoter-luciferase construct and transactivation by HIF1, HIF2, or GFP control plasmids (n=4
transfections/group). (C) Dual luciferase reporter assay in AD-293 cells with human WNT5A promoterluciferase construct containing wild-type sequence (-2000wt) or mutations of distal (-1648mut, 1548mut, -631mut) and proximal (-296mut and +82mut) HREs with transactivation by HIF1, HIF2, or
GFP control plasmids (n=4 transfections/group).
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To understand if any specific HRE motif of the WNT5A promoter is required for its
activation by HIF2, we performed mutational analyses. We engineered transversion point
mutations on the guanine and cytosine nucleotides of three distal and two proximal putative HRE
sites within the promoter, and transfected AD-293 cells with these constructs to perform promoter
activation studies (Figure 36C and Figure 37). We found that independently mutating the two
most distal HREs in the WNT5A promoter had the most impact on HIF2-induced transactivation,
and that these two HREs are differentially regulated by HIF2. The point mutation at the HRE in
position -1548 significantly diminished the previously observed HIF2-induced promoter
activation, suggesting that the -1548HRE is necessary for HIF2’s ability to bind and positively
regulate the WNT5A promoter (Figure 36C). Importantly, this -1548HRE resides upstream of a
HAS, which is also in close proximity to an E-box (Figure 36A and Figure 37). Conversely,
mutating the -1648HRE resulted in an increased ability of HIF2 to transactivate the WNT5A
promoter, suggesting that it might be a repressive HRE. Although the HRE at -1648 resides nearby
E-box and HAS motifs, HRE sites that are preceded by cytosine nucleotides on 5’ form E-box
binding sites of other basic helix-loop-helix transcription factor families, and HIFs rarely
recognize these.215 Moreover, while HIF2-induced gene upregulation is largely mediated by direct
HIF2 binding to DNA motifs, HIF2-induced gene repression tends to occur indirectly through
transcriptional co-repressors.30 Thus, we posit that direct binding of HIF2 to the -1548HRE
promotes WNT5A transcription, whereas HIF2 interaction with the -1648HRE promotes the
recruitment of repressive transcriptional machinery. The point mutations of the HREs at positions
-631, -296, and +82 did not alter the activation of the WNT5A promoter by HIF2 (Figure 36C).
Taken all together, our results indicate that HIF2 directly activates the WNT5A promoter, possibly
by binding the -1548HRE.
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Figure 37. Sequences of the Human WNT5A promoter WT and HRE mutant constructs used for
dual luciferase assays.

Wnt5a Increases Intestinal Stem Cell Survival and Cryptogenic Potential Following
Radiations
Wnt5a is a non-canonical Wnt ligand that has been shown to promote the formation of
new intestinal crypts in order to re-establish homeostasis after intestinal mucosal injury.205 To
evaluate whether Wnt5a mediates HIF2-afforded GI radioprotection, we performed a spheroid
formation assay, which is an ex vivo microcolony assay that allows us to evaluate potential
radiation modulators in small intestinal organoid cultures.206 We treated CBRLuc-mCherry, a
murine duodenal mCherry reporter organoid line,206 with recombinant Wnt5a (rWnt5a) 10 hours
prior to irradiation, then exposed them to 0-8Gy of Xrays, and re-seeded single cells in Matrigel
(Figure 38A-B). CBRLuc-mCherry organoids that were pre-treated with rWnt5a produced
significantly higher relative bioluminescence levels six days after irradiation, compared to
vehicle-treated organoids, indicating that rWnt5a increased the number of regenerating crypts
(Figure 38B). Pre-treatment with rWnt5a significantly increased the cryptogenic capacity of
CBRLuc-mCherry organoids exposed to 2 Gy and 4 Gy by 2-fold and 6-fold, respectively, and
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Figure 38. Wnt5a prevents, but does not mitigate, radiation-induced intestinal crypt cell death.
(A) Schematic representation illustrating how spheroid formation assays were performed using murine
duodenal CBRLuc-mCherry reporter organoids to test rWnt5a. (B) CBRLuc-mCherry organoids treated
with vehicle (PBS) or 1 µg/ml rWnt5a for 10h were exposed to the indicated doses of ionizing radiation.
Bioluminescence was measured 6 days post-radiation (n = 3 per group). (C) CBRLuc-mCherry duodenal
reporter organoids treated with vehicle (PBS) or 1 µg/ml rWnt5a for 10h were exposed to the indicated
doses of ionizing radiation, and then were treated with rWnt5a again immediately after the spheroid
formation assay was seeded, and 48h later. Bioluminescence was measured (continued in next page)
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also increased the cryptogenic capacity of organoids exposed to 6 Gy by 2.8-fold, but this was not
statistically significant (Figure 38B). Interestingly, CBRLuc-mCherry organoids that continued
receiving rWnt5a treatment after irradiation did not display improved cryptogenic capacity
(Figure 38C). Moreover, initiating rWnt5a treatments only after irradiation merely improved the
cryptogenic capacity of CBRLuc-mCherry organoids (Figure 38D). These results suggest that
Wnt5a could be radioprotective to small intestinal crypts but does not mitigate radiation damage
after it has occurred. A possible explanation for these results is that Wnt5a suppresses intestinal
organoid proliferation by inducing TGF-β signaling,205 which would protect cycling ISCs from
radiation, but would dampen their capacity to regenerate crypts if Wnt5a treatment was continued
after the radiation injury was incited.
To understand whether Wnt5a is necessary for intestinal crypt regeneration following
radiation injury, we generated conditional Wnt5a knockout (Wnt5aCKO) duodenal organoids from
Wnt5afl/fl mice and transduced them with Adeno-Cre-GFP or control Adeno-GFP vectors. In
agreeance with published work demonstrating that Wnt5a is dispensable for homeostasis in the
gut postnatally,216 deletion of Wnt5a did not affect organoid growth or morphology (Figure 39A).
We then performed a modified spheroid formation assay using the Wnt5aCKO duodenal organoids
and z-stack imaging, rather than bioluminescence, to quantify regenerating organoids (Figure
39B). Loss of Wnt5a did not affect the cryptogenic capacity of unirradiated duodenal organoids
(Continued Figure 38 legend) 6 days post-radiation (n = 3 per group). Continuous rWnt5a treatment
does not improve clonogenic capacity of CBRLuc-mCherry organoids exposed to radiation. (D)
CBRLuc-mCherry duodenal reporter organoids were exposed to the indicated doses of ionizing
radiation, and then were treated with vehicle (PBS) or 1 µg/ml rWnt5a for 5h and 48h after irradiation.
Bioluminescence was measured 6 days post-radiation (n = 3 per group). Post-radiation rWnt5a treatment
does not improve clonogenic capacity of CBRLuc-mCherry organoids. All error bars represent mean ±
SEM. *P < 0.05, **P < 0.01, by Student’s t test.
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Figure 39. Wnt5a is necessary for crypt regeneration in response to radiation. (A) Wnt5afl/fl
duodenal organoids were transduced with Adeno-Cre-GFP or control Adeno-GFP to generate Wnt5a
knockouts. Representative bright field and GFP images are shown. (B) Schematic representation
illustrating how spheroid formation assays were performed using Wnt5afl/fl duodenal organoids to test
whether Wnt5a is necessary for crypt regeneration following radiation. (C) Left: Wnt5afl/fl duodenal
organoids infected with Adeno-Cre-GFP or Adeno-GFP were exposed to the indicated doses of ionizing
radiation. Z-stack images were stitched and organoids larger than 150 µm in diameter were quantified
6 days post-radiation and mean surviving fraction is plotted (n = 3 per group). Right: Representative
stitched bright field Z-stack images are shown. All error bars represent mean (continued in next page)
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Figure 40. rWnt5a treatment rescues crypt regeneration in irradiated Wnt5aCKO duodenal
organoids. Wnt5afl/fl organoids were infected with Adeno-Cre-GFP or control Adeno-GFP, treated with
vehicle or rWnt5a (600 ng/ml), and then treated with the indicated doses of ionizing radiation. (A)
Representative bright field images with (B) quantification of viable organoids are shown 6 days after
irradiation (n = 3 per group). All error bars represent mean ± SEM. *P < 0.05, **P < 0.01, ***P <
0.001, ****P < 0.0001, by Tukey’s multiple comparisons test.

(Figure 39C), again confirming that Wnt5a is dispensable for crypt homeostasis (Figure 39A).216
On the other hand, deletion of Wnt5a significantly reduced the fraction of surviving duodenal
organoids after 6 Gy of radiation (Figure 39C), indicating that Wnt5a is necessary for crypt
regeneration following radiation. Furthermore, treatment with recombinant Wnt5a (rWnt5a)
rescued Wnt5a-depleted duodenal organoids from radiation-induced ISC death (Figure 40).
Taken together, these results suggest that Wnt5a increases ISC survival and is both necessary and
sufficient for ISC radioprotection.

(Continued Figure 39 legend) ± SEM. *P < 0.05, **P < 0.01, by Student’s t test.
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4.5 Discussion
Radiation therapy for abdominal and pelvic tumors is challenging because the small
intestine is exquisitely radiosensitive, which limits the dose that can be delivered to tumors
without major GI toxicity.139-142,

201

Unfortunately, there are no FDA-approved therapies to

prevent GI radiotoxicities. Multiple groups, including our own, have shown that HIF2
stabilization by pharmacological EGLN inhibition protects the small intestine against
radiation.164-167 However, the mechanism by which HIF2 radioprotects ISC and prevents GI
radiotoxicity remains unclear. The current study provides mechanistic insight into how HIF2
reduces the radiosensitivity of the intestinal crypt. Moreover, to the best of our knowledge, this is
the first study that evidences a convergence between non-canonical Wnt signaling and hypoxia
signaling.
Here we used ISC-enriched 3D duodenal organoid cultures to mimic the small intestinal
crypt and studied the mechanism of HIF2 radioprotecion by both transient and stable HIF2
overexpression. Unsurprisingly, the HIF2-induced intestinal transcriptome included many genes
that are essential for normal GI homeostasis and barrier function, and interestingly, some of these
genes have been implicated in cellular response to radiation. We took a candidate approach and
focused our attention on Wnt5a, which has been shown to play roles in the development of the
intestinal tract, the proliferation of ISCs, and their capacity to regenerate upon GI injury.205, 216, 217
In zebrafish embryos, Wnt5a has also been shown to regulate gastrulation and to ameliorate
radiation-induced toxicity.217 Here we provide evidence that Wnt5a is a direct HIF2 target. We
identified five major HRE sites within the human WNT5A promoter and our experiments in human
cells confirmed that HIF2 directly activates the WNT5A promoter through a functional HRE motif
located 1548 nucleotides upstream of the transcriptional start site. This -1548HRE site resides
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near HAS and E-box sequences, which help recruit transcriptional co-activators.215 Nevertheless,
our promoter studies were focused on 2,2000 nucleotides surrounding the WNT5A transcriptional
start site, thus, there could be additional distal HRE sites that are regulated by HIF2.
Our study is the first to show that Wnt5a could be a potential target to prevent GI
radiotoxicity. We showed that Wnt5a is both necessary and sufficient for ISC survival and crypt
regeneration after exposure to radiation. Deletion of Wnt5a completely impaired the ability of
ISCs to form crypt spheres after being irradiated, and addition of rWnt5a rescued ISCs from
radiation-induced cell death. Importantly, our phenotype was only reproducible when rWnt5a was
administered before radiation treatments. Wnt5a signaling has been shown to inhibit both
intestinal and hematopoietic stem cell proliferation.205, 218 Because radiation is more toxic to
rapidly proliferating cells, suppression of cell proliferation prior to radiation would allow ISCs to
sustain the effects of radiation. Wnt5a binds to the Frizzled (Fzd) family of cell surface receptors,
including Fzd-1/2/4/5/7/8,219 and its canonical co-receptors Lrp5/6 or its non-canonical coreceptors Ror1/2 and Ryk, and activates either the canonical Wnt/Beta-catenin pathway, the noncanonical planar cell polarity pathway, or the non-canonical Wnt/Ca2+ pathways.211 In intestinal
organoids, non-canonical Wnt5a signaling through Ror2 induces TGF-β signaling and Smad3
phosphorylation with subsequent nuclear translocation, leading to increased expression of
multiple cyclin-dependent kinase inhibitors, and ultimately arrest of cell proliferation.205 Thus,
activation of these downstream signaling pathways could be a possible explanation for the relative
success of Wnt5a as a radioprotector while failing to mitigate radiation injury post-exposure. It is
important to note that our studies were limited to ex vivo duodenal organoid models and that our
observations should be validated using in vivo GI radiation models.
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Wnt5a has been implicated in tumor progression, raising concerns about its potential use as
a GI radioprotective agent in cancer patients.220, 221 While this concern is warranted, HIF2 would
only be activated for a short period only during radiation to reduce normal tissue toxicity, which
may reduce the potential oncogenic effects of this molecule. Additional pre-clinical studies using
cancer models to assess this relative risk are warranted before Wnt5a can be considered for clinical
translation. Furthermore, we note that our radiation model employs conventional single fractions,
whereas many GI radiation oncology regimens employ fractionated radiation. Accordingly, the
extent of Wnt5a-afforded ISC radioprotection would need to be evaluated in the setting of
fractionated regimens.
We note that HIF2 may have additional molecular mechanisms by which it promotes ISC
survival and intestinal radioprotection. Prior studies have shown that HIF2 both protects and
mitigates GI radiation injury,164 yet our results here suggest that Wnt5a does not mitigate intestinal
crypt radiation injury. Thus, future studies should assess which HIF2 targets are potential GI
radiation mitigators. For example, the Neuroepithelial cell transforming 1 (Net1) gene, which was
significantly upregulated in our HIF2 dataset, has been shown to play a role in DNA damage
repair after ionizing radiation.222, 223 Similarly, Ets1 and Klf4 are transcription factors that are
essential for stem cell self-renewal and can regulate DNA damage repair,224, 225 and both were
significantly upregulated by HIF2.
Moreover, our study was limited to the ISC compartment of the small intestine. However,
other cellular compartments, such as the intestinal stromal niche, gut macrophages and the
endothelial compartment have established roles in the intestinal response to injury.226, 227 Further
investigation into these cellular compartments is required to fully dissect the role of HIF2 in the
radiation responses of the intestinal tract.
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Chapter IV: Discussion

112

5.1 Summary of Conclusions
Pancreatic cancer is an utterly deadly disease that affects the lives of thousands of patients.
It is characterized –from its inception to its progression– by profound hypoxia and an exaggerated
desmoplastic response that leads to extensive stromal deposition.70, 73 This fibroinflammatory
tumor stroma is well known to drive suppression of anti-tumor immune responses and resistance
to chemotherapy and immunotherapy.72,

79, 80

Moreover, the pancreatic tumor hypoxia also

contributes to resistance to chemotherapy and immunotherapy, as well as radiotherapy.29 Despite
the implications of both the tumor stroma and the hypoxic response in pancreatic treatment
recalcitrance, the complex interplay between HIFs, the TME/stroma, and immunosuppression
remains unclear. This dissertation aims to (1) close the long-standing gap in knowledge about the
relative roles of the HIFs in pancreatic cancer, specifically how they modulate TME
immunosuppression, and (2) elucidate mechanisms by which HIF2 promotes intestinal
radioprotection, with the objective of improving PDAC radiotherapy.
In Chapter 1, we discussed the roles of the oxygen sensing and hypoxic response pathways
in healthy and pathological states, emphasizing how the EGLN/HIF axis are hijacked by tumors
and their microenvironmental mileu to thrive and progress. In particular, we highlighted that HIF1
seems to be tumor suppressive in pancreatic cancer, whereas HIF2 seems to play oncogenic roles.
The therapeutic options for pancreatic cancer were also reviewed, underscoring that
immunotherapies fail due to tumor immunosuppression, whereas radiotherapies fail due to GI
radiotoxicity. Lastly, we explained why CAFs are central to pancreatic cancer biology and
immunosuppression, and the importance of understanding whether HIF signaling modulates their
function. We hypothesized that stromal-derived HIFs play a role in PDAC immunosuppression.
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Moreover, in Chapter 1 we discussed that HIF2 has tissue healing functions and that it has
been shown to promote intestinal regeneration following radiation injury.164, 165 We hypothesize
that HIF2’s regenerative function could be exploited to counteract GI radiotoxicity in PDAC.
Because PDAC displays maximal stabilization of the HIFs,165 we believe that targeting HIF2 or
its downstream pathways could enable optimization of PDAC radiotherapy without protecting
tumors. In conclusion, in this dissertation my objectives were to understand the role of HIF2
in normal tissue dynamics and in the TME.
In Chapter 2, we elucidated the role of the HIFs in pancreatic aSMA+ CAFs and the
TME.228 We showed that aSMA+ CAF-specific expression of HIF2, but not HIF1, drives
paracrine signals that increase tumor infiltration with immunosuppressive TAMs and Tregs.
Using both genetic and pharmacologic approaches, we found that inhibition of HIF2 improved
survival in autochthonous and syngeneic mouse models. Mice with CAF-HIF2 KO had fewer
PanIN lesions, slower growing tumors, and possibly higher tumor clearance, indicating that HIF2
plays an oncogenic role in the CAF compartment. Importantly, our approach of directly targeting
HIF2 functions in CAFs does not overtly physically disrupt the tumor stroma or increase
metastasis, as has been the case with other attempts to modulate aSMA+ CAFs.134 Not only did
aSMA+ CAF-HIF2 KO not change total quantity of CAFs, but it had minimal impact on tumor
fibrosis. Instead, our data suggests that abrogation of HIF2 signaling in aSMA+ CAFs relieves
tumor immunosuppression and enables immunologic clearance of cancer.
Using ex vivo CAF and TAM cultures, we showed that HIF2 signaling in aSMA+ CAFs
drives TAM migration and polarization into an immunosuppressive M2 phenotype. Moreover, by
leveraging scRNA-seq and IHC, we found that CAF-HIF2 KO tumors contained fewer iCAFs,
TAMs, and Tregs, and more CD56+ NK cells, NK T cells, and naïve CD8+ T cells. The
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observation of fewer iCAFs in aSMA+ CAF-depleted tumors is interesting, and requires further
investigation (see section 5.2 Future Directions). These TAMs and Tregs were a major source
of checkpoint proteins CD80/CD86, PD-L1, and CTLA-4. Together, these results suggested that
abrogation of HIF2 signaling in CAFs could prime PDAC for immunotherapy success. Indeed,
we showed that PT2399, an analog of the FDA-approved belzutifan, enhanced responses to
checkpoint blockade with anti-CTLA-4 and anti-PD-1 antibodies in two syngeneic PDAC models.
Furthermore, aSMA+ CAFs are largely considered to be myCAFs with contractile and profibrotic functions. However, our data suggests that myCAFs can also be immunomodulatory.
Taken together, our studies indicate that stromal-derived HIF2 coordinates pancreatic TME
immunosuppression.
In Chapter 3, we focused on improving radiotherapy for PDAC by investigating
mechanisms by which HIF2 prevents intestinal radiotoxicity. We showed that HIF2 confers
radioprotection to the small intestine, at least in part, by inducing Wnt5a expression to promote
survival of the ISCs in the crypts.229 Using ISC-enriched 3D duodenal organoid cultures, we
studied the HIF2-induced intestinal transcriptome and found induction of a panoply of genes that
are essential for normal intestinal homeostasis and barrier function, some of which have been
implicated in the cellular response to radiation. We took a candidate approach and focused our
attention on Wnt5a, which plays a role in the development of the intestinal tract, the proliferation
of ISCs, and their capacity to regenerate upon GI injury.205, 216, 217 We found that HIF2 directly
transactivates the WNT5A promoter through a functional HRE motif located upstream of the
transcriptional start site and in proximity to HAS and E-box sequences. Nevertheless, our
promoter studies were focused on 2,2000 nucleotides surrounding the WNT5A transcriptional start
site, thus, there could be additional distal HRE sites that are regulated by HIF2. Moreover, we
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showed that Wnt5a is both necessary and sufficient for ISC survival and crypt regeneration in the
context of radiation injury. Though we did not look into the mechanism by which Wnt5a achieves
this, we speculate that this is through arrest of cell proliferation, which would allow ISCs to
sustain the effects of radiation. In intestinal organoids, non-canonical Wnt5a signaling through
Ror2 induces TGF-β signaling and Smad3 phosphorylation, leading to upregulation of several
cyclin-dependent kinase inhibitors, and ultimately arrest of cell proliferation.205
In summary, in Chapter 2 we concluded that HIF2 is oncogenic in PDAC and
that HIF2 inhibition is a novel (and feasible) strategy to improve immunotherapy
efficacy, while in Chapter 3 we proposed that stabilization of HIF2 could aid in
optimizing radiotherapy. These seemingly contrasting conclusions can be reconciled
by the fact that HIF2 seems to be maximally expressed in PDAC, but not in the
intestinal tract. 165 Thus, stabilization of HIF2 using FG-4592 increases HIF2
expression in the intestines but not in PDAC. 165 Hence, in theory, a short-term course
of FG-4592 to cover the usual ~5 days of SBRT could have a net benefit for patients,
by enabling radiation dose escalation and better tumor control.

5.2 Future Directions
As discussed in the introductory chapter, pancreatic TME biology is quite
complex. This dissertation has helped to bridge the gap in knowledge about the relative
roles of HIF2 in the PDAC stroma (Chapter 2). By that same token, it has opened new
avenues of research. To thoroughly understand HIF2’s role in the pancreatic TME, and
to use this approach to improve immunotherapy for PDAC, several important biological
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gaps should be filled, together with additional pre-clinical and clinical studies, and
these are outlined below.
(1) Biological/mechanistic studies in CAFs (1.1), macrophages and immune
cells (1.2), and PDAC cells (1.3). (1.1) Here we targeted aSMA+ CAFs, which include
myCAFs and apCAFs. 122 Interestingly, this led to a reduction in the proportion of
iCAFs, which despite not reaching statistical significance may carry great biological
significance. Moreover, my in vitro data suggests that hypoxia suppresses the myCAF
phenotype and induces an iCAF phenotype. This is impactful, because if this proves
correct, HIF2 inhibition could not only prevent harmful CAF-TAM crosstalk, but it
could also fully reprogram CAFs. However, as mentioned previously, our evaluation
of the intrinsic roles of HIF2 in aSMA+ CAFs has four limitations that can be improved
upon:
(1.1.1) Our characterization of the stromal and immune landscape was performed
in late-stage tumors, when they are notoriously overtaken by myCAFs. 135 Thus, to
properly understand HIF2’s role in CAF/stromal evolution throughout PDAC
progression, earlier timepoints need to be used.
(1.1.2) The CAF subtype analyses that I performed (scRNA-seq and in vitro
experiments) were limited to a small panel of phenotypic markers. As discussed in the
introductory chapter, CAFs are quite heterogeneous and dynamic, so additional subtype
markers should be evaluated to have a better understanding of how hypoxia and HIF2
impact CAF phenotype (e.g. Ctgf, Mmp11, Hopx, Tagln, Il6, Il11, Pdgfra, Cxcl2, and Cxcl12).
Moreover, these phenotypic analyses must be coupled to functional analyses,
considering the diverse functions of myCAFs, iCAFs, and apCAFs (fibrosis/contrac117

tility, immune modulation, and antigen-presentation; see section 1.5 The Role of the
Tumor Stroma in Pancreatic Cancer Therapy Failure). Our analysis of the extracellular
matrix was limited to collagen abundancy. Despite the fact that we saw only modest changes
in tumor fibrosis, it is possible that HIF2 impacts the composition, organization, and/or stiffness
of the stroma, and thus, this should be evaluated in vivo and/or in vitro.
(1.1.3) Our ex vivo CAF model employs 2-D cultures, which have been shown
to enrich for the myCAF phenotype, even when the originally isolated CAF is an iCAF
or apCAF. 122,
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For example, our 2-D model prevents CAFs from expressing CD74.

Because we targeted HIF2 in both myCAFs and apCAFs through aSMACreERT2, finding
more appropriate techniques to model myCAF and apCAF biology is of utmost importance.
CAFs should be sorted by a panel of known markers and directly cultured in optimal
conditions: myCAFs in 2-D and iCAFs in 3-D with KPC conditioned media. 123 CAFs
could be derived from Hif1 CKO , Hif2 CKO , and Arnt CKO tumor-bearing mice. It is unclear
what the best method to model apCAFs ex vivo is, but a 3-D model is probably better
suited than a 2-D model, since CAFs respond to spatial cues.
(1.1.4) The pancreatic TME contains a higher proportion of iCAFs in earlier
stages of the disease. 124 Interestingly, pancreatic iCAFs have upregulation of Hif1 a. 122
Because hypoxia ensues before invasive cancer does, 83, 91 exploring the relative roles
of HIF1 and HIF2 in other CAF subtypes, particularly iCAFs, is important to obtain a
comprehensive understanding of hypoxia and the pancreatic TME. For this purpose,
our dual recombinase approach can be employed using different Cre drivers, such as
Fsp1 191 or Fap. 124
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(1.2) The most conspicuous changes in CAF-HIF2 KO tumors compared to CAFHIF2 WT tumors was the downregulation of pathways involving macrophages. We
demonstrated that HIF2 signaling in CAFs regulates macrophage migration and
polarization to an M2 phenotype through an unknown paracrine mechanism. As
mentioned previously, pancreatic TAMs originate from both circulating monocytes and
embryonically-derived tissue resident macrophages, with the former giving rise
predominantly to antigen-presenting M1 macrophages, and the latter giving rise
predominantly to pro-fibrotic M2 macrophages. 109 Our bulk RNA-seq, scRNA-seq, and
IHC analyses indicate that abrogation of HIF2 results in less chemotaxis of monocytes
to tumors. Moreover, based on our observation that CAF-HIF2 KO tumors did not have
overt changes in collagen content, it is tempting to hypothesize that HIF2 signaling in
CAFs activates monocytes, rather than tissue resident macrophages. However, beyond
migration, we did not evaluate how CAFs impact TAM pro-fibrotic or inflammatory
functions (see point 1.2.2 below). To fully close the gap in knowledge regarding the
role of HIF2 in the pancreatic tumor stroma (to which TAMs contribute greatly) I
propose five impending questions to answer:
(1.2.1) Does HIF2 play a direct role in pancreatic TAMs? We found that MDSCs, Mrc1+
macrophages, and Arg1+ macrophages had high expression of Hif2a (Epas1), which can be
targeted with global (systemic) HIF2 inhibition using PT2399. In our experiments using RAW
264.7 macrophages, we showed that these cells became activated with CAF conditioned
media, but not directly in hypoxia or with normal fibroblast conditioned media,
indicating that HIF2 regulates them in a non-cell autonomous fashion via CAFs.
However, experiments using BMDMs gave slightly different results: I found that
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BMDMs are responsive to hypoxia in a HIF2-dependent manner, as has been shown
previously, 106,

107, 230

and they are also responsive to normal fibroblast conditioned

media. (For reasons beyond my control, I could not assess their response to CAF
conditioned media at the time, but this should be evaluated.) As discussed previously,
these observed differences can be due to the fact that RAW 264.7 macrophages are
transformed, whereas BMDMs are primary cells. Thus, BMDMs are a better model of
macrophage physiology than RAW 264.7 macrophages, and they should be used to
evaluate whether PT2399 inhibits their activation to an M2 phenotype. HIF2 inhibition
would be an even more succesful approach to improve tumor responses to
immunotherapy if it could tame both CAFs and TAMs!
(1.2.2) Similar to the case of CAF subtypes being dynamic, TAM subtypes are
dynamic. Thus, in addition to expanding the panel of markers used to assess M1 vs M2
phenotype, future investigations should be complemented with functional studies to
properly

determine

whether

abrogation

of

HIF2

signaling

in

CAFs

alters

immunosuppression by TAMs. Specifically, it should be determined whether HIF2
plays a direct and/or indirect role (via CAFs) on TAM-mediated suppression of CD8 +
T cell proliferation and activation, as well as on TAM-mediated induction of Treg
proliferation and activation. For this, specific T cell populations can be isolated for
spleens, labeled with CFSE, and co-cultured with TAMs (or CAFs, or their conditioned
media), followed by multi-parameter flow cytometry to measure CFSE dilution and
cytokines that mark activated (IL-2, TNFa, IFN-y, Granzyme B) or exhausted (CD27,
CD28, CD57, KLRG-1, and PD-1) CD8 + T cells. Similarly, Treg activity could be
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measured via CTLA-4, IL-10, and TGF-β. Furthermore, the fibrotic TAM functions should
also be assessed by evaluating their production and secretion of matrix components.
(1.2.3) Perhaps the most immediate question to answer is: what is this paracrine
signal driving HIF2-dependent CAF-TAM crosstalk? We are currently performing
deeper analyses of our scRNA-seq dataset to predict receptor-ligand interactions
between these cells. These analyses can be complemented with metabolome and
secretome analyses of CAFs.
(1.2.4) Are there additional HIF2-dependent communication methods between CAFs and
TAMs? Our CAF-TAM crosstalk experiments employed indirect co-cultures by using
conditioned media and indicated a paracrine signaling mechanism, but these findings do not rule
out juxtacrine or autocrine HIF2-driven signals. Direct co-cultures of CAFs and BMDMs should
be used to assess whether there are additional juxtacrine signals. HIF2-driven CAF autocrine
signals can be evaluated using our sc-RNAseq dataset, as well as the metabolomics and
secretomics experiments mentioned above.
(1.2.5) Do MDSCs play a role in our CAF-HIF2 KO phenotype? MDSCs are
quite abundant in PDAC and might be relevant to our phenotype. Before diving into a
dozen sets of experiments (like the ones already performed in macrophages and the
additional ones described above), it might be more informative to analyze tumor
sections for MDSC markers such as CD11b.
(1.3) Lastly, because the most striking changes in KPF CAF-HIF2 KO tumors
were in macrophages, this work focused on these and other immune cells, but it would
be interesting to explore HIF2-dependent CAF-Epithelial crosstalk. Our scRNA-seq data
revealed changes in the clustering of the epithelial compartment, suggesting that there are HIF2121

dependent alterations in PDAC cells. A previous study showed that HIF2 directly upregulates
Pdl1 expression in clear cell renal carcinoma cells in a cell-autonomous fashion.231 It could be the
case that in PDAC, cancer cells are modulated by HIF2 in a non-cell autonomous fashion.
(2) Pre-clinical studies. Importantly, since a large percentage of PDAC patients
receive radiotherapy at some point of their treatment, and because HIF2 plays an
important role in the intestinal recovery from radiation, it would be important to
determine whether pharmacologic HIF2 inhibition sensitizes ISCs to radiation. This
can be evaluated using patient-derived enteroids and a clinically-relevant mouse
radiation model. 232 These experiments would inform the design of a future clinical trial
(i.e. whether it is a safe approach for patients needing to undergo radiation).
(3) Clinical studies. Lastly, given the net negative roles of HIF2 in
immunosuppression, our data strongly suggests that HIF2 inhibition is a promising tool
to improve the efficacy of immunotherapy in PDAC. Belzutifan is a second-generation
HIF2 inhibitor (analogue to PT2399) that recently received FDA approval for use in VHLassociated renal cell carcinoma.184, 199 A Phase 1b/2a clinical trial could be designed to
evaluate if Belzutifan improves checkpoint immunotherapy responses in PDAC
patients.
Finally, the role of other oxygen sensors (JmjC-KDMs, ETC Complex IV, etc)
has not been explored in PDAC and could be important pieces of the hypoxic puzzle in
this devastating disease.
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5.3 Significance and Impact
This dissertation investigates the multiple roles that HIF2 plays in normal and cancerous
tissues, and provides evidence to support the targeting of HIF2 to improve cancer immunotherapy
and radiotherapy. Chapter 2 addresses a long-standing knowledge gap about the mechanism by
which hypoxia immunosuppresses the PDAC microenvironment. We identified HIF2 as the
critical isoform expressed by CAFs that drives hypoxia-related TAM immunosuppression in
pancreatic cancer. TAMs are essential cells in the TME and play critical roles in maintaining
immunosuppression and tumor fibrosis. Thus, optimal therapeutic targeting requires a deep
understanding of the crosstalk between CAFs and TAMs and their coordination of stromagenesis
and immunosuppression. Additionally, we present a novel way of targeting the PDAC stroma.
Belzutifan is a second-generation HIF2 inhibitor that recently received FDA approval for use in
VHL-associated renal cell carcinoma,179,

199

thus this is an approach that could be quickly

translated to the clinic. Given the net negative roles of HIF2 in PDAC (Table 2) and in light of
our findings, HIF2 inhibitors are a promising tool to improve the efficacy of immunotherapy and
prolong the life of pancreatic cancer patients.228, 233
Moreover, in Chapter 3 study we provide mechanistic insight into how HIF2 reduces the
radiosensitivity of the intestinal crypt. Because GI radiotoxicity is so common among cancer
patients, this could be impactful not just for PDAC patients, but for the broader patient population
that requires abdominal radiotherapy for other GI malignancies. To the best of my knowledge,
this is the first study to show that Wnt5a could be a potential target to prevent GI radiotoxicity.

123

Bibliography
1.

Biello D. The Origin of Oxygen in Earth's Atmosphere. Scientific American: Springer
Nature, 2009.

2.

Lee KE, Simon MC. SnapShot: Hypoxia-Inducible Factors. Cell 2015;163:12881288.e1.

3.

Rytkönen KT, Williams TA, Renshaw GM, Primmer CR, Nikinmaa M. Molecular
Evolution of the Metazoan PHD–HIF Oxygen-Sensing System. Molecular Biology and
Evolution 2011;28:1913-1926.

4.

West CM, van der Wel H, Wang ZA. Prolyl 4-hydroxylase-1 mediates O2 signaling
during development of Dictyostelium. Development 2007;134:3349-3358.

5.

Hughes BT, Espenshade PJ. Oxygen-regulated degradation of fission yeast SREBP by
Ofd1, a prolyl hydroxylase family member. The EMBO Journal 2008;27:1491-1501.

6.

Giaccia AJ, Simon MC, Johnson R. The biology of hypoxia: the role of oxygen sensing
in development, normal function, and disease. Genes & Development 2004;18:21832194.

7.

Fetzner S. Oxygenases without requirement for cofactors or metal ions. Applied
Microbiology and Biotechnology 2002;60:243-257.

8.

Fetzner S, Steiner RA. Cofactor-independent oxidases and oxygenases. Applied
Microbiology and Biotechnology 2010;86:791-804.

9.

Schaab MR, Barney BM, Francisco WA. Kinetic and Spectroscopic Studies on the
Quercetin 2,3-Dioxygenase from Bacillus subtilis. Biochemistry 2006;45:1009-1016.

124

10.

Hegg EL, Jr LQ. The 2-His-1-Carboxylate Facial Triad — An Emerging Structural
Motif in Mononuclear Non-Heme Iron(II) Enzymes. European Journal of Biochemistry
1997;250:625-629.

11.

Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nature Reviews
Molecular Cell Biology 2004;5:343-354.

12.

Solomon EI, Brunold TC, Davis MI, Kemsley JN, Lee S-K, Lehnert N, Neese F, Skulan
AJ, Yang Y-S, Zhou J. Geometric and Electronic Structure/Function Correlations in
Non-Heme Iron Enzymes. Chemical Reviews 2000;100:235-350.

13.

Nobel-Prize-Outreach. Press release: The Nobel Prize in Physiology or Medicine 2019.
NobelPrize.org, 2019.

14.

Gallipoli P, Huntly Brian JP. Histone modifiers are oxygen sensors. Science
2019;363:1148-1149.

15.

Jain I, Aguirre-Ghiso J, Jakob U, Simon C. Oxygen Sensing: After the Nobel. Cell
2020;180:7-8.

16.

Hancock RL, Dunne K, Walport LJ, Flashman E, Kawamura A. Epigenetic regulation by
histone demethylases in hypoxia. Epigenomics 2015;7:791-791–811.

17.

Magnani F, Nenci S, Millana Fananas E, Ceccon M, Romero E, Fraaije Marco W,
Mattevi A. Crystal structures and atomic model of NADPH oxidase. Proceedings of the
National Academy of Sciences 2017;114:6764-6769.

18.

Matuleviciute R, Cunha PP, Johnson RS, Foskolou IP. Oxygen regulation of TET
enzymes. The FEBS Journal 2021;288:7143-7161.

125

19.

McDonough MA, Loenarz C, Chowdhury R, Clifton IJ, Schofield CJ. Structural studies
on human 2-oxoglutarate dependent oxygenases. Current Opinion in Structural Biology
2010;20:659-672.

20.

Keith B, Simon MC. Hypoxia-Inducible Factors, Stem Cells, and Cancer. Cell
2007;129:465-472.

21.

Bruick RK, McKnight SL. A Conserved Family of Prolyl-4-Hydroxylases That Modify
HIF. Science 2001;294:1337.

22.

Kaelin WG, Ratcliffe PJ. Oxygen Sensing by Metazoans: The Central Role of the HIF
Hydroxylase Pathway. Molecular Cell 2008;30:393-402.

23.

Gruber M, Hu C-J, Johnson RS, Brown EJ, Keith B, Simon MC. Acute postnatal
ablation of Hif-2α results in anemia. Proceedings of the National Academy of Sciences
2007;104:2301.

24.

Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS,
Kaelin Jr WG. HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation:
Implications for O2 Sensing. Science 2001;292:464.

25.

Jaakkola P, Mole DR, Tian Y-M, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim Av,
Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ.
Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated
Prolyl Hydroxylation. Science 2001;292:468.

26.

Yu F, White SB, Zhao Q, Lee FS. HIF-1α binding to VHL is regulated by stimulussensitive proline hydroxylation. Proceedings of the National Academy of Sciences
2001;98:9630.

126

27.

Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ. Independent function of two
destruction domains in hypoxia-inducible factor-α chains activated by prolyl
hydroxylation. The EMBO Journal 2001;20:5197-5206.

28.

Epstein ACR, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji
M, Metzen E, Wilson MI, Dhanda A, Tian Y-M, Masson N, Hamilton DL, Jaakkola P,
Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ. C. elegans
EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF
by Prolyl Hydroxylation. Cell 2001;107:43-54.

29.

Huang Y, Lin D, Taniguchi CM. Hypoxia inducible factor (HIF) in the tumor
microenvironment: friend or foe? Science China Life Sciences 2017;60:1114-1124.

30.

Schödel J, Mole DR, Ratcliffe PJ. Pan-genomic binding of hypoxia-inducible
transcription factors. Biological Chemistry 2013;394:507-517.

31.

Dengler VL, Galbraith MD, Espinosa JM. Transcriptional regulation by hypoxia
inducible factors. Critical Reviews in Biochemistry and Molecular Biology 2014;49:115.

32.

Batie M, Frost J, Frost M, Wilson James W, Schofield P, Rocha S. Hypoxia induces
rapid changes to histone methylation and reprograms chromatin. Science
2019;363:1222-1226.

33.

Chakraborty Abhishek A, Laukka T, Myllykoski M, Ringel Alison E, Booker Matthew
A, Tolstorukov Michael Y, Meng Yuzhong J, Meier Samuel R, Jennings Rebecca B,
Creech Amanda L, Herbert Zachary T, McBrayer Samuel K, Olenchock Benjamin A,
Jaffe Jacob D, Haigis Marcia C, Beroukhim R, Signoretti S, Koivunen P, Kaelin William

127

G. Histone demethylase KDM6A directly senses oxygen to control chromatin and cell
fate. Science 2019;363:1217-1222.
34.

He C. Grand Challenge Commentary: RNA epigenetics? Nature Chemical Biology
2010;6:863-865.

35.

Fry NJ, Law BA, Ilkayeva OR, Holley CL, Mansfield KD. N6-methyladenosine is
required for the hypoxic stabilization of specific mRNAs. RNA 2017;23:1444-1455.

36.

Choudhry H, Harris AL. Advances in Hypoxia-Inducible Factor Biology. Cell
Metabolism 2018;27:281-298.

37.

Jia B, Tang K, Chun BH, Jeon CO. Large-scale examination of functional and sequence
diversity of 2-oxoglutarate/Fe(II)-dependent oxygenases in Metazoa. Biochimica et
biophysica acta. General subjects 2017;1861:2922-2933.

38.

Huang Y, Chen D, Liu C, Shen W, Ruan Y. Evolution and conservation of JmjC domain
proteins in the green lineage. Molecular Genetics and Genomics 2016;291:33-49.

39.

Chang Y, Wu J, Tong X-J, Zhou J-Q, Ding J. Crystal structure of the catalytic core of
Saccharomyces cerevesiae histone demethylase Rph1: insights into the substrate
specificity and catalytic mechanism. Biochemical Journal 2010;433:295-302.

40.

Xia X, Lemieux Madeleine E, Li W, Carroll Jason S, Brown M, Liu XS, Kung Andrew
L. Integrative analysis of HIF binding and transactivation reveals its role in maintaining
histone methylation homeostasis. Proceedings of the National Academy of Sciences
2009;106:4260-4265.

41.

Ho-Youl L, Kang C, Hookeun O, Young-Kwon P, Hyunsung P. HIF-1-Dependent
Induction of Jumonji Domain-Containing Protein (JMJD) 3 under Hypoxic Conditions.
Molecules and Cells 2014;37:43-50.
128

42.

Beyer S, Kristensen MM, Jensen KS, Johansen JV, Staller P. The Histone Demethylases
JMJD1A and JMJD2B Are Transcriptional Targets of Hypoxia-inducible Factor HIF*.
Journal of Biological Chemistry 2008;283:36542-36552.

43.

Pollard Patrick J, Loenarz C, Mole David R, McDonough Michael A, Gleadle
Jonathan M, Schofield Christopher J, Ratcliffe Peter J. Regulation of Jumonji-domaincontaining histone demethylases by hypoxia-inducible factor (HIF)-1α. Biochemical
Journal 2008;416:387-394.

44.

Wellmann S, Bettkober M, Zelmer A, Seeger K, Faigle M, Eltzschig HK, Bührer C.
Hypoxia upregulates the histone demethylase JMJD1A via HIF-1. Biochemical and
Biophysical Research Communications 2008;372:892-897.

45.

Niu X, Zhang T, Liao L, Zhou L, Lindner DJ, Zhou M, Rini B, Yan Q, Yang H. The von
Hippel–Lindau tumor suppressor protein regulates gene expression and tumor growth
through histone demethylase JARID1C. Oncogene 2012;31:776-786.

46.

Yang J, Ledaki I, Turley H, Gatter KC, Montero J-CM, Li J-L, Harris AL. Role of
Hypoxia-Inducible Factors in Epigenetic Regulation via Histone Demethylases. Annals
of the New York Academy of Sciences 2009;1177:185-197.

47.

Chen S, Yin C, Lao T, Liang D, He D, Wang C, Sang N. AMPK-HDAC5 pathway
facilitates nuclear accumulation of HIF-1α and functional activation of HIF-1 by
deacetylating Hsp70 in the cytosol. Cell Cycle 2015;14:2520-2536.

48.

Camuzi D, de Amorim ÍS, Ribeiro Pinto LF, Oliveira Trivilin L, Mencalha AL, Soares
Lima SC. Regulation Is in the Air: The Relationship between Hypoxia and Epigenetics
in Cancer. Cells 2019;8.

129

49.

Burr S, Caldwell A, Chong M, Beretta M, Metcalf S, Hancock M, Arno M, Balu S,
Kropf VL, Mistry RK, Shah AM, Mann GE, Brewer AC. Oxygen gradients can
determine epigenetic asymmetry and cellular differentiation via differential regulation of
Tet activity in embryonic stem cells. Nucleic Acids Research 2018;46:1210-1226.

50.

Zhang C, Samanta D, Lu H, Bullen John W, Zhang H, Chen I, He X, Semenza Gregg L.
Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and
ALKBH5-mediated m6A-demethylation of NANOG mRNA. Proceedings of the
National Academy of Sciences 2016;113:E2047-E2056.

51.

Schumacker PT. Current Paradigms in Cellular Oxygen Sensing, In Hypoxia, Boston,
MA, 2003, Springer US, 2003.

52.

Zhao RZ, Jiang S, Zhang L, Yu ZB. Mitochondrial electron transport chain, ROS
generation and uncoupling (Review). Int J Mol Med 2019;44:3-15.

53.

Gao L, Ortega-Saenz P, Moreno-Dominguez A, López Barneo J. Mitochondrial redox
signaling in O2-sensing chemoreceptor cells. Antioxidants & Redox Signaling 2022.

54.

Schroedl C, McClintock DS, Budinger GRS, Chandel NS. Hypoxic but not anoxic
stabilization of HIF-1α requires mitochondrial reactive oxygen species. American
Journal of Physiology-Lung Cellular and Molecular Physiology 2002;283:L922-L931.

55.

López-Barneo J. Oxygen-sensing by ion channels and the regulation of cellular
functions. Trends in Neurosciences 1996;19:435-440.

56.

López-Barneo J, del Toro R, Levitsky KL, Chiara MD, Ortega-Sáenz P. Regulation of
oxygen sensing by ion channels. Journal of Applied Physiology 2004;96:1187-1195.

130

57.

Hoidal JR, Brar SS, Sturrock AB, Sanders KA, Dinger B, Fidone S, Kennedy TP. The
Role of Endogenous NADPH Oxidases in Airway and Pulmonary Vascular Smooth
Muscle Function. Antioxidants & Redox Signaling 2003;5:751-758.

58.

Weissmann N, Sommer N, Schermuly RT, Ghofrani HA, Seeger W, Grimminger F.
Oxygen sensors in hypoxic pulmonary vasoconstriction. Cardiovascular Research
2006;71:620-629.

59.

Weissmann N, Zeller S, Schäfer RU, Turowski C, Ay M, Quanz K, Ghofrani HA,
Schermuly RT, Fink L, Seeger W, Grimminger F. Impact of Mitochondria and NADPH
Oxidases on Acute and Sustained Hypoxic Pulmonary Vasoconstriction. American
Journal of Respiratory Cell and Molecular Biology 2006;34:505-513.

60.

Stenmark KR, Fagan KA, Frid MG. Hypoxia-Induced Pulmonary Vascular Remodeling.
Circulation Research 2006;99:675-691.

61.

Liu JQ, Zelko IN, Erbynn EM, Sham JSK, Folz RJ. Hypoxic pulmonary hypertension:
role of superoxide and NADPH oxidase (gp91phox). American Journal of PhysiologyLung Cellular and Molecular Physiology 2006;290:L2-L10.

62.

Tafani M, Sansone L, Limana F, Arcangeli T, De Santis E, Polese M, Fini M, Russo
MA. The Interplay of Reactive Oxygen Species, Hypoxia, Inflammation, and Sirtuins in
Cancer Initiation and Progression. Oxidative Medicine and Cellular Longevity
2016;2016:3907147.

63.

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA: A Cancer
Journal for Clinicians 2022;72:7-33.

64.

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA: A Cancer
Journal for Clinicians 2021;71:7-33.
131

65.

Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM.
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid,
Liver, and Pancreas Cancers in the United States. Cancer Research 2014;74:2913-2921.

66.

Post E. Five-Year Pancreatic Cancer Survival Rate Increases to 11%. In: Team PMR, ed.
Pancreatic Cancer News: Pancreatic Cancer Action Network, 2022.

67.

Maitra A, Hruban RH. Pancreatic Cancer. Annual Review of Pathology: Mechanisms of
Disease 2008;3:157-188.

68.

Lee JS, Ruppin E. Multiomics Prediction of Response Rates to Therapies to Inhibit
Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1. JAMA Oncology
2019;5:1614-1618.

69.

Hayashi H, Kohno T, Hiraoka N, Sakamoto Y, Kondo S, Morizane C, Saito M, Shimada
K, Ichikawa H, Komatsu Y, Ueno H, Okusaka T. Gene Mutation Profile of Pancreatic
Cancer Obtained Using Targeted Deep Sequencing and Its Association with Prognosis.
Annals of Oncology 2014;25:iv234.

70.

Iacobuzio-Donahue CA, Ryu B, Hruban RH, Kern SE. Exploring the Host Desmoplastic
Response to Pancreatic Carcinoma: Gene Expression of Stromal and Neoplastic Cells at
the Site of Primary Invasion. The American Journal of Pathology 2002;160:91-99.

71.

Raphael BJ, Hruban RH, Aguirre AJ, Moffitt RA, Yeh JJ, Stewart C, Robertson AG,
Cherniack AD, Gupta M, Getz G, Gabriel SB, Meyerson M, Cibulskis C, Fei SS, Hinoue
T, Shen H, Laird PW, Ling S, Lu Y, Mills GB, Akbani R, Loher P, Londin ER,
Rigoutsos I, Telonis AG, Gibb EA, Goldenberg A, Mezlini AM, Hoadley KA, Collisson
E, Lander E, Murray BA, Hess J, Rosenberg M, Bergelson L, Zhang H, Cho J, Tiao G,
Kim J, Livitz D, Leshchiner I, Reardon B, Van Allen E, Kamburov A, Beroukhim R,
132

Saksena G, Schumacher SE, Noble MS, Heiman DI, Gehlenborg N, Kim J, Lawrence
MS, Adsay V, Petersen G, Klimstra D, Bardeesy N, Leiserson MDM, Bowlby R,
Kasaian K, Birol I, Mungall KL, Sadeghi S, Weinstein JN, Spellman PT, Liu Y,
Amundadottir LT, Tepper J, Singhi AD, Dhir R, Paul D, Smyrk T, Zhang L, Kim P,
Bowen J, Frick J, Gastier-Foster JM, Gerken M, Lau K, Leraas KM, Lichtenberg TM,
Ramirez NC, Renkel J, Sherman M, Wise L, Yena P, Zmuda E, Shih J, Ally A,
Balasundaram M, Carlsen R, Chu A, Chuah E, Clarke A, Dhalla N, Holt RA, Jones SJM,
Lee D, Ma Y, Marra MA, Mayo M, Moore RA, Mungall AJ, Schein JE, Sipahimalani P,
Tam A, Thiessen N, Tse K, Wong T, Brooks D, Auman JT, Balu S, Bodenheimer T,
Hayes DN, Hoyle AP, Jefferys SR, Jones CD, Meng S, Mieczkowski PA, Mose LE,
Perou CM, Perou AH, Roach J, Shi Y, Simons JV, Skelly T, Soloway MG, Tan D,
Veluvolu U, Parker JS, Wilkerson MD, Korkut A, Senbabaoglu Y, Burch P,
McWilliams R, Chaffee K, Oberg A, Zhang W, Gingras M-C, Wheeler DA, Xi L, Albert
M, Bartlett J, Sekhon H, Stephen Y, Howard Z, Judy M, Breggia A, Shroff RT,
Chudamani S, Liu J, Lolla L, Naresh R, Pihl T, Sun Q, Wan Y, Wu Y, Jennifer S,
Roggin K, Becker K-F, Behera M, Bennett J, Boice L, Burks E, Carlotti Junior CG,
Chabot J, Pretti da Cunha Tirapelli D, Sebastião dos Santos J, Dubina M, Eschbacher J,
Huang M, Huelsenbeck-Dill L, Jenkins R, Karpov A, Kemp R, Lyadov V, Maithel S,
Manikhas G, Montgomery E, Noushmehr H, Osunkoya A, Owonikoko T, Paklina O,
Potapova O, Ramalingam S, Rathmell WK, Rieger-Christ K, Saller C, Setdikova G,
Shabunin A, Sica G, Su T, Sullivan T, Swanson P, Tarvin K, Tavobilov M, Thorne LB,
Urbanski S, Voronina O, Wang T, Crain D, Curley E, Gardner J, Mallery D, Morris S,
Paulauskis J, Penny R, Shelton C, Shelton T, Janssen K-P, Bathe O, Bahary N, Slotta133

Huspenina J, Johns A, Hibshoosh H, Hwang RF, Sepulveda A, Radenbaugh A, Baylin
SB, Berrios M, Bootwalla MS, Holbrook A, Lai PH, Maglinte DT, Mahurkar S, Triche
TJ, Jr., Van Den Berg DJ, Weisenberger DJ, Chin L, Kucherlapati R, Kucherlapati M,
Pantazi A, Park P, Saksena G, Voet D, Lin P, Frazer S, Defreitas T, Meier S, Chin L,
Kwon SY, Kim YH, Park S-J, Han S-S, Kim SH, Kim H, Furth E, Tempero M, Sander
C, Biankin A, Chang D, Bailey P, Gill A, Kench J, Grimmond S, Johns A, Cancer
Genome I, Postier R, Zuna R, Sicotte H, Demchok JA, Ferguson ML, Hutter CM, Mills
Shaw KR, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zhang J, Felau I,
Zenklusen JC. Integrated Genomic Characterization of Pancreatic Ductal
Adenocarcinoma. Cancer Cell 2017;32:185-203.e13.
72.

Koay EJ, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, Kang Ya, Bhosale
PR, Tamm EP, Crane CH, Javle M, Katz MH, Gottumukkala VN, Rozner MA, Shen H,
Lee JE, Wang H, Chen Y, Plunkett W, Abbruzzese JL, Wolff RA, Varadhachary GR,
Ferrari M, Fleming JB. Transport properties of pancreatic cancer describe gemcitabine
delivery and response. The Journal of Clinical Investigation 2014;124:1525-1536.

73.

Koong AC, Mehta VK, Le QT, Fisher GA, Terris DJ, Brown JM, Bastidas AJ, Vierra M.
Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys
2000;48:919-22.

74.

Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, Fearon D,
Greten FR, Hingorani SR, Hunter T, Hynes RO, Jain RK, Janowitz T, Jorgensen C,
Kimmelman AC, Kolonin MG, Maki RG, Powers RS, Puré E, Ramirez DC, ScherzShouval R, Sherman MH, Stewart S, Tlsty TD, Tuveson DA, Watt FM, Weaver V,

134

Weeraratna AT, Werb Z. A framework for advancing our understanding of cancerassociated fibroblasts. Nature Reviews Cancer 2020;20:174-186.
75.

Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. Dynamics
of the Immune Reaction to Pancreatic Cancer from Inception to Invasion. Cancer
Research 2007;67:9518-9527.

76.

Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat? Therapeutic
Advances in Gastroenterology 2013;6:321-337.

77.

Hammel P, Huguet F, van Laethem J-L, Goldstein D, Glimelius B, Artru P, Borbath I,
Bouché O, Shannon J, André T, Mineur L, Chibaudel B, Bonnetain F, Louvet C. Effect
of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced
Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib:
The LAP07 Randomized Clinical Trial. JAMA 2016;315:1844-1853.

78.

Murphy JD, Christman-Skieller C, Kim J, Dieterich S, Chang DT, Koong AC. A
Dosimetric Model of Duodenal Toxicity After Stereotactic Body Radiotherapy for
Pancreatic Cancer. International Journal of Radiation Oncology*Biology*Physics
2010;78:1420-1426.

79.

Olive Kenneth P, Jacobetz Michael A, Davidson Christian J, Gopinathan A, McIntyre D,
Honess D, Madhu B, Goldgraben Mae A, Caldwell Meredith E, Allard D, Frese
Kristopher K, DeNicola G, Feig C, Combs C, Winter Stephen P, Ireland-Zecchini H,
Reichelt S, Howat William J, Chang A, Dhara M, Wang L, Rückert F, Grützmann R,
Pilarsky C, Izeradjene K, Hingorani Sunil R, Huang P, Davies Susan E, Plunkett W,
Egorin M, Hruban Ralph H, Whitebread N, McGovern K, Adams J, Iacobuzio-Donahue

135

C, Griffiths J, Tuveson David A. Inhibition of Hedgehog Signaling Enhances Delivery
of Chemotherapy in a Mouse Model of Pancreatic Cancer. Science 2009;324:1457-1461.
80.

De Jaeghere EA, Denys HG, De Wever O. Fibroblasts Fuel Immune Escape in the
Tumor Microenvironment. Trends in Cancer 2019;5:704-723.

81.

Patiar S, Harris AL. Role of hypoxia-inducible factor-1α as a cancer therapy target.
Endocrine-Related Cancer Endocr Relat Cancer 2006;13:S61-S75.

82.

Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell 2000;100:57-70.

83.

Criscimanna A, Duan L-J, Rhodes JA, Fendrich V, Wickline E, Hartman DJ, Monga
SPS, Lotze MT, Gittes GK, Fong G-H, Esni F. PanIN-Specific Regulation of Wnt
Signaling by HIF2α during Early Pancreatic Tumorigenesis. Cancer Research
2013;73:4781.

84.

Choueiri TK, Kaelin WG. Targeting the HIF2–VEGF axis in renal cell carcinoma.
Nature Medicine 2020;26:1519-1530.

85.

Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and
therapeutics. Oncogene 2010;29:625-634.

86.

Colbert LE, Fisher SB, Balci S, Saka B, Chen Z, Kim S, El-Rayes BF, Adsay NV,
Maithel SK, Landry JC, Curran WJ, Jr. High nuclear hypoxia-inducible factor 1 alpha
expression is a predictor of distant recurrence in patients with resected pancreatic
adenocarcinoma. Int J Radiat Oncol Biol Phys 2015;91:631-9.

87.

Sun H-C, Qiu Z-J, Liu J, Sun J, Jiang T, Huang K-J, Yao M, Huang C. Expression of
hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal
adenocarcinoma and their impact on prognosis. Int J Oncol 2007;30:1359-1367.

136

88.

Shibaji T, Nagao M, Ikeda N, Kanehiro H, Hisanaga M, Ko S, Fukumoto A, Nakajima
Y. Prognostic significance of HIF-1 alpha overexpression in human pancreatic cancer.
Anticancer research 2003;23:4721-4727.

89.

Zhang Q, Lou Y, Zhang J, Fu Q, Wei T, Sun X, Chen Q, Yang J, Bai X, Liang T.
Hypoxia-inducible factor-2α promotes tumor progression and has crosstalk with Wnt/βcatenin signaling in pancreatic cancer. Molecular Cancer 2017;16:119.

90.

Zhou X, Guo X, Chen M, Xie C, Jiang J. HIF-3α Promotes Metastatic Phenotypes in
Pancreatic Cancer by Transcriptional Regulation of the RhoC–ROCK1 Signaling
Pathway. Molecular Cancer Research 2018;16:124-134.

91.

Lee KE, Spata M, Bayne LJ, Buza EL, Durham AC, Allman D, Vonderheide RH, Simon
MC. Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic
Neoplasia. Cancer Discov 2016;6:256-69.

92.

Tiwari A, Tashiro K, Dixit A, Soni A, Vogel K, Hall B, Shafqat I, Slaughter J, Param N,
Le A, Saunders E, Paithane U, Garcia G, Campos AR, Zettervall J, Carlson M, Starr TK,
Marahrens Y, Deshpande AJ, Commisso C, Provenzano PP, Bagchi A. Loss of HIF1A
From Pancreatic Cancer Cells Increases Expression of PPP1R1B and Degradation of p53
to Promote Invasion and Metastasis. Gastroenterology 2020;159:1882-1897.e5.

93.

Roghanian A, Fraser C, Kleyman M, Chen J. B Cells Promote Pancreatic
Tumorigenesis. Cancer Discovery 2016;6:230-232.

94.

Shukla SK, Purohit V, Mehla K, Gunda V, Chaika NV, Vernucci E, King RJ, Abrego J,
Goode GD, Dasgupta A, Illies AL, Gebregiworgis T, Dai B, Augustine JJ, Murthy D,
Attri KS, Mashadova O, Grandgenett PM, Powers R, Ly QP, Lazenby AJ, Grem JL, Yu
F, Matés JM, Asara JM, Kim J-w, Hankins JH, Weekes C, Hollingsworth MA, Serkova
137

NJ, Sasson AR, Fleming JB, Oliveto JM, Lyssiotis CA, Cantley LC, Berim L, Singh PK.
MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to
Impart Gemcitabine Resistance to Pancreatic Cancer. Cancer Cell 2017;32:71-87.e7.
95.

Milićević NM, Nohroudi K, Milićević Ž, Hedrich H-J, Westermann J. T cells are
required for the peripheral phase of B-cell maturation. Immunology 2005;116:308-317.

96.

Fu Z, Mowday AM, Smaill JB, Hermans IF, Patterson AV. Tumour Hypoxia-Mediated
Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer
Immunotherapy. Cells 2021;10.

97.

Spivak-Kroizman TR, Hostetter G, Posner R, Aziz M, Hu C, Demeure MJ, Von Hoff D,
Hingorani SR, Palculict TB, Izzo J, Kiriakova GM, Abdelmelek M, Bartholomeusz G,
James BP, Powis G. Hypoxia Triggers Hedgehog-Mediated Tumor–Stromal Interactions
in Pancreatic Cancer. Cancer Research 2013;73:3235.

98.

Yuen A, Díaz B. The impact of hypoxia in pancreatic cancer invasion and metastasis.
Hypoxia (Auckl) 2014;2:91-106.

99.

Masamune A, Kikuta K, Watanabe T, Satoh K, Hirota M, Shimosegawa T. Hypoxia
stimulates pancreatic stellate cells to induce fibrosis and angiogenesis in pancreatic
cancer. American Journal of Physiology-Gastrointestinal and Liver Physiology
2008;295:G709-G717.

100.

Erkan M, Reiser-Erkan C, Michalski CW, Deucker S, Sauliunaite D, Streit S, Esposito I,
Friess H, Kleeff J. Cancer-Stellate Cell Interactions Perpetuate the Hypoxia-Fibrosis
Cycle in Pancreatic Ductal Adenocarcinoma. Neoplasia 2009;11:497-508.

138

101.

Kim J-w, Evans C, Weidemann A, Takeda N, Lee YS, Stockmann C, Branco-Price C,
Brandberg F, Leone G, Ostrowski MC, Johnson RS. Loss of Fibroblast HIF-1α
Accelerates Tumorigenesis. Cancer Research 2012;72:3187-3195.

102.

Branco-Price C, Zhang N, Schnelle M, Evans C, Katschinski Dörthe M, Liao D, Ellies
L, Johnson Randall S. Endothelial Cell HIF-1α and HIF-2α Differentially Regulate
Metastatic Success. Cancer Cell 2012;21:52-65.

103.

McGettrick AF, O’Neill LAJ. The Role of HIF in Immunity and Inflammation. Cell
Metabolism 2020;32:524-536.

104.

Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy.
Immunity 2014;41:49-61.

105.

Zhang A, Qian Y, Ye Z, Chen H, Xie H, Zhou L, Shen Y, Zheng S. Cancer-associated
fibroblasts promote M2 polarization of macrophages in pancreatic ductal
adenocarcinoma. Cancer Med 2017;6:463-470.

106.

Imtiyaz HZ, Williams EP, Hickey MM, Patel SA, Durham AC, Yuan L-J, Hammond R,
Gimotty PA, Keith B, Simon MC. Hypoxia-inducible factor 2α regulates macrophage
function in mouse models of acute and tumor inflammation. The Journal of Clinical
Investigation 2010;120:2699-2714.

107.

Nishide S, Matsunaga S, Shiota M, Yamaguchi T, Kitajima S, Maekawa Y, Takeda N,
Tomura M, Uchida J, Miura K, Nakatani T, Tomita S. Controlling the Phenotype of
Tumor-Infiltrating Macrophages via the PHD-HIF Axis Inhibits Tumor Growth in a
Mouse Model. iScience 2019;19:940-954.

108.

Gok Yavuz B, Gunaydin G, Gedik ME, Kosemehmetoglu K, Karakoc D, Ozgur F, Guc
D. Cancer associated fibroblasts sculpt tumour microenvironment by recruiting
139

monocytes and inducing immunosuppressive PD-1(+) TAMs. Scientific Reports
2019;9:3172.
109.

Zhu Y, Herndon JM, Sojka DK, Kim K-W, Knolhoff BL, Zuo C, Cullinan DR, Luo J,
Bearden AR, Lavine KJ, Yokoyama WM, Hawkins WG, Fields RC, Randolph GJ,
DeNardo DG. Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma
Originate from Embryonic Hematopoiesis and Promote Tumor Progression. Immunity
2017;47:323-338.e6.

110.

Cowman SJ, Koh MY. Revisiting the HIF switch in the tumor and its immune
microenvironment. Trends in Cancer 2022;8:28-42.

111.

Hsu T-S, Lin Y-L, Wang Y-A, Mo S-T, Chi P-Y, Lai AC-Y, Pan H-Y, Chang Y-J, Lai
M-Z. HIF-2α is indispensable for regulatory T cell function. Nature Communications
2020;11:5005.

112.

Stromnes IM, DelGiorno KE, Greenberg PD, Hingorani SR. Stromal reengineering to
treat pancreas cancer. Carcinogenesis 2014;35:1451-1460.

113.

Liu T, Han C, Wang S, Fang P, Ma Z, Xu L, Yin R. Cancer-associated fibroblasts: an
emerging target of anti-cancer immunotherapy. Journal of Hematology & Oncology
2019;12:86.

114.

Neesse A, Bauer CA, Öhlund D, Lauth M, Buchholz M, Michl P, Tuveson DA, Gress
TM. Stromal biology and therapy in pancreatic cancer: ready for clinical translation? Gut
2019;68:159.

115.

Whittle MC, Hingorani SR. Fibroblasts in Pancreatic Ductal Adenocarcinoma:
Biological Mechanisms and Therapeutic Targets. Gastroenterology 2019;156:20852096.
140

116.

Provenzano PP, Hingorani SR. Hyaluronan, fluid pressure, and stromal resistance in
pancreas cancer. British Journal of Cancer 2013;108:1-8.

117.

Chauhan VP, Boucher Y, Ferrone CR, Roberge S, Martin JD, Stylianopoulos T,
Bardeesy N, DePinho RA, Padera TP, Munn LL, Jain RK. Compression of pancreatic
tumor blood vessels by hyaluronan is caused by solid stress and not interstitial fluid
pressure. Cancer Cell 2014;26:14-5.

118.

Turley SJ, Cremasco V, Astarita JL. Immunological hallmarks of stromal cells in the
tumour microenvironment. Nature Reviews Immunology 2015;15:669-682.

119.

Tjomsland V, Niklasson L, Sandström P, Borch K, Druid H, Bratthäll C, Messmer D,
Larsson M, Spångeus A. The Desmoplastic Stroma Plays an Essential Role in the
Accumulation and Modulation of Infiltrated Immune Cells in Pancreatic
Adenocarcinoma. Clinical and Developmental Immunology 2011;2011:212810.

120.

Helms E, Onate MK, Sherman MH. Fibroblast Heterogeneity in the Pancreatic Tumor
Microenvironment. Cancer Discovery 2020;10:648-656.

121.

Öhlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, Corbo
V, Oni TE, Hearn SA, Lee EJ, Chio IIC, Hwang C-I, Tiriac H, Baker LA, Engle DD,
Feig C, Kultti A, Egeblad M, Fearon DT, Crawford JM, Clevers H, Park Y, Tuveson
DA. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic
cancer. Journal of Experimental Medicine 2017;214:579-596.

122.

Elyada E, Bolisetty M, Laise P, Flynn WF, Courtois ET, Burkhart RA, Teinor JA,
Belleau P, Biffi G, Lucito MS, Sivajothi S, Armstrong TD, Engle DD, Yu KH, Hao Y,
Wolfgang CL, Park Y, Preall J, Jaffee EM, Califano A, Robson P, Tuveson DA. Cross-

141

Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals AntigenPresenting Cancer-Associated Fibroblasts. Cancer Discovery 2019;9:1102.
123.

Biffi G, Oni TE, Spielman B, Hao Y, Elyada E, Park Y, Preall J, Tuveson DA. IL1Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in
Pancreatic Ductal Adenocarcinoma. Cancer Discovery 2019;9:282.

124.

McAndrews KM, Chen Y, Darpolor JK, Zheng X, Yang S, Carstens JL, Li B, Wang H,
Miyake T, Correa de Sampaio P, Kirtley ML, Natale M, Wu C-C, Sugimoto H, LeBleu
VS, Kalluri R. Identification of Functional Heterogeneity of Carcinoma-Associated
Fibroblasts with Distinct IL-6 Mediated Therapy Resistance in Pancreatic Cancer.
Cancer Discovery 2022:candisc.1484.2020.

125.

Rhim Andrew D, Oberstein Paul E, Thomas Dafydd H, Mirek Emily T, Palermo
Carmine F, Sastra Stephen A, Dekleva Erin N, Saunders T, Becerra Claudia P, Tattersall
Ian W, Westphalen CB, Kitajewski J, Fernandez-Barrena Maite G, Fernandez-Zapico
Martin E, Iacobuzio-Donahue C, Olive Kenneth P, Stanger Ben Z. Stromal Elements Act
to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma. Cancer Cell
2014;25:735-747.

126.

De Jesus-Acosta A, Sugar EA, O’Dwyer PJ, Ramanathan RK, Von Hoff DD, Rasheed Z,
Zheng L, Begum A, Anders R, Maitra A, McAllister F, Rajeshkumar NV, Yabuuchi S,
de Wilde RF, Batukbhai B, Sahin I, Laheru DA. Phase 2 study of vismodegib, a
hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with
untreated metastatic pancreatic adenocarcinoma. British Journal of Cancer
2020;122:498-505.

142

127.

Madden JI. Infinity Reports Update from Phase 2 Study of Saridegib Plus Gemcitabine
in Patients with Metastatic Pancreatic Cancer. BusinessWire, 2012.

128.

Lee John J, Perera Rushika M, Wang H, Wu D-C, Liu XS, Han S, Fitamant J, Jones
Phillip D, Ghanta Krishna S, Kawano S, Nagle Julia M, Deshpande V, Boucher Y, Kato
T, Chen James K, Willmann Jürgen K, Bardeesy N, Beachy Philip A. Stromal response
to Hedgehog signaling restrains pancreatic cancer progression. Proceedings of the
National Academy of Sciences 2014;111:E3091-E3100.

129.

Catenacci DVT, Junttila MR, Karrison T, Bahary N, Horiba MN, Nattam SR, Marsh R,
Wallace J, Kozloff M, Rajdev L, Cohen D, Wade J, Sleckman B, Lenz H-J, Stiff P,
Kumar P, Xu P, Henderson L, Takebe N, Salgia R, Wang X, Stadler WM, de Sauvage
FJ, Kindler HL. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or
Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic
Cancer. Journal of Clinical Oncology 2015;33:4284-4292.

130.

Kim EJ, Sahai V, Abel EV, Griffith KA, Greenson JK, Takebe N, Khan GN, Blau JL,
Craig R, Balis UG, Zalupski MM, Simeone DM. Pilot Clinical Trial of Hedgehog
Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in
Patients with Metastatic Pancreatic Adenocarcinoma. Clinical Cancer Research
2014;20:5937-5945.

131.

Ozdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai
H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P,
Mahmood U, Chin L, Moses HL, Weaver VM, Maitra A, Allison JP, LeBleu VS, Kalluri
R. Depletion of carcinoma-associated fibroblasts and fibrosis induces

143

immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell
2014;25:719-34.
132.

Ramanathan RK, McDonough SL, Philip PA, Hingorani SR, Lacy J, Kortmansky JS,
Thumar J, Chiorean EG, Shields AF, Behl D, Mehan PT, Gaur R, Seery T, Guthrie KA,
Hochster HS. Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated
Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With
Metastatic Pancreatic Adenocarcinoma: SWOG S1313. Journal of Clinical Oncology
2019;37:1062-1069.

133.

Hingorani SR, Zheng L, Bullock AJ, Seery TE, Harris WP, Sigal DS, Braiteh F, Ritch
PS, Zalupski MM, Bahary N, Oberstein PE, Wang-Gillam A, Wu W, Chondros D, Jiang
P, Khelifa S, Pu J, Aldrich C, Hendifar AE. HALO 202: Randomized Phase II Study of
PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in
Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. Journal of
Clinical Oncology 2017;36:359-366.

134.

Wang-Gillam A. Targeting Stroma: A Tale of Caution. Journal of Clinical Oncology
2019;37:1041-1043.

135.

Dominguez CX, Müller S, Keerthivasan S, Koeppen H, Hung J, Gierke S, Breart B,
Foreman O, Bainbridge TW, Castiglioni A, Senbabaoglu Y, Modrusan Z, Liang Y,
Junttila MR, Klijn C, Bourgon R, Turley SJ. Single-Cell RNA Sequencing Reveals
Stromal Evolution into LRRC15+ Myofibroblasts as a Determinant of Patient Response
to Cancer Immunotherapy. Cancer Discovery 2020;10:232-253.

136.

Murray ER, Menezes S, Henry JC, Williams JL, Alba-Castellón L, Baskaran P, Quétier
I, Desai A, Marshall JJT, Rosewell I, Tatari M, Rajeeve V, Khan F, Wang J, Kotantaki
144

P, Tyler EJ, Singh N, Reader CS, Carter EP, Hodivala-Dilke K, Grose RP, Kocher HM,
Gavara N, Pearce O, Cutillas P, Marshall JF, Cameron AJM. Disruption of pancreatic
stellate cell myofibroblast phenotype promotes pancreatic tumor invasion. Cell Reports
2022;38.
137.

Lo A, Wang L-CS, Scholler J, Monslow J, Avery D, Newick K, O'Brien S, Evans RA,
Bajor DJ, Clendenin C, Durham AC, Buza EL, Vonderheide RH, June CH, Albelda SM,
Puré E. Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing
Stromal Cells. Cancer Research 2015;75:2800-2810.

138.

Krishnan S, Chadha AS, Suh Y, Chen H-C, Rao A, Das P, Minsky BD, Mahmood U,
Delclos ME, Sawakuchi GO, Beddar S, Katz MH, Fleming JB, Javle MM, Varadhachary
GR, Wolff RA, Crane CH. Focal Radiation Therapy Dose Escalation Improves Overall
Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction
Chemotherapy and Consolidative Chemoradiation. International Journal of Radiation
Oncology*Biology*Physics 2016;94:755-765.

139.

Kelly P, Das P, Pinnix CC, Beddar S, Briere T, Pham M, Krishnan S, Delclos ME,
Crane CH. Duodenal Toxicity After Fractionated Chemoradiation for Unresectable
Pancreatic Cancer. International Journal of Radiation Oncology*Biology*Physics
2013;85:e143-e149.

140.

Elhammali A, Patel M, Weinberg B, Verma V, Liu J, Olsen JR, Gay HA. Late
gastrointestinal tissue effects after hypofractionated radiation therapy of the pancreas.
Radiation Oncology 2015;10:186.

141.

Kyong Joo L, Hong In Y, Moon Jae C, Jeong Youp P, Seungmin B, Seung-woo P, Jin
Sil S, Si Young S. A Comparison of Gastrointestinal Toxicities between Intensity145

Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy for
Pancreatic Cancer. Gut and Liver 2016;10:303-309.
142.

Raturi VP, Tochinai T, Hojo H, Rachi T, Hotta K, Nakamura N, Zenda S, Motegi A,
Ariji T, Hirano Y, Baba H, Ohyoshi H, Nakamura M, Okumura M, Bei Y, Akimoto T.
Dose-Volume and Radiobiological Model-Based Comparative Evaluation of the
Gastrointestinal Toxicity Risk of Photon and Proton Irradiation Plans in Localized
Pancreatic Cancer Without Distant Metastasis. Frontiers in oncology 2020;10:517061517061.

143.

Paris F, Fuks Z, Kang A, Capodieci P, Juan G, Ehleiter D, Haimovitz-Friedman A,
Cordon-Cardo C, Kolesnick R. Endothelial Apoptosis as the Primary Lesion Initiating
Intestinal Radiation Damage in Mice. Science 2001;293:293-297.

144.

Booth C, Tudor G, Tudor J, Katz BP, MacVittie TJ. Acute Gastrointestinal Syndrome in
High-Dose Irradiated Mice. Health Physics 2012;103.

145.

Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, Haegebarth A,
Korving J, Begthel H, Peters PJ, Clevers H. Identification of stem cells in small intestine
and colon by marker gene Lgr5. Nature 2007;449:1003-1007.

146.

Shaker A, Rubin DC. Intestinal stem cells and epithelial-mesenchymal interactions in the
crypt and stem cell niche. Translational Research 2010;156:180-187.

147.

Potten CS, Booth C, Pritchard DM. The intestinal epithelial stem cell: the mucosal
governor. International Journal of Experimental Pathology 1997;78:219-243.

148.

Hoffe S, Frakes JM, Aguilera TA, Czito B, Palta M, Brookes M, Schweizer C, Colbert
L, Moningi S, Bhutani MS, Pant S, Tzeng CW, Tidwell RS, Thall P, Yuan Y, Moser EC,
Holmlund J, Herman J, Taniguchi CM. Randomized, Double-Blinded, Placebo146

controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in
Combination with High Dose Stereotactic Body Radiation Therapy (SBRT) in Locally
Advanced Pancreatic Cancer (PC). International Journal of Radiation Oncology,
Biology, Physics 2020;108:1399-1400.
149.

Kim SK, Wu C-C, Horowitz DP. Stereotactic body radiotherapy for the pancreas: a
critical review for the medical oncologist. Journal of gastrointestinal oncology
2016;7:479-486.

150.

Koukourakis MI. Amifostine in clinical oncology: current use and future applications.
Anti-Cancer Drugs 2002;13.

151.

Peterson DE, Bensadoun RJ, Roila F. Management of oral and gastrointestinal
mucositis: ESMO Clinical Practice Guidelines. Annals of Oncology 2011;22:vi78-vi84.

152.

Koukourakis MI, Giatromanolaki A, Zois CE, Kalamida D, Pouliliou S, Karagounis IV,
Yeh T-L, Abboud MI, Claridge TDW, Schofield CJ, Sivridis E, Simopoulos C,
Tokmakidis SP, Harris AL. Normal tissue radioprotection by amifostine via Warburgtype effects. Scientific Reports 2016;6:30986.

153.

Kligerman MM, Glover DJ, Turrisi AT, Norfleet AL, Yuhas JM, Coia LR, Simone C,
Glick JH, Goodman RL. Toxicity of WR-2721 administered in single and multiple
doses. International Journal of Radiation Oncology, Biology, Physics 1984;10:17731776.

154.

Smoluk GD, Fahey RC, Calabro-Jones PM, Aguilera JA, Ward JF. Radioprotection of
Cells in Culture by WR-2721 and Derivatives: Form of the Drug Responsible for
Protection1. Cancer Research 1988;48:3641-3647.

147

155.

Molkentine JM, Fujimoto TN, Horvath TD, Grossberg AJ, Garcia CJG, Deorukhkar A,
de la Cruz Bonilla M, Lin D, Samuel ELG, Chan WK, Lorenzi PL, Piwnica-Worms H,
Dantzer R, Tour JM, Mason KA, Taniguchi CM. Enteral Activation of WR-2721
Mediates Radioprotection and Improved Survival from Lethal Fractionated Radiation.
Scientific Reports 2019;9:1949.

156.

Sishc Brock J, Ding L, Nam T-K, Heer Collin D, Rodman Samuel N, Schoenfeld Joshua
D, Fath Melissa A, Saha D, Pulliam Casey F, Langen B, Beardsley Robert A, Riley
Dennis P, Keene Jeffery L, Spitz Douglas R, Story Michael D. Avasopasem manganese
synergizes with hypofractionated radiation to ablate tumors through the generation of
hydrogen peroxide. Science Translational Medicine 2021;13:eabb3768.

157.

Galera Therapeutics I. RUCOSOPASEM (GC4711), 2022.

158.

Singh VK, Romaine PLP, Seed TM. Medical Countermeasures for Radiation Exposure
and Related Injuries: Characterization of Medicines, FDA-Approval Status and Inclusion
into the Strategic National Stockpile. Health Physics 2015;108.

159.

Singh VK, Seed TM. Entolimod as a radiation countermeasure for acute radiation
syndrome. Drug Discovery Today 2021;26:17-30.

160.

Graham CH, Forsdike J, Fitzgerald CJ, Macdonald-Goodfellow S. Hypoxia-mediated
stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor
expression. International Journal of Cancer 1999;80:617-623.

161.

Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK,
Hansen KR, Thompson LF, Colgan SP. Ecto-5′-nucleotidase (CD73) regulation by
hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. The
Journal of Clinical Investigation 2002;110:993-1002.
148

162.

Zheng L, Kelly CJ, Colgan SP. Physiologic hypoxia and oxygen homeostasis in the
healthy intestine. A Review in the Theme: Cellular Responses to Hypoxia. American
Journal of Physiology-Cell Physiology 2015;309:C350-C360.

163.

Taylor CT, Colgan SP. Hypoxia and gastrointestinal disease. Journal of Molecular
Medicine 2007;85:1295-1300.

164.

Taniguchi CM, Miao YR, Diep AN, Wu C, Rankin EB, Atwood TF, Xing L, Giaccia AJ.
PHD Inhibition Mitigates and Protects Against Radiation-Induced Gastrointestinal
Toxicity via HIF2. Science Translational Medicine 2014;6:236ra64.

165.

Fujimoto TN, Colbert LE, Huang Y, Molkentine JM, Deorukhkar A, Baseler L, de la
Cruz Bonilla M, Yu M, Lin D, Gupta S, Cabeceiras PK, Kingsley CV, Tailor RC,
Sawakuchi GO, Koay EJ, Piwnica-Worms H, Maitra A, Taniguchi CM. Selective EGLN
Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable
Pancreatic Cancer. Cancer Research 2019;79:2327.

166.

Ayrapetov MK, Xu C, Sun Y, Zhu K, Parmar K, D'Andrea AD, Price BD. Activation of
Hif1α by the Prolylhydroxylase Inhibitor Dimethyoxalyglycine Decreases
Radiosensitivity. PLOS ONE 2011;6:e26064.

167.

Jalili-Firoozinezhad S, Prantil-Baun R, Jiang A, Potla R, Mammoto T, Weaver JC,
Ferrante TC, Kim HJ, Cabral JMS, Levy O, Ingber DE. Modeling radiation injuryinduced cell death and countermeasure drug responses in a human Gut-on-a-Chip. Cell
Death & Disease 2018;9:223.

168.

Hakim N, Patel R, Devoe C, Saif MW. Why HALO 301 Failed and Implications for
Treatment of Pancreatic Cancer. Pancreas (Fairfax, Va.) 2019;3:e1-e4.

149

169.

Brown JM, Giaccia AJ. The Unique Physiology of Solid Tumors: Opportunities (and
Problems) for Cancer Therapy. Cancer Research 1998;58:1408.

170.

Young NP, Crowley D, Jacks T. Uncoupling Cancer Mutations Reveals Critical Timing
of p53 Loss in Sarcomagenesis. Cancer Research 2011;71:4040.

171.

Lee C-L, Moding EJ, Huang X, Li Y, Woodlief LZ, Rodrigues RC, Ma Y, Kirsch DG.
Generation of primary tumors with Flp recombinase in FRT-flanked p53 mice. Disease
Models &amp;amp; Mechanisms 2012;5:397.

172.

Schonhuber N, Seidler B, Schuck K, Veltkamp C, Schachtler C, Zukowska M, Eser S,
Feyerabend TB, Paul MC, Eser P, Klein S, Lowy AM, Banerjee R, Yang F, Lee CL,
Moding EJ, Kirsch DG, Scheideler A, Alessi DR, Varela I, Bradley A, Kind A, Schnieke
AE, Rodewald HR, Rad R, Schmid RM, Schneider G, Saur D. A next-generation dualrecombinase system for time- and host-specific targeting of pancreatic cancer. Nature
Medicine 2014;20:1340-1347.

173.

Wendling O, Bornert JM, Chambon P, Metzger D. Efficient temporally-controlled
targeted mutagenesis in smooth muscle cells of the adult mouse. Genesis 2009;47:14-8.

174.

Bardeesy N, Aguirre AJ, Chu GC, Cheng KH, Lopez LV, Hezel AF, Feng B, Brennan C,
Weissleder R, Mahmood U, Hanahan D, Redston MS, Chin L, Depinho RA. Both
p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic
adenocarcinoma in the mouse. Proc Natl Acad Sci U S A 2006;103:5947-52.

175.

Counter CM, Hahn WC, Wei W, Caddle SD, Beijersbergen RL, Lansdorp PM, Sedivy
JM, Weinberg RA. Dissociation among in vitro telomerase activity, telomere
maintenance, and cellular immortalization. Proceedings of the National Academy of
Sciences 1998;95:14723.
150

176.

Pereira PM, Albrecht D, Culley S, Jacobs C, Marsh M, Mercer J, Henriques R. Fix Your
Membrane Receptor Imaging: Actin Cytoskeleton and CD4 Membrane Organization
Disruption by Chemical Fixation. Frontiers in Immunology 2019;10:675.

177.

Leyton-Puig D, Kedziora KM, Isogai T, van den Broek B, Jalink K, Innocenti M. PFA
fixation enables artifact-free super-resolution imaging of the actin cytoskeleton and
associated proteins. Biology Open 2016;5:1001-1009.

178.

Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or
without a reference genome. BMC Bioinformatics 2011;12:323.

179.

Chen W, Hill H, Christie A, Kim MS, Holloman E, Pavia-Jimenez A, Homayoun F, Ma
Y, Patel N, Yell P, Hao G, Yousuf Q, Joyce A, Pedrosa I, Geiger H, Zhang H, Chang J,
Gardner KH, Bruick RK, Reeves C, Hwang TH, Courtney K, Frenkel E, Sun X,
Zojwalla N, Wong T, Rizzi JP, Wallace EM, Josey JA, Xie Y, Xie XJ, Kapur P, McKay
RM, Brugarolas J. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature
2016;539:112-117.

180.

Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell
transcriptomic data across different conditions, technologies, and species. Nature
Biotechnology 2018;36:411-420.

181.

Zhang L, Nie Q. scMC learns biological variation through the alignment of multiple
single-cell genomics datasets. Genome Biology 2021;22:10.

182.

Lee JJ, Bernard V, Semaan A, Monberg ME, Huang J, Stephens BM, Lin D, Rajapakshe
KI, Weston BR, Bhutani MS, Haymaker CL, Bernatchez C, Taniguchi CM, Maitra A,
Guerrero PA. Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor

151

Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies.
Clinical Cancer Research 2021;27:5912.
183.

Ryan HE, Poloni M, McNulty W, Elson D, Gassmann M, Arbeit JM, Johnson RS.
Hypoxia-inducible Factor-1α Is a Positive Factor in Solid Tumor Growth. Cancer
Research 2000;60:4010.

184.

Cho H, Du X, Rizzi JP, Liberzon E, Chakraborty AA, Gao W, Carvo I, Signoretti S,
Bruick RK, Josey JA, Wallace EM, Kaelin WG. On-target efficacy of a HIF-2α
antagonist in preclinical kidney cancer models. Nature 2016;539:107-111.

185.

Barsoum IB, Smallwood CA, Siemens DR, Graham CH. A Mechanism of HypoxiaMediated Escape from Adaptive Immunity in Cancer Cells. Cancer Research
2014;74:665-674.

186.

Lequeux A, Noman MZ, Xiao M, Sauvage D, Van Moer K, Viry E, Bocci I, Hasmim M,
Bosseler M, Berchem G, Janji B. Impact of hypoxic tumor microenvironment and tumor
cell plasticity on the expression of immune checkpoints. Cancer Letters 2019;458:13-20.

187.

Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, Bronte V, Chouaib S.
PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced
MDSC-mediated T cell activation. Journal of Experimental Medicine 2014;211:781-790.

188.

Lee WS, Yang H, Chon HJ, Kim C. Combination of anti-angiogenic therapy and
immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer
immunity. Experimental & Molecular Medicine 2020;52:1475-1485.

189.

Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci
JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK,
Schuchter LM, Ishwaran H, Mick R, Pryma DA, Xu X, Feldman MD, Gangadhar TC,
152

Hahn SM, Wherry EJ, Vonderheide RH, Minn AJ. Radiation and dual checkpoint
blockade activate non-redundant immune mechanisms in cancer. Nature 2015;520:373377.
190.

Erstad DJ, Sojoodi M, Taylor MS, Ghoshal S, Razavi AA, Graham-O'Regan KA,
Bardeesy N, Ferrone CR, Lanuti M, Caravan P, Tanabe KK, Fuchs BC. Orthotopic and
heterotopic murine models of pancreatic cancer and their different responses to
FOLFIRINOX chemotherapy. Disease Models & Mechanisms 2018;11:dmm034793.

191.

Tsutsumi R, Xie C, Wei X, Zhang M, Zhang X, Flick LM, Schwarz EM, O'Keefe RJ.
PGE2 Signaling Through the EP4 Receptor on Fibroblasts Upregulates RANKL and
Stimulates Osteolysis. Journal of Bone and Mineral Research 2009;24:1753-1762.

192.

Sousa CM, Biancur DE, Wang X, Halbrook CJ, Sherman MH, Zhang L, Kremer D,
Hwang RF, Witkiewicz AK, Ying H, Asara JM, Evans RM, Cantley LC, Lyssiotis CA,
Kimmelman AC. Pancreatic stellate cells support tumour metabolism through
autophagic alanine secretion. Nature 2016;536:479-483.

193.

Auciello FR, Bulusu V, Oon C, Tait-Mulder J, Berry M, Bhattacharyya S, Tumanov S,
Allen-Petersen BL, Link J, Kendsersky ND, Vringer E, Schug M, Novo D, Hwang RF,
Evans RM, Nixon C, Dorrell C, Morton JP, Norman JC, Sears RC, Kamphorst JJ,
Sherman MH. A Stromal Lysolipid–Autotaxin Signaling Axis Promotes Pancreatic
Tumor Progression. Cancer Discovery 2019;9:617.

194.

Zhao H, Yang L, Baddour J, Achreja A, Bernard V, Moss T, Marini JC, Tudawe T,
Seviour EG, San Lucas FA, Alvarez H, Gupta S, Maiti SN, Cooper L, Peehl D, Ram PT,
Maitra A, Nagrath D. Tumor microenvironment derived exosomes pleiotropically
modulate cancer cell metabolism. eLife 2016;5:e10250.
153

195.

Kim WY, Perera S, Zhou B, Carretero J, Yeh JJ, Heathcote SA, Jackson AL,
Nikolinakos P, Ospina B, Naumov G, Brandstetter KA, Weigman VJ, Zaghlul S, Hayes
DN, Padera RF, Heymach JV, Kung AL, Sharpless NE, Kaelin WG, Jr., Wong K-K.
HIF2α cooperates with RAS to promote lung tumorigenesis in mice. The Journal of
Clinical Investigation 2009;119:2160-2170.

196.

Wierenga ATJ, Vellenga E, Schuringa JJ. Convergence of Hypoxia and TGFβ Pathways
on Cell Cycle Regulation in Human Hematopoietic Stem/Progenitor Cells. PLOS ONE
2014;9:e93494.

197.

Sherman MH, Yu RT, Tseng TW, Sousa CM, Liu S, Truitt ML, He N, Ding N, Liddle
C, Atkins AR, Leblanc M, Collisson EA, Asara JM, Kimmelman AC, Downes M, Evans
RM. Stromal cues regulate the pancreatic cancer epigenome and metabolome.
Proceedings of the National Academy of Sciences 2017;114:1129.

198.

Mallya K, Gautam SK, Aithal A, Batra SK, Jain M. Modeling pancreatic cancer in mice
for experimental therapeutics. Biochimica et Biophysica Acta (BBA) - Reviews on
Cancer 2021;1876:188554.

199.

Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard
S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM,
Srinivasan R. Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease. New
England Journal of Medicine 2021;385:2036-2046.

200.

Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs.
Nature Reviews Cancer 2011;11:239-253.

201.

Klopp AH, Yeung AR, Deshmukh S, Gil KM, Wenzel L, Westin SN, Gifford K,
Gaffney DK, Small W, Thompson S, Doncals DE, Cantuaria GHC, Yaremko BP, Chang
154

A, Kundapur V, Mohan DS, Haas ML, Kim YB, Ferguson CL, Pugh SL, Kachnic LA,
Bruner DW. Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation
Therapy: NRG Oncology–RTOG 1203. Journal of Clinical Oncology 2018;36:25382544.
202.

Miyoshi H, Stappenbeck TS. In vitro expansion and genetic modification of
gastrointestinal stem cells in spheroid culture. Nature Protocols 2013;8:2471-2482.

203.

Kim WY, Safran M, Buckley MRM, Ebert BL, Glickman J, Bosenberg M, Regan M,
Kaelin Jr WG. Failure to prolyl hydroxylate hypoxia-inducible factor α phenocopies
VHL inactivation in vivo. The EMBO Journal 2006;25:4650-4662.

204.

Flanagan DJ, Austin CR, Vincan E, Phesse TJ. Wnt Signalling in Gastrointestinal
Epithelial Stem Cells. Genes 2018;9.

205.

Miyoshi H, Ajima R, Luo CT, Yamaguchi TP, Stappenbeck TS. Wnt5a Potentiates TGFβ Signaling to Promote Colonic Crypt Regeneration After Tissue Injury. Science
2012;338:108.

206.

de la Cruz Bonilla M, Stemler KM, Taniguchi CM, Piwnica-Worms H. Stem cell
enriched-epithelial spheroid cultures for rapidly assaying small intestinal radioprotectors
and radiosensitizers in vitro. Scientific Reports 2018;8:15410.

207.

Ryu YK, Collins SE, Ho H-YH, Zhao H, Kuruvilla R. An autocrine Wnt5a-Ror
signaling loop mediates sympathetic target innervation. Developmental Biology
2013;377:79-89.

208.

Taniguchi CM, Finger EC, Krieg AJ, Wu C, Diep AN, LaGory EL, Wei K, McGinnis
LM, Yuan J, Kuo CJ, Giaccia AJ. Cross-talk between hypoxia and insulin signaling

155

through Phd3 regulates hepatic glucose and lipid metabolism and ameliorates diabetes.
Nature Medicine 2013;19:1325-1330.
209.

Yan Q, Bartz S, Mao M, Li L, Kaelin William G. The Hypoxia-Inducible Factor 2α NTerminal and C-Terminal Transactivation Domains Cooperate To Promote Renal
Tumorigenesis In Vivo. Molecular and Cellular Biology 2007;27:2092-2102.

210.

Leng N, Dawson JA, Thomson JA, Ruotti V, Rissman AI, Smits BMG, Haag JD, Gould
MN, Stewart RM, Kendziorski C. EBSeq: an empirical Bayes hierarchical model for
inference in RNA-seq experiments. Bioinformatics 2013;29:1035-1043.

211.

Katula KS, Joyner-Powell NB, Hsu C-C, Kuk A. Differential Regulation of the Mouse
and Human Wnt5a Alternative Promoters A and B. DNA and Cell Biology
2012;31:1585-1597.

212.

Franken NAP, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of
cells in vitro. Nature Protocols 2006;1:2315-2319.

213.

Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, van Es JH,
Abo A, Kujala P, Peters PJ, Clevers H. Single Lgr5 stem cells build crypt-villus
structures in vitro without a mesenchymal niche. Nature 2009;459:262-265.

214.

Kimura H, Weisz A, Ogura T, Hitomi Y, Kurashima Y, Hashimoto K, D'Acquisto F,
Makuuchi M, Esumi H. Identification of Hypoxia-inducible Factor 1 Ancillary Sequence
and Its Function in Vascular Endothelial Growth Factor Gene Induction by Hypoxia and
Nitric Oxide *. Journal of Biological Chemistry 2001;276:2292-2298.

215.

Rashid I, Pathak AK, Kumar R, Srivastava P, Singh M, Murali S, Kushwaha B.
Genome-Wide Comparative Analysis of HIF Binding Sites in Cyprinus Carpio for In

156

Silico Identification of Functional Hypoxia Response Elements. Frontiers in genetics
2019;10:659-659.
216.

Bakker ERM, Raghoebir L, Franken PF, Helvensteijn W, van Gurp L, Meijlink F, van
der Valk MA, Rottier RJ, Kuipers EJ, van Veelen W, Smits R. Induced Wnt5a
expression perturbs embryonic outgrowth and intestinal elongation, but is well-tolerated
in adult mice. Developmental Biology 2012;369:91-100.

217.

Si J, Zhou R, Zhao B, Xie Y, Gan L, Zhang J, Wang Y, Zhou X, Ren X, Zhang H.
Effects of ionizing radiation and HLY78 on the zebrafish embryonic developmental
toxicity. Toxicology 2019;411:143-153.

218.

Murdoch B, Chadwick K, Martin M, Shojaei F, Shah KV, Gallacher L, Moon RT,
Bhatia M. Wnt-5A augments repopulating capacity and primitive hematopoietic
development of human blood stem cells. Proceedings of the National Academy of
Sciences 2003;100:3422.

219.

Masckauchán TNH, Agalliu D, Vorontchikhina M, Ahn A, Parmalee NL, Li C-M, Khoo
A, Tycko B, Brown AMC, Kitajewski J. Wnt5a Signaling Induces Proliferation and
Survival of Endothelial Cells In Vitro and Expression of MMP-1 and Tie-2. Molecular
Biology of the Cell 2006;17:5163-5172.

220.

Douglass SM, Fane ME, Sanseviero E, Ecker BL, Kugel CH, Behera R, Kumar V,
Tcyganov EN, Yin X, Liu Q, Chhabra Y, Alicea GM, Kuruvilla R, Gabrilovich DI,
Weeraratna AT. Myeloid-Derived Suppressor Cells Are a Major Source of Wnt5A in the
Melanoma Microenvironment and Depend on Wnt5A for Full Suppressive Activity.
Cancer Research 2021;81:658.

157

221.

Zhou Y, Kipps TJ, Zhang S. Wnt5a Signaling in Normal and Cancer Stem Cells. Stem
Cells International 2017;2017:5295286.

222.

Cheng C, Seen D, Zheng C, Zeng R, Li E. Role of Small GTPase RhoA in DNA
Damage Response. Biomolecules 2021;11.

223.

Oh W, Frost JA. Rho GTPase independent regulation of ATM activation and cell
survival by the RhoGEF Net1A. Cell Cycle 2014;13:2765-2772.

224.

Legrand AJ, Choul-Li S, Spriet C, Idziorek T, Vicogne D, Drobecq H, Dantzer F,
Villeret V, Aumercier M. The Level of Ets-1 Protein Is Regulated by Poly(ADP-Ribose)
Polymerase-1 (PARP-1) in Cancer Cells to Prevent DNA Damage. PLOS ONE
2013;8:e55883.

225.

Zhou Z, Huang F, Shrivastava I, Zhu R, Luo A, Hottiger M, Bahar I, Liu Z, Cristofanilli
M, Wan Y. New insight into the significance of KLF4 PARylation in genome stability,
carcinogenesis, and therapy. EMBO Molecular Medicine 2020;12:e12391.

226.

Gazit VA, Swietlicki EA, Liang MU, Surti A, McDaniel R, Geisman M, Alvarado DM,
Ciorba MA, Bochicchio G, Ilahi O, Kirby J, Symons WJ, Davidson NO, Levin MS,
Rubin DC. Stem cell and niche regulation in human short bowel syndrome. JCI Insight
2020;5.

227.

Wu N, Sun H, Zhao X, Zhang Y, Tan J, Qi Y, Wang Q, Ng M, Liu Z, He L, Niu X,
Chen L, Liu Z, Li H-B, Zeng YA, Roulis M, Liu D, Cheng J, Zhou B, Ng LG, Zou D,
Ye Y, Flavell RA, Ginhoux F, Su B. MAP3K2-regulated intestinal stromal cells define a
distinct stem cell niche. Nature 2021;592:606-610.

228.

Garcia Garcia CJ, Huang Y, Fuentes NR, Turner MC, Monberg ME, Lin D, Nguyen ND,
Fujimoto TN, Zhao J, Lee JJ, Bernard V, Yu M, Delahoussaye AM, Jimenez Sacarello I,
158

Caggiano EG, Phan JL, Deorukhkar A, Molkentine JM, Saur D, Maitra A, Taniguchi
CM. Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer
Microenvironment. Gastroenterology 2022;162:P2018-2031.
229.

García García CJ, Acevedo Diaz AC, Kumari N, Govindaraju S, de la Cruz Bonilla M,
San Lucas FA, Nguyen ND, Jiménez Sacarello I, Piwnica-Worms H, Maitra A,
Taniguchi CM. HIF2 Regulates Intestinal Wnt5a Expression. Frontiers in Oncology
2021;11.

230.

Laoui D, Van Overmeire E, Di Conza G, Aldeni C, Keirsse J, Morias Y, Movahedi K,
Houbracken I, Schouppe E, Elkrim Y, Karroum O, Jordan B, Carmeliet P, Gysemans C,
De Baetselier P, Mazzone M, Van Ginderachter JA. Tumor Hypoxia Does Not Drive
Differentiation of Tumor-Associated Macrophages but Rather Fine-Tunes the M2-like
Macrophage Population. Cancer Research 2014;74:24-30.

231.

Messai Y, Gad S, Noman MZ, Le Teuff G, Couve S, Janji B, Kammerer SF, RiouxLeclerc N, Hasmim M, Ferlicot S, Baud V, Mejean A, Mole DR, Richard S, Eggermont
AMM, Albiges L, Mami-Chouaib F, Escudier B, Chouaib S. Renal Cell Carcinoma
Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha,
is Regulated by von Hippel–Lindau Gene Mutation Status. European Urology
2016;70:623-632.

232.

Verginadis II, Kanade R, Bell B, Koduri S, Ben-Josef E, Koumenis C. A Novel Mouse
Model to Study Image-Guided, Radiation-Induced Intestinal Injury and Preclinical
Screening of Radioprotectors. Cancer Research 2017;77:908-917.

159

233.

Ramakrishnan S. HIF-2 in Cancer-Associated Fibroblasts Polarizes Macrophages and
Creates an Immunosuppressive Tumor Microenvironment in Pancreatic Cancer.
Gastroenterology.

160

Vita
Carolina Jannet García García was born in Mayagüez, Puerto Rico on June 12, 1992, the
daughter of Evelyn Jannet García López, Esq. and Eugenio Enrique García Molina, P.E. After
completing her work at the Escuela San Germán Interamericana (Interamerican University
School), San Germán, Puerto Rico in 2010, she entered the University of Puerto Rico in
Mayagüez, Puerto Rico. She received the degree of Bachelor of Science with a major in biology
in May, 2014. In June of 2014 she entered the tri-institutional collaborative MD/PhD program in
the University of Puerto Rico School of Medicine and The University of Texas MD Anderson
Cancer Center UTHealth Graduate School of Biomedical Sciences, sponsored by the U54
Partnership for Excellence in Cancer Research, where she pursued a Ph.D. in Cancer Biology.

161

